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Summary
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1. The aim of this study was to characterise vasodilator responses in the perfused ciliary 
vascular bed of the bovine eye
2. When bovine eyes were perfused at a constant rate of 2.5 ml min"\ infusion of the 
powerful vasodilator, papaverine (150 pM), produced a veiy small reduction in 
perfusion pressure. Under the same conditions, the nitric oxide synthase inhibitor, L- 
NAME (100 pM), had no effect but the inhibitor of soluble guanylate cyclase, ODQ (10 
pM), produced a small vasoconstrictor response. These results indicate that there is a 
small component of intrinsic (myogenic) tone that may be suppressed by a basal release 
of nitric oxide.
3. In the bovine eye, vasodilatation to acetylcholine or bradyldnin was unaffected by L- 
NAME (100 pM), or the cyclo-oxygenase inhibitor, flurbiprofen (30 pM), but was 
significantly attenuated following treatment with a high concentration of KCl (30 mM), 
or by damaging the endothelium with the detergent, CHAPS (0.3%, 2 min). Thus 
agonist-induced vasodilatation is not mediated by nitric oxide or prostacyclin but 
involves a conductance and is endothelium-dependent.
4. Acetylcholine-induced vasodilatation in the bovine eye was unaffected by 
glibenclamide (10 pM), an inhibitor of ATP-sensitive channels ( K a t p ) ,  but was 
significantly attenuated by TEA (10 mM), a non-selective inhibitor of channels. The 
blockade of vasodilatation by TEA but not glibenclamide could indicate that a calcium- 
sensitive channel is involved in the response.
5. The small conductance calcium-sensitive channel (SKca) inhibitor, apamin (100 
nM), and the large conductance calcium-sensitive channel (BKca) inhibitor, 
iberiotoxin (50 nM), had no significant effect on acetylcholine-induced vasodilatation. 
In contrast, the intermediate (IKca)/large conductance calcium-sensitive channel 
inhibitor, chaiybdotoxin (50 nM), powerfully blocked these vasodilator responses, and
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uncovered a vasoconstrictor response. Thus, vasodilator responses appear to involve the 
opening of IKca channels.
6. The combination of apamin (100 nM) with a sub-threshold concentration of 
charybdotoxin (10 nM) significantly attenuated acetylcholine-induced vasodilatation, 
but the combination of apamin (100 nM) with iberiotoxin (50 nM) had no effect. This 
profile of blockade is consistent with the vasodilator responses being mediated by 
endothelium-derived hyperpolarizing factor (EDHF).
7. Ascorbate is known to protect nitric oxide dependent vasodilatation under conditions 
of oxidant stress, however, EDHF-mediated vasodilator responses induced by 
acetylcholine or bradykinin were powerfully blocked when ascorbate (50 pM, 120 min) 
was included in the perfusion medium; with acetylcholine a normally masked 
muscarinic vasoconstrictor response was also uncovered. These results indicate that, 
ascorbate at a physiologically relevant concentration, can inhibit EDHF-mediated 
vasodilatations.
8. The blockade of EDFIF-mediated vasodilatation by ascorbate was time-dependent 
(maximum blockade at 120 min) and concentration-dependent (10-150 pM). Thus, the 
blocking action of ascorbate has a slow onset and occurs concentrations across the 
normal plasma concentration range (10-150 pM).
9. The ability of ascorbate to block EDHF-mediated vasodilatation in the bovine eye is 
likely to result from its reducing properties, since this action was mimicked by two 
other reducing agents, namely, N-acetyl-L-cysteine (1 mM) and dithiotlueitol (100 pM), 
but not by the redox-inactive analogue, dehydroascorbate (50 pM).
10. In the bovine eye, vasodilatations induced by the K a t p  opener, levcromakalim (100 
pmol-30 mnol), or the nitric oxide donor, glyceryl trinitrate (10 nmol), were completely 
unaffected by the infusion of ascorbate (50 pM). Furthermore, the L-NAME induced
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vasoconstrictor response in the presence of U46619 (-200 nM) was unaffected by 
infusion of ascorbate (50 pM). Thus, the blockade of EDHF-mediated vasodilatation by 
ascorbate is highly selective and does not result from non-selective damage of the 
endothelium as basal release of nitric oxide is unaffected.
11. Ascorbate (50 pM) also blocked acetylcholine-induced, EDHF-mediated vasodilator 
responses in the rat mesenteric arterial bed in a time-dependent manner (maximum 
blockade at 180 min), indicating that this effect of ascorbate is not exclusive to the eye.
12. In rings of porcine coronary artery the EDHF-mediated vasodilatation induced by 
bradykinin (0.1-30 nM) was unaffected by chaiybdotoxin (100 nM), slightly inhibited 
by apamin (100 nM), but virtually abolished by the combination of the two blockers. In 
the presence of ascorbate (150 pM) this EDHF-mediated vasodilatation induced by 
bradykinin was unaffected. Furthermore, ascorbate failed to cause further inhibition of 
vasodilatation when combined with either charybdotoxin or apamin alone, or in 
combination. These results indicate that ascorbate cannot block EDHF-mediated 
vasodilatation in all vascular preparations.
13. Interfering with the ability of bovine eyes to accumulate ascorbate, either by 
flushing the anterior and posterior chambers or by draining these chambers and the 
vitreous cavity, did not affect the ability of ascorbate (50 pM) to inhibit acetylcholine 
(10 nmol)-induced EDHF-mediated vasodilatations. Thus, the ascorbate-induced 
inhibition of EDHF-mediated vasodilator responses is independent of the eyes ability to 
accumulate ascorbate.
14. These results indicate that, in the bovine eye there is basal release of nitric oxide, 
which suppresses perfusion pressure but does not contribute to agonist-induced 
vasodilatation. However, acetylcholine- and bradykinin-induced, endothelium- 
dependent vasodilatations in the perfused ciliaiy vascular bed of the bovine eye are
mediated entirely by EDHF. These EDHF-mediated vasodilator responses are inhibited 
by the antioxidant, ascorbate, at concentrations similar to those noimally found in the 
blood plasma. An antioxidant mechanism accounts for the blockade of EDHF-mediated 
vasodilatation by ascorbate and this blockade is highly selective. Ascorbate also blocks 
EDHF-mediated vasodilatation in the perfused rat mesentery, however, results from the 
porcine coronary artery indicate that ascorbate does not block EDHF in all vascular 
preparations.
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Chapter 1
Introduction
SCgRlT/üi
1.1 The bovine eye
1.1.1 Anatomy of the bovine eye
The eye is a fluid-filled sphere, the globe of which is essentially made up of three 
different layers: the outermost layer consists of the cornea and the sclera and its function 
is mainly to provide structural strength to the eye and, as such, it also acts as a 
protective barrier; the middle layer, the uvea, consists of the highly vascular choroid, the 
ciliary body and the iris; and the innermost layer of the eye is the retina, which is the 
light-sensing layer containing all the neural cell types essential for vision (Figure 1.1).
There are three fluid-filled chambers within the eye: the anterior chamber, the posterior 
chamber and the vitreous cavity (Figure 1.1). The anterior and posterior chambers are 
filled with aqueous humour, a clear, colourless liquid that supplies nutrients to the 
avascular structures of the eye such as the cornea and lens (Millar & Kaufman, 
1995)(see Section 1.1.3). The anterior and posterior chambers are continuous via the 
pupil of the eye. The vitreous cavity is located behind the lens and ciliary body and is 
the largest of the three chambers; it is filled with a clear jelly-like substance, the 
vitreous humour.
The cornea is the transparent avascular structure that covers the anterior surface of the 
globe (Figure 1.1). The cornea consists of four layers: the epithelium, stroma, 
Descemef s membrane and endothelium and is the major refractive component of the 
eye. Another refractive component of the eye is the lens, a transparent and crystalline 
structure; it is located immediately posterior to the iris (Figure 1.1) and functions to 
focus light on to the retina. The lens is supported by the suspensory ligaments, which 
are attached to the ciliary body (Prince et a l ,  1960).
Choroid
Vitreous chamberSclera
Ciliary body
Cornea
LensAnterior chamber
Pupil
Iris
Posterior chamber
Ora ciliaris retinae Retina
anterior posterior
Figure 1.1 Schematic diagram of the vertical cross section of the bovine eye, showing 
the gross anatomy of the globe including: the three layers of the globe (retina, choroid 
and sclera), the ocular chambers, the iris, the ciliary body and the lens.
The iris is the anterior portion of the uvea and is often darkly pigmented; it is located 
between the cornea and the lens and forms the boundary between the anterior and 
posterior chambers (Figure 1.1). In the bovine eye the iris forms an oval pupil, which is 
oriented in the horizontal plane, but becomes almost circular when dilated (Prince et a l , 
1960). This is in contrast to the circular pupil of human eyes. Indeed, the anatomy of the 
eye varies greatly amongst mammalian species and anatomical knowledge of the human 
eye may lead to misinterpretation of the anatomical arrangement of the bovine eye; 
therefore Table 1.1 displays a list of some major anatomical differences between bovine 
and human eyes.
The ciliaiy body extends from the termination of the retina (ora ciliaris retinae; Figure
1.1) to the root of the iris (Prince et a l ,  1960). The majority of the ciliary body’s mass 
is the ciliary muscle, aiTanged into three orientations; radial, circular and longitudal 
(Millar & Kaufman, 1995). The ciliary muscle functions to stretch the lens in order to 
focus light on the retina. However, there is little evidence for functional activity of the 
ciliary muscle in the bovine eye (Prince et a l ,  1960); perhaps indicating that, like other 
ungulates, the bovine eye has a limited ability for accommodation (Diescem, 1975). A 
number of projections, termed ciliary processes, radiate from the ciliary body into the 
posterior chamber. The anatomy of the ciliary body is described in more detail in 
Section 1.1.3.1.
1.1.2 Vascular system
In most mammalian eyes, there are two distinct vascular systems to supply the anterior 
and posterior of the eye; blood is usually supplied to the retina by retinal and short 
posterior ciliary arteries, and to the anterior eye from long posterior ciliary arteries and
Anatomical feature Human eye Bovine eye
Globe dimensions (mm) 21-26 (anterior-posterior) 
23-25 (diameter) ^
28-30 (anterior-posterior) 
30 (diameter) ^
Main arterial blood supply Internal ophthalmic artery^ External ophthalmic artery 
(via ciliary artery) ^
Lens dimensions (mm) ~4 (anterior-posterior) 
~10  (diameter) ^
-13 (anterior-posterior) 
-19  (diameter) ^
Lens Volume (ml) 0.2" 2.2'*
End of retina/start of 
ciliary body
Ora serrata " Ora ciliaris retinae ^
Ciliary muscle Well developed Poorly developed ^
Accommodation Extensive Limited ^
Scleral spur Present " Absent ^
Anterior chamber volume 
(ml)
0.35" 1.7''
Ciliary processes -70  " 90-110"
Pupil Circular Oval "
Corneal dimensions (mm) -11.7 (horizontal) " 
- 10.6 (vertical)
- 1  (thickness)
27-34.5 (horizontal) 
20-30.5 (vertical) 
0.7-1.5 (thickness)
Canal of Schlemm Present " Absent "
Table 1.1 Some anatomical differences between the bovine and human eye, adapted 
from ^(Doughty, 1997) ^(Doughty et a l ,  1995) ^(Prince et a l ,  1960) "^(Shahidullah, 
1994) ^(Tripathi & Tripathi, 1984) ^Williams & Warwick, 1980).
anterior ciliary arteries (Aim, 1992). In the bovine eye, the majority of the blood is 
supplied by the ciliary arteries (Figure 1.2)(Prince et a l ,  1960), which branch off from 
the external ophthalmic artery; this is in contrast to human eyes where most of the blood 
is supplied by the internal ophthalmic artery (Table 1.1). In the bovine eye, many of the 
arteries supplying the extraocular muscles are formed from the external ophthalmic 
artery, and there are usually several to each extraocular muscle. The anterior ciliary 
arteries are branches of these muscular arteries and enter the sclera near the root of the 
iris (Prince et a l ,  1960).
In the bovine eye the ciliary artery is aligned with the optic nerve; here it divides into 
the large medial and the smaller lateral ciliary artery, both running in parallel, loosely 
attached to the optic nerve (Figure 1.2). These arteries bifurcate before entering the 
globe forming many short posterior ciliary arteries. Some of the small posterior ciliary 
arteries enter the globe at the same point as the optic nerve and of these, some branch to 
form the retinal arteries (Prince et a l ,  1960). The other short posterior ciliary arteries 
enter the sclera at varying distances from the optic nerve, some running along the 
choroid towards the iris and ciliary body forming branches to the surrounding tissues.
The large medial ciliary artery also bifurcates to form two long posterior ciliary arteries, 
both of which travel along the globe of the eye, one along the medial side, and the other 
along the lateral side (Figure 1.2). The long posterior ciliary arteries enter the sclera 
posterior to the equator and travel along the horizontal plane on the internal surface of 
the choroid, in the vitreous chamber, to the root of the iris. Here they anastomose with 
the anterior ciliary arteries and form the major arterial circle of the iris (Figure 1.3) at 
the periphery o f the iris, thus supplying blood to the ciliary body and iris (Caprioli,
Medial long posterior
ciliary artery Vortex veins
Internal ophthalmic artery
Medial ciliary artery Cornea
Ciliary
artery
Lateral ciliary 
artery
Lateral long posteriorMuscular artery
ciliary artery
Figure 1.2 Schematic diagram showing the major arterial blood supply and the vortex 
veins of the bovine eye. Most of the blood is supplied via the eiliary artery, with a minor 
contribution from the internal ophthalmie artery. Blood is supplied to the anterior 
structures of the eye such as the ciliary body and iris mostly by the long posterior ciliary 
arteries. This blood is returned to the systemic circulation by the four vortex veins 
located around the equator of the globe. Adapted from (Prince et a l ,  1960)
A n terio r c ilia ry  a r te ry
Sclera
Long posterior* 
ciliary artery
C ornea
Ciliary processes
Figure 1.3 Schematic diagram of the ciliary body of the human eye, showing the 
components of ciliary muscle and the major arterial circle of the iris and the blood 
supply to the ciliary processes. LCM, longitudinal ciliary muscle; RCM, radial ciliary 
muscle; and CCM, circular ciliary muscle. N.B. Although the anatomy of the bovine 
ciliary body is similar to that of the human there are some major differences (see Table
1.1); for example there is no scleral spur in the bovine eye. In addition, in the bovine 
eye, the long posterior ciliary arteries are much larger than the anterior ciliary arteries 
and as such supply most of the blood to the major arterial circle. Adapted from 
(Caprioli, 1992).
1992); the major arterial circle of the iris is well developed in bovine eyes (Prince et a l ,  
1960).
The venons system of the eye is also complex and, as with the arterial system, can vary 
significantly among species. In most manmialian eyes, including the bovine, blood 
returning from the retina drains through the ciliary veins, which pass along the optic 
nerve and eventually drain into the internal maxillary vein (Prince et a l ,  1960). The 
blood supplied to the choroid via the small posterior ciliary arteries and that supplied to 
the iris and ciliary body by the long posterior and the anterior ciliary arteries is drained 
by the vortex veins (Prince et a l ,  1960). There are four vortex veins in the bovine eye, 
which leave the eye in the region of the equator and are fairly evenly spaced around the 
globe ( Figure 1.2; Prince et a l ,  1960).
1.1.3 The eiliary body, aqueous humour formation and dynamics
1.1.3.1 Anatomy of the ciliary body and ciliary processes
As described in section 1.1.1, the ciliary body forms a muscular ring along the inner 
wall of the eye posterior to the iris, anterior to the retina, and is involved in stretching 
the lens to focus light on the retina. The ciliary body is also the tissue responsible for 
the formation of aqueous humour, which is the source of nutrients to the avascular 
structures of the eye.
A large number of villus-like structures project from the inner surface of the ciliaiy 
body into the posterior chamber of the eye. These are the ciliary processes and they are 
the locus of aqueous humour formation (Figure 1.3; Millar & Kaufman, 1995). In the 
bovine eye there are about 90-110 of these ciliary processes (Prince et a l ,  1960) and
their dimensions can vary. In the human eye, for example, the ciliary processes average 
2 mm in length and 0.5 mm width and 1 mm high (Millar & Kaufman, 1995). The 
processes have a convoluted shape, they consist of capillaries surrounded by connective 
tissue (the stroma) and are covered by a double epithelial layer, the ciliary epithelium 
(Millar & Kaufman, 1995).
Blood is supplied to the ciliary processes from the major arterial circle of the iris via 
radial ciliaiy arteries. The blood is then drained via ciliary venules to the vortex veins 
(Millar & Kaufman, 1995). The capillaries of the ciliary processes are large, thin walled 
and highly fenestrated; therefore they are highly permeable. Combined with the 
convoluted shape, this provides the ciliary processes with a large, porous surface area 
from which to secrete aqueous humour. The capillaries are surrounded by the stroma, 
which consists mainly of loose connective tissue and collagen. A basement membrane 
separates the stroma from the ciliary epithelium (Millar & Kaufman, 1995).
The ciliaiy epithelium consists of a double layer of cells, one pigmented and the other 
non-pigmented and represent the continuation of the retinal pigmented epithelium and 
the retinal neuroepithelium, respectively (Bill, 1975). A striking feature of the ciliary 
epithelium is that the apical surfaces of the pigmented and non-pigmented ciliary 
epithelial cells face each other (Figure 1.4). The basolateral surface of the pigmented 
epithelium is attached to the basement membrane, whereas the basolateral surface of the 
non-pigmented epithelial cells bounds the posterior chamber (Figure 1.4). Prominent 
features of the ciliary epithelial cells include interdigitations between the lateral surfaces 
of neighbouring cells and basal infoldings on the non-pigmented cells (Caprioli, 1992);
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Nonpigmented ciliary epithelial 
cell
Pigmenleci 
ciliary epithelial 
cell
Figure 1.4 Schematic diagram of the pigmented and non-pigmented epithelial cells. The 
apices of the cells face each other and they form the double-layered ciliary epithelium 
surrounding the ciliary processes. The basolateral side of the non-pigmented cells is in 
the posterior chamber, whereas the basolateral surface of the pigmented cells faces the 
stroma of the ciliary processes. BI, basal infoldings; BM, basement membrane; CC, 
ciliary channels; DES, desmosomes; FE, fenestrated capillary endothelium; GJ, gap 
junction; MEL, melanosome; MIT, mitochondrion; RBC, red blood cell; RER, rough 
endoplasmic reticulum; and TJ, tight junction. Adapted from (Caprioli, 1992).
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both of these features are characteristic of epithelial cells involved in secretion (Bill,
1975). Furthermore, there are also tight junctions between lateral interdigitations of the 
non-pigmented cells. These exclude large molecules and form an integral part of the 
blood-aqueous barrier (Millar & Kaufman, 1995).
1.1.3.2 Aqueous humour dynamics
As stated in Section 1.1.3.1, the ciliary processes are the sites of aqueous humour 
production. The aqueous humour is a clear liquid, similar in chemical composition to 
blood plasma (Table 1.2), which supplies the avascular structures of the eye with 
nutrients and oxygen, while removing metabolites and carbon dioxide. The aqueous 
humour is continually formed and drained (Millar & Kaufman, 1995). In brief, aqueous 
humour is made ultimately from the blood plasma in the capillaries of the ciliary 
processes, by a process involving passive diffusion, ultrafiltration and active transport; 
indeed, active transport of solutes across the ciliary epithelium is thought to be the 
primary process in aqueous humour formation (Caprioli, 1992).
Once the aqueous humour is formed it flows through the posterior and anterior 
chambers and drains into the bloodstream via two main pathways. The first and major 
route is through the trabecular meshwork, a network of connective tissue covered by 
endothelial cells (Fatt & Weissman, 1992), which in primates, leads to the canal of 
Schlemm; aqueous humour drained from the trabecular pathway enters the aqueous 
veins from where it is returned to the systemic circulation via the vortex veins. The 
second pathway may account for up to 2 0% of aqueous drainage and is thought to be 
simple diffusion of aqueous tluough the ciliaiy muscle and sclera into the orbit where 
the lymphatic system absorbs it. This pathway is often termed the uveoscleral or trans- 
scleral route (Fatt & Weissman, 1992).
12
Substance Bovine AH Human AH Plasma
Electrolytes
Na^ (mM) 143.8-149.5 ^ 142^ 130-145
(mM) 4.5-7.1 4" 3.5-5.0
C r (mM) 116.3-124" 131-136^ 92-125
HCO3- (mM) 36*' 2 0 ^ 24-30
Organic substances
Ascorbate (mM) 2 ' 1.0-1.1 0.04-0.06
Lactate (mM) 7.6-S.2 ‘ 4.5 0.5-1.9"’^
Glucose (mM) 2.2  ' 2.8-3.9" 5.6-6.4
Protein (mg mf^) 0 .2 -0.8 0.3-0.7^ 60-70
Table 1.2 The composition of some common electrolytes and organic solutes in the 
bovine and human aqueous humour (AH) and blood plasma (from a range of species). 
Adapted from \B ito  L.Z. & Salvador E.V, 1970) ^(Caprioli, 1992) ^(Carter et al., 1973) 
\C ole, 1984) ^(Johnson a/., 1986) ^(Shahidullah, 1994) and ^(Davson, 1969).
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As described above, the composition of the aqueous humour is similar to that of blood 
plasma (Table 1.2). However, there are some major differences in their composition. 
For example, the blood aqueous barrier largely excludes plasma proteins, thus limiting 
levels of protein to about 1% of that normally seen in plasma. Indeed, elevated levels of 
protein in the aqueous humour is indicative of a breakdown of the blood aqueous barrier 
(Caprioli, 1992). The relative composition of proteins in the aqueous humour is also 
different to blood plasma. Low-molecular weight proteins such as albumin are present 
in aqueous humour and plasma, whereas larger proteins such as immunogoblins are 
noimally only found in plasma, and are absent from the aqueous under normal 
conditions (Caprioli, 1992).
In contrast to the low levels of protein, the endogenous low-molecular weight 
antioxidant, ascorbate (Halliwell & Gutteridge, 1989), is found at higher concentrations 
in the aqueous humour than in the blood plasma (Table 1.2). The normal plasma 
concentration of ascorbate in humans is 46 ± 8 pM (range 30 -150 pM; Keaney & Vita, 
1995; Levine et a l ,  1996) whereas the concentration of this antioxidant in aqueous 
humour is around 1 mM in humans and a wide range of animal species (Caprioli, 1992; 
Davson, 1980; Halliwell & Gutteridge, 1989). There is much speculation over why 
ascorbate is so concentrated in the aqueous humour, but since it avidly scavenges the 
superoxide anion (Som et a l ,  1983), it may be to compensate for the particularly low 
levels of superoxide dismutase found in the eye (Halliwell & Gutteridge, 1989).
1.1.3.3 Aqueous humour, intraocular pressure and disease
The intraocular pressure (lOP) is essential for maintaining the internal structures and 
shape of the eye. lOP is dictated by the rates of formation and drainage of aqueous
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humour from the eye and the pressure in the episcleral veins to which it drains. A 
change in aqueous humour formation, or a change in resistance to drainage will cause a 
proportionate change in lOP. The normal lOP in the human eye is approximately 15 
mmHg (range, 10.5-20.5 mmHg, for healthy eyes (Davson, 1984).
The Glaucomas are a group of diseases that lead to progressive damage of the retina 
and optic neiwe head leading to loss of peripheral vision and eventually blindness 
(Leopold & Duzmami, 1986; Seiie, 1994). A high lOP (>21 mmHg; Fatt & Weissman, 
1992) is a well known risk factor for the development of glaucoma, although in low 
tension glaucoma the pathological changes to the field of vision occur within normal 
lOP boundaries. Regardless, in some forms of the disease, such as open-angle and 
closed-angle glaucoma, the increase in the lOP is due to decreased drainage of aqueous 
(although increased production may contribute to open angle glaucoma; Fatt & 
Weissman, 1992). Indeed, many of the current treatments for glaucoma work by 
decreasing the resistance to drainage of aqueous from the eye, thereby lowering lOP. 
For example, topically applied prostaglandin Fsa analogues, such as latanoprost (Willis 
et a l ,  2002) increase uveoscleral drainage, whereas cholinergic agents, such as 
pilocarpine, increase drainage thi’ough the trabecular meshwork (Hurvitz et a l ,  1991). 
An alternative treatment for glaucoma is to decrease aqueous humour formation (and 
therefore lOP) using either an (%2-adrenoceptor agonist, such as apraclonidine, or (3- 
adrenoceptor antagonists such as timolol, which bind to receptors on the ciliary 
epithelium (Hurvitz et a l ,  1991).
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1.2 Endothelium-dependent vasodilator mechanisms
1.2.1 Anatomy of arteries
The arteries are responsible for ti-ansport of blood from the heart to the tissues of the 
body. The aorta is the largest artery and along with its major branches is termed an 
elastic arteiy, these arteries distend during systole and recoil during diastole in order to 
dampen the pulse wave of the heart beat, helping to even out the flow of blood. These 
branch to form muscular arteries, which have thicker walls to prevent collapse when 
joints bend. In turn, the muscular arteries branch to form resistance vessels and even 
smaller resistance arterioles, which present the largest resistance to flow of blood and 
are largely responsible for generating blood pressure (Aaronson et a l ,  1999; Berne & 
Levy, 2000).
Regardless of the type of artery, they all have a similar anatomy. Arteries are essentially 
tubes of smooth muscle consisting of three layers (Figure 1.5a); the intimai layer 
consisting of a single layer of endothelial cells; the thick medial layer consisting of 
smooth muscle cells; and the outer adventitial layer, which is mainly connective tissue 
(Aaronson et a l ,  1999).
The intimai, endothelial cell layer lines the vascular lumen and the chambers of the 
heart. The endothelial cells are joined by tight junctions and can act as a barrier to 
restrict movement of large molecules (Aaronson et a l ,  1999). During the inflammatory 
response there is vasodilatation and an increase of blood flow, the endothelial barrier is 
“opened” increasing vascular permeability, leading to exudation of fluid and 
inflammation. Furthermore, atherosclerosis is associated with increased endothelial cell 
permeability and turnover, abnormally activated macrophages release cytokines causing
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Figure 1.5 Schematic diagram of (a) the major anatomical features of a muscular artery, 
including the main components of the intimai, medial and adventitial layers, and (b) a 
single vascular smooth muscle cell. Taken from (Aaronson et al., 1999)0.
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an inflammatory response that leads to formation of a plaque. The endothelial cells 
have other flinctions, for example they are involved in processes such as haemostasis. In 
haemostasis damage of he endothelium exposes collagen to the blood, activating 
platelets, which leads to vasoconstriction and formation of a blood clot. However, under 
normal conditions endothelial cells also release nitric oxide and prostacyclin, which 
prevent platelet aggregation. They also release thrombomodulin, which starts a chemical 
cascade eventually leading to fibrinolysis, the breakdown of a blood clot. The 
endothelial cells are also involved in controlling vascular tone and can release a number 
of vasoeonstrictor and vasodilator agents which can act on the underlying smooth 
muscle layer. For example, angiotensin converting enzyme (ACE), found on the plasma 
membrane of endothelial cells, converts angiotensin I to form angiotensin II, a potent 
vasoconstrictor (Rang et a l ,  1999). ACE also functions to inactivate the potent 
vasodilator, bradykinin (Rang et a l ,  1999). The vasodilator mechanisms of endothelial 
cells are discussed in sections 1.2.2, 1.2.3 and 1.2.4.
The medial layer is separated from the endothelial cells by the internal elastic lamina 
(Figure la) and consists mainly of smooth muscle cells in an extracellular matrix of 
collagen. The smooth muscle cells have a shape similar to an irregular cylinder (Figure 
1.5b), or spindle, and are arranged in a circular manner in order to oppose the radial 
force of pressure and so that when they contract, the lumen diameter of the arteiy is 
decreased (Aaronson et a l ,  1999).
The outer, adventitial layer is separated from the medial layer by the external elastic 
lamina, the collagen-rich connective tissue that makes up its bulk and supports nerves 
and fibroblasts. In larger arteries, the adventitial layer may also contain small blood
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vessels (the vasa vasorum) to supply the medial layer with nutrients. Most arteries are 
innervated with sympathetic fibres that release noradrenaline to cause vasoconstriction. 
Some specialised arteries may also be innervated by parasympathetic nerve fibres, 
which release a variety of transmitters such as CGRP in the rat mesenteric artery 
(Kawasaki et a l ,  1988) (sensory neiwes) or nitric oxide in penile (Burnett et a l ,  1992) 
and cerebral arteries (Bredt et a l ,  1990), to cause vasodilatation.
1.2.2 Nitric oxide
1.2.2.1 Characterisation of endothelium-derived relaxing factor as nitric oxide.
Furchgott and Zawadski (1980) first demonstrated that the acetylcholine-induced 
relaxation of rabbit aorta was dependent upon the presence of the endothelium and that 
a diffusible substance released by the endothelium was responsible for the relaxation. 
Vasodilator responses mediated by this endothelium-derived relaxing factor (EDRF) 
were later demonstrated in almost every vascular preparation from a wide variety of 
species to many different chemical stimuli (e.g. bradykinin, calcium ionophore A23187 
and substance P (for review see: Moncada et a l ,  1991). EDRF-mediated vasodilatation 
was also shown to be stimulated by blood flow (Rubyani et a l ,  1986). Furthermore, 
EDRF was shown to be released spontaneously, i.e. under unstimulated conditions, in 
some preparations (Martin et a l ,  1986).
It was soon established that EDRF was a substance with a half-life of a few seconds 
(Cocks et a l ,  1985; Griffith et a l ,  1984) and that its effects were mediated through 
stimulation of soluble guanylate cyclase in smooth muscle cells to raise cyclic GMF 
levels (Rapoport & Murad, 1983); raising cyclic GMP levels which activates protein 
kinase G which causes relaxation of vascular smooth muscle by lowering the
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intracellular calcium levels and phosphorylating myosin light-chain kinase (MLCK; 
Collins et a l ,  1986). Indeed, the actions of EDRF were attenuated by inhibitors of 
guanylate cyclase such as methylene blue (Martin et a l ,  1985), or the more recently 
introduced ODQ (Gaidhwaite et a l ,  1995). The EDRF was also shown to inliibit platelet 
aggregation and cause disaggregation of aggregated platelets (Azuma et a l ,  1986; 
Radomski et a l ,  1987). In 1986 it was concluded that due to the similar 
pharmacological profiles of EDRF and nitric oxide, EDRF might indeed be nitric oxide 
(Furchgott, 1988; Ignarro et a l ,  1988). Experiments comparing the effects of EDRF and 
nitric oxide on vascular strips and on platelets, found that the two were 
indistinguishable (Moncada et a l ,  1988; Palmer et a l ,  1987). Thus it is widely accepted 
that EDRF is nitric oxide. Figure 1.6 shows an overview of the nitric oxide pathway.
1.2.2.2 Synthesis of nitric oxide
Nitric oxide is enzymatically synthesised by nitric oxide synthase, a dimerised enzyme 
with both reductase and oxidase functions (Hobbs et a l ,  1999). Nitric oxide synthase 
cleaves the terminal guanidine nitrogen group of the amino acid, L-arginine, in the 
presence of O2, in a five-electron oxidation to form nitric oxide and L-citmlline at an 
active site containing a heme-moiety. Nitric oxide synthase also requires several co­
factors including: Ca '^ ,^ which is involved in activating the enzyme; calmodulin, which 
in the presesnce of Ca^ "^  binds to the enzyme tightly and is involved in electron transfer 
between the reductase and oxidase domains of the enzyme (Abu-Soud & Stuehr, 1993); 
NADPH, to supply the electrons for the oxidation of L-arginine; flavin adenine 
dinucleotide is involved in electron transfer from NADPH to the heme site (Stuehr & 
Ghosh, 2000), flavin mononucleotide is also involved in this process; and
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Figure 1.6 Schematic diagram showing the synthesis, release and cellular targets of 
nitric oxide (NO) and prostacyclin (PGI2) (see text for details). NO is synthesised in 
endothelial cells (EC) by NO synthase (NOS). NO diffuses to smooth muscle cells 
where it activates soluble guanylate cyclase (sGC), which produces cyclic GMP 
(cGMP). cGMP causes relaxation by activating protein kinase G (PKG), thus inhibiting 
myosin light chain kinase, by phosphorylating it (MLCK-P); and inhibition of receptor- 
operated Ca^’*’ channels (ROC) or activation of Ca^^-ATPase. PGI2 produced by 
cyclooxygenase (COX) stimulates adenylate cyclase (AC), producing cyclic AMP 
which activates protein kinase A (PKA) which phosphoiylates MLCK, opens ATP- 
sensitive (K atp) and large conductance calcium-sensitive (B K ca) potassium channels, 
resulting in hyperpolarization and relaxation. R, G-protein coupled receptor.
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tetrahydrobiopterin is essential to link to two dimers of nitric oxide together, a process 
that is required for maximal activity (Hevel & Marietta, 1992).
There are three known subtypes of nitric oxide synthase: neuronal nitric oxide synthase 
(nNOS or NOS I), which was first identified in brain tissue (Bredt & Snyder, 1990) and 
some other tissues including peripheral nerves, lung and stomach (Schmidt et al., 1992); 
inducible nitric oxide synthase (iNOS or NOS II) which is found in most cell types but 
is only expressed when induced by substances such as bacterial lipopolysaccharide 
(Hevel et a l ,  1991; Stuehi’ et a l ,  1991); and endothelial nitric oxide synthase (eNOS or 
NOS III), which is the isoform found in the vascular endothelium as well as in platelets 
(Radomski et a l ,  1990). Both neuronal and endothelial nitric oxide synthase are 
expressed constitutively in cells and are Ca^Vcalmodulin sensitive and, as such, are 
activated by rises in the intracellular Ca^^ concentration; inducible nitric oxide synthase 
is Ca^'^-independent but does bind calmodulin and is activated by this co-factor, even if 
Ca^^ levels are low (Cho et a l ,  1992).
As nitric oxide synthase requires many cofactors it can be inhibited in a variety of ways 
including agents which: interfere with substrate or co-factor synthesis, availability or 
uptake; interfere with the heme-moiety; or prevent the binding of substrate to the 
enzyme (for review see; Hobbs et a l ,  1999). The most commonly used method of 
attenuating nitric oxide synthase activity is to prevent binding of L-arginine to the 
enzyme by using stmctural analogues (Hobbs et a l ,  1999). The analogue of L-arginine 
first described as an inhibitor of nitric oxide synthase was N^-monomethyl-L-arginine 
(L-NMMA; Hibbs et a l ,  1987) which was used to identify many of nitric oxide’s 
physiological actions (Moncada et a l ,  1989). Other commonly used analogues of L-
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arginine ineliide N^-nitro-L-arginine (L-NA) and N‘^ -nitro-L-arginine methyl ester (L- 
NAME); all are competitive, reversible inhibitors of all the nitric oxide synthase 
subtypes (Rees et a l ,  1990).
1.2.2.3 Release of nitric oxide
(i) Agonist-induced release
As discussed in Section 1.2.2.1 nitric oxide (EDRF) is released from the acetylcholine- 
stimulated endothelium in the rabbit aorta (Furchgott & Zawadzki, 1980). Agents that 
increase intracellular calcium in a receptor-independent manner, such as the calcium 
ionophore A23187, can release nitric oxide from the endothelium. There are many other 
examples of agonists such as acetylcholine, substance P, bradykinin and histamine that 
produce nitric oxide-dependent vasodilatation (for review see; Calver et a l ,  1993; 
Moncada et a l ,  1991) by stimulating G-proteins on endothelial cells; these stimulate 
inositol trisphosphate production, which eventually leads to an increase in intracellular 
calcium by stimulating calcium influx (Schilling & Elliott, 1992), thus activating 
Ca^"^/calmodulin-sensitive nitric oxide synthase.
(ii) Basal and flow-induced release
Inhibition of nitric oxide synthase induees endothelium-dependent vasoconstriction in 
isolated arteries from a wide range of species, including human (see below). 
Furthermore, cultured endothelial cells spontaneously release nitric oxide (Palmer et a l ,  
1988). It is thought that this basal release of nitric oxide reflects stimulation of nitric 
oxide synthase by the resting calcium concentration in the endothelial cell (Long & 
Stone, 1985; Miller et a l ,  1985). This basal release of nitric oxide can also be observed 
as an increase in tone or pressure upon addition of an inhibitor of nitric oxide synthase
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ill perfused vessels (Amezcua et a l ,  1988), and in vivo (Mügge et a l ,  1991); It is 
possible that in vivo neural release or flow-induced release may contribute to this basal 
release of nitric oxide. However, basal release of nitric oxide can be observed in isolated 
arteries where the effects of flow or neural release can be excluded (Martin et a l ,  1986).
Flow-induced release of nitric oxide was first observed by Rubanyi et a l  (1986) and 
flow-induced shear stress on endothelial cells is now known to be an important stimulus 
for this release. Exposure of cultured endothelial cells to shear stress leads to release of 
nitrie oxide (Kanai et a l ,  1995; Kuchan & Frangos, 1994) and increased expression of 
endothelial nitric oxide synthase (Ranjan et a l ,  1995; Ziegler et a l ,  1998). Shear stress 
causes increases in the intracellular Ca^ "^  concentration (Jen et a l ,  2000) and opening of 
ion channels (Hoyer et a l ,  1998; Olesen et a l ,  1988); stretch-activated Ca^ "^  channels 
appear to be responsible for the increase of endothelial intracellular Ca^”^ concentration 
produced by shear stress (Brakemeier et a l ,  2002; Naruse & Sokabe, 1993). As well as 
shear stress, the heartbeat causes pulsatile distension of the vascular wall and this can 
release nitric oxide in the coronary circulation of dogs (Canty & Schwartz, 1994; 
Recchia et a l ,  1996) and rabbits (Lamontagne et a l ,  1992). It is thought that nitric 
oxide released by pulsatile stretch may be of particular importance to vasomotor control 
in the coronary circulation, where during systole there is virtually no flow-induced shear 
stress (Dube & Canty, 2001). Interestingly, flow-induced vasodilatation in the dog 
coronary circulation appears to be partially mediated by another factor distinct from 
nitric oxide (Canty & Schwartz, 1994).
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(iii) neural release of nitric oxide
Neuronal nitric oxide synthase was first observed in brain tissue and this isozyme is also 
found in neurones supplying the cerebral vasculature (Bredt & Snyder, 1990) as well as 
blood vessels supplying the eye (for review see; Koss, 1999), Indeed nitric oxide is the 
neurotransmitter released by some non-adrenergic, non-cholinergic (NANC) nerves in 
the autonomic nervous system (Gillespie et a i ,  1989; Bult et a l ,  1990; Rand, 1992). 
Such nerves are now termed nitrergic neiwes. With the localisation of neuronal nitric 
oxide synthase in some blood vessels it is unsurprising that neuronal release of nitric 
oxide can play a part in cardiovascular control. For example, inhibition of nitric oxide 
synthase can increase sympathetic nerve-induced contractions in dog mesenteric artery 
and attenuate parasympathetic (nitrergic) nerve-induced vasodilatations in dog cerebral 
arteries (Toda & Okamura, 1990); furthermore, nitric oxide is released by nitrergic 
nerves in the penile arteries (Burnett et a l ,  1992), causing vasodilatation and erection 
by filling of the corpus cavemosum (Raj 1er et a l ,  1992).
1.2.2.4 Nitric oxide in vascular disease
Many vascular diseases such as hypertension (Linder et a l ,  1990), 
hypercholesterolaemia and atherosclerosis (Shimokawa & Vanhoutte, 1989), diabetes 
(Timimi et a l ,  1998; Ting et a l ,  1996), and chronic heart failure (Ellis et a l ,  2001; 
Hornig et a l ,  1998) are associated with reduced endothelium-dependent relaxation. In 
addition, some ocular diseases such as glaucoma (Henry et a l ,  1999) and diabetic 
retinopathy (Schmetterer et a l ,  1997) have a vascular component and are associated 
with endothelial dysfunction. In human hypertension, vasodilatation to acetylcholine is 
reduced, as are vasoconstrictions to inhibitors of nitric oxide synthase, indicating that 
nitric oxide activity is reduced compared to control patients (Panza et a l ,  1993). Indeed,
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dysfunction of the nitric oxide pathway can, indirectly, lead to vascular remodelling that 
may facilitate the pathology of diseases such as hypertension and atherosclerosis 
(Taddei et a l ,  1998a). Many of these vascular diseases are associated with oxidant 
stress and acute treatment with antioxidants such as vitamin C (ascorbic acid) has been 
shown to restore impaired nitric oxide vasodilatation in essential hypertension (Natali et 
a l ,  2000; Taddei et a l ,  1998b), chronic heart failure (Ellis et a l ,  2001; Hornig et a l ,  
1998), atherosclerosis (Levine et a l ,  1996), hypercholesterolaemia (Ting et a l ,  1997) 
and diabetes (Timimi et a l ,  1998; Ting et a l ,  1996). This protective action of ascorbate 
may be due to its ability to scavenge the superoxide anion which destroys nitric oxide 
(Gryglewski et a l ,  1986; Rubanyi & Vanhoutte, 1986), but ascorbate may also help 
increase nitric oxide production by elevating levels of tetrahydrobiopterin, a cofactor 
for nitric oxide synthase (Heller et a l ,  2001; Huang et a l ,  2000).
Some pathological states, such as migraine, are associated with an overproduction of 
nitric oxide (Olesen et a l ,  1994a). It is thought that in migraine, 5-HT stimulates nitric 
oxide release from endothelial cells of the cerebral vasculature. The nitric oxide then 
causes sensory fibres to release neurotransmitters which cause oedema, inducing pain. 
The ability of some nitric oxide donor drugs such as amyl nitrite to cause migraine-like 
headache seems to support this hypothesis (Olesen et a l ,  1994a). Septic shock, a 
clinical syndrome characterised by severe hypotension and cardiovascular failure, is 
also associated with excess nitric oxide production. Under normal conditions production 
of nitric oxide by the inducible nitric oxide synthase protects against invasion by micro­
organisms (Colasanti & Suzuki H., 2000), However, in septic shock bacterial 
endotoxins cause an over-expression of inducible nitric oxide synthase. The excess 
nitric oxide may be cytotoxic and causes vasodilatation leading to myocardial
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depression and circulatoiy failure (see Forstennann et a l ,  1994; Moncada et a l ,  1991). 
Inhibitors of nitric oxide synthase are effective against septic shock in animal models 
(Kilbourn et a l ,  1994) but have the disadvantage of inliibiting the constitutive isoforms 
as well i.e. impairing all physiological functions such as neurotransmission. The 
development of selective inducible nitric oxide synthase inhibitors such as 1400W 
(Garvey et a l ,  1997) should offer a safer therapy for septic shock.
1.2.3 Prostacyclin
Prostacyclin (prostaglandin I2, PGI2) is the principal metabolite of arachidonic acid 
produced by cyclooxygenase in the endothelium of most blood vessels (Moncada et a l ,
1976). Like nitric oxide, it is released from endothelial cells by a variety of stimuli, that 
increase intracellular Ca^’*’ such as agonist stimulation and flow-induced release, leading 
to vasodilatation and inhibition of platelet aggregation. Prostacyclin stimulates 
adenylate cyclase on target cells leading to increases in intracellular cyclic AMP 
(Tateson et a l ,  1977). In experimental settings, prostacyclin-mediated responses can be 
inhibited using antagonists of cycloxygenase such as indomethacin. In most vascular 
preparations, prostacyclin-induced increases of smooth muscle cell cyclic AMP 
concentration leads to vasodilator responses by stimulation of protein kinase A, which 
leads to a decrease in intracellular calcium concentration and phosphorylation of 
MCLK. In some tissues prostacyclin can cause vasodilatation and hyperpolarization by 
the opening of the ATP-sensitive channel ( K a t p ) ,  since these vasodilatations can be 
inhibited by glibenclamide (Jackson et a l ,  1993; Murphy & Brayden, 1995). In 
addition, in some tissues prostacyclin-induced vasodilatation can involve the opening of 
large-conductance, calcium-sensitive potassium channels (BKca) (Schubert et a l ,  1997) 
resulting in hyperpolarization of the smooth muscle cells leading to a decrease in the
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intracellular calcium concentration, causing relaxation. An overview of prostacyclin- 
induced vasodilatation can be seen in Figure 1.6.
1.2.4 Endothelium-derived hyperpolarizing factor
In some vascular preparations a significant vasodilator response can still be obseiwed 
after inhibition of both the nitric oxide and prostacyclin pathways. This vasodilator 
pathway is associated with a hyperpolarization of the underlying smooth muscle and is 
believed to be mediated by an agent termed endothelium-derived hypeipolarizing factor 
(EDHF; Chen et a l ,  1988; Feletou M & Vanhoutte P.M, 1988). In general it would 
appear that nitric oxide is the predominant endogenous vasodilator in larger vessels and 
EDHF assumes more importance in smaller arteries (Adeagbo & Triggle, 1993; Garland 
et a l ,  1995; Nagao et a l ,  1992); however, EDHF-mediated vasodilatations can be 
observed in many large conduit arteries such as the porcine (Fisslthaler et a l ,  1999; 
Fleming et a l ,  1999) and bovine (Campbell et a l ,  1996; Drummond & Cocks, 1996) 
coronary arteries. Like nitric oxide, EDHF can be released by flow and, in the coronary 
circulation of humans and pigs, EDHF appears to be released by both shear stress (Dube 
& Canty, 2001; Miura et a l ,  2001) and pulsatile stretch (Popp et a l ,  1998).
1.2.4.1 Mechanism of action of endothelium-derived hyperpolarizing factor
It is generally accepted that EDHF’s relaxant mechanism involves the hyperpolarization 
of vascular smooth muscle cells; this hyperpolarization of the smooth muscle cell leads 
to a decrease in the intracellular Ca^ "^  concentration by reducing the open probability of 
L-type voltage-dependent calcium channels, leading to vasodilatation (Feletou & 
Vanhoutte, 1999).
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The initial step in the EDHF response appears to be a rise in the intracellular Ca^ "^  
concentration of endothelial cells (Chen & Suzuki, 1990). Indeed, agonists that evoke 
EDHF-mediated responses by activating endothelial G-protein-coupled receptors cause 
a rise in the intracellular Ca^ "^  concentration (Busse et a l ,  2002). Furthermore, EDHF- 
mediated responses can be elicited by agents which can increase the endothelial 
intracellular Ca^^ concentration, such as the calcium ionophore A23187 (Hutcheson et 
a l ,  1999; Plane et a l ,  1995) or the inhibitors of Ca^^-ATPase, thapsigargin and 
cyclopiaznoic acid (Fukao et a l ,  1995; Illiano et a l ,  1992).
EDHF-mediated vasodilatation involves increases in conductance as it is sensitive to 
depolarising concentrations of K'*' (above 25 mM; Adeagbo & Triggle, 1993) and 
inhibitors of certain channels (see below). Furthermore, EDHF-mediated responses 
are associated with an increase in rubidium efflux (Chen et a l ,  1988; Taylor et a l ,  
1988) and decreases in membrane resistance, suggesting that they are due to the opening 
of a channel, not the closing of a chloride channel, nor the closing of some other 
cation conductance (Feletou & Vanhoutte, 1999). An overview of EDHF-mediated 
vasodilatation can be found in Figure 1.7.
1.2.4.2 Characterisation and location of the channels involved in the EDHF 
response
Endothelium-dependent hyperpolarizations resistant to blockade of NOS and 
cyclooxygenase are not sensitive to the blocker of ATP-sensitive K  channels (K atp), 
glibenclamide (Busse et a l ,  2002). In contrast, non-selective inhibition of Ca^^-sensitive 
potassium channels (Kca) with tetraethylammonium inhibits EDHF-mediated responses
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Figure 1.7 Schematic diagram showing the current hypotheses of how EDHF may 
function (see text for details). Rises in intracellular [Ca^^] (Ca^^i) may cause 
endothelium-dependent vasodilatation in several ways, (i) Activation of small and 
inteimediate calcium-sensitive K channels (S/IKca), will release into the intracellular 
space, thus stimulating Na/K-ATPase or inward-rectifler K  ( K ir )  channels on smooth 
muscle cells (SMC), causing hyperpolarization and relaxation, (ii) Stimulation of 
cytochrome P450 (CP450) in endothelial cells (EC) may produce EETs, which could 
either directly stimulate large conductance calcium-sensitive K chamiels (BKca) on 
SMC or modulate myo-endothelial gap junctions (GJ), endothelial Kca channels, or Ca^ *^  
release from endothelial stores. Hyperpolarization may spread electrotonically from the 
EC to SMC via GJs; alternatively a diffusible substance may pass through GJs to 
hyperpolarize SMC.
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(Chen & Cheung, 1997; Honing et a l ,  2000). Furthermore, blocking K ca channels with 
specific toxins causes blockade of EDHF-mediated responses; the characteristic 
blockade of EDHF is by the combination of apamin, an inhibitor of small-conductance 
Kca (SKca) channels (Castle, 1 9 9 9 )  and chaiybdotoxin a non-selective inhibitor of large 
and intermediate conductance K ca channels (Garcia et a l ,  1 9 9 1 )(B K ca  and IKca, 
respectively) and voltage gated channels (Kv) (Corriu et a l ,  1 9 9 6 ; Garland & Plane,
1996; Zygmunt & Hogestatt, 1996). In some preparations either apamin (bovine 
coronary artery) (Drummond et a l ,  2000) or chaiybdotoxin (human coronary artery)
(Miura et a l ,  1999) alone can inhibit EDHF-mediated responses. In preparations where 
the combination of chaiybdotoxin and apamin is required to block EDHF-mediated 
responses, the selective BKca inhibitor, iberiotoxin (Garcia et a l ,  1991), cannot 
substitute for chaiybdotoxin (Zygmunt & Hogestatt, 1996); thus, EDHF-mediated |
responses involve the opening of both SKca and IKca but not BKca channels.
There are no reports of Kca channels on vascular smooth muscle cells that are sensitive 
to charybdotoxin but not iberiotoxin. In other words, it is unlikely there are IKca 
channels on vascular smooth muscle cells. In contrast, both SKca and IKca are present in 
endothelial cells (Burnham et a l ,  2002; Cai et a l ,  1998). Indeed, it has been observed 
that endothelial chamiels are activated by rises in intracellular Ca^ "^  concentration 
(Busse et a l ,  1988). Furthermore, endothelial cell hyperpolarization elicited by either 
acetylcholine, in rat hepatic arteries (Edwards et a l ,  1998), or bradykinin, in the porcine 
coronary artery, (Edwards et a l ,  2000), is inhibited by the combination of 
charybdotoxin and apamin. In addition, the putative opener of IKca channels, 1-EBIO 
(Adeagbo, 1999) can induce hyperpolarization of endothelial cells associated with an
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endothelium-dependent hyperpolarization of smooth muscle cells (Coleman et a l , 2001 ; 
Edwards et a l ,  1999a). However, care should be taken with interpreting results with 1- 
EBIO as Walker and colleagues (Walker et a l ,  2001) found that it could induce 
relaxation of smooth muscle at concentrations below those required to produce 
endothelium-dependent hyperpolarization. Nevertheless, the majority of evidence 
suggests that when EDHF responses are blocked by the combination of charybdotoxin 
and apamin, this occurs through inhibition of SKca and IKca located on the endothelium, 
rather than on smooth muscle cells.
1.2.4.3 The nature of endothelium-derived hyperpolarizing factor
There have been many different hypotheses on the chemical nature of EDHF. 
Suggestions have included the endogenous cannabinoid, anandamide (Randall et a l ,  
1996), epoxyeicosatrienoic acids (Campbell et a l ,  1996), potassium ions (Edwards et 
a l ,  1998), nitric oxide (Cohen et a l ,  1997) and hydrogen peroxide (Matoba et a l ,  
2000); for a recent review see (Feletou & Vanhoutte, 2000)). Indeed, none of these 
candidates can be ruled out as all can be synthesised by the endothelium and can cause 
hypeipolarization of the underlying smooth muscle. However, the vast majority of 
evidence currently supports three hypotheses: (i) hyperpolarization is transmitted 
directly to the smooth muscle from the endothelial cell via gap junctions; (ii) the 
increase in endothelial intracellular Ca^”^ activates cytochi'ome P450 and the resultant 
metabolites are essential for EDHF-mediated responses; (iii) is released from 
endothelial cells by the opening of Kca channels and the elevated concentration of in 
the extracellular space hyperpolarizes smooth muscle by activating the inward rectifier 
( K ir )  or Na/K-ATPase on the smooth muscle cells. Of course, it is possible that some 
combination of these mechanisms may account for the EDHF-response in any particular
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tissue, and the relative importance of each mechanism may differ among different 
vascular beds.
(i) Gap Junctions
Hypeipolarization of the endothelium causes hypeipolarization of vascular smooth 
muscle with the same time course (Beny, 1990); perhaps by electrotonic spread of 
hyperpolarization through myo-endothelial gap junctions. Indeed, myo-endothelial gap 
junctions could provide the low-resistance electrical pathway that would be necessary to 
couple the endothelial cells to smooth muscle cells (Christ et a l ,  1996). Furthermore, it 
has been demonstrated that the number of myo-endothelial gap junctions increases as 
vessel diameter decreases in the mesenteric arterial bed of the rat (Sandow & Hill, 
2000); this correlates well with the observation that the contribution of EDHF to 
vasomotor control increases as vessel diameter decreases. It has been demonstrated that 
EDHF-mediated responses can be inhibited using the specific inhibitors of gap 
junctions, the GAP peptides (e.g.GAP 27) (Chaytor et a l ,  1998; Chaytor et a l ,  2001). 
However, the ability of GAP peptides to inhibit gap-junctions is only infeired from their 
ability to prevent dye coupling in cultured cells (Chaytor et a l ,  2001) and it is only an 
assumption that the myo-endothelial gap junctions are the target for GAP peptides; it is 
also possible that they could affect endothelial-endothelial or smooth muscle-smooth 
muscle gap junctions. Other agents such as 18a-glycyrrhetinic acid and carbonexolone 
have been used to investigate the role of gap junctions in EDHF-mediated response. 
However these agents are notoriously non-specific and can inhibit the Na/K-ATPase, 
therefore, care should be taken in interpreting results obtained with such agents.
Another possibility is that a diffusible substance (e.g. EDHF), rather than electrical 
current, could pass through myo-endothelial gap junctions. Such a mediator would have
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to be small in size and hydrophilic in order to pass through the aqueous pore of the gap 
junction and would need to be generated in large quantities over a sustained period in 
order to overcome extensive dilution when transferred to the underlying smooth muscle 
(Busse et a l ,  2002). Cyclic AMP appears to serve as a diffusible endothelium- 
dependent hyperpolarizing factor (Chaytor et a l ,  2001). However, it seems unlikely that 
transfer of cyclic AMP through myo-endothelial gap junctions undeipins the EDHF 
response, since relaxing smooth muscle with prostacyclin elevates cyclic AMP resulting 
in the opening of K a t p  channels. However, EDHF-mediated responses are unaffected by 
blockade of Katp channels therefore cyclic AMP is more likely to be involved in 
regulation of gap junctions than actually functioning as EDHF (Busse et a l ,  2002).
(ii) Cyclooxygenase P450 metabolites
It has been suggested that epoxyeicosatrienoic acids (EETs), short-lived metabolites of 
arachidonic acid produced by cytochrome P450, could account for EDHF-mediated 
responses in coronary arteries from a wide range of species including cattle (Bauersachs 
et al., 1994; Campbell et a l ,  1996) and pigs (Bauersachs et a l ,  1994; Popp et a l ,  1996). 
Unfortunately, most of the blockers of cytochrome P450 used in these experiments are 
notoriously non-specific. Nevertheless, EDHF-mediated responses were inhibited in 
experiments with newer, more selective blockers of cytochrome P450 such as 
sulfaphenazole, a selective inhibitor of cytochrome P450 2C9 (Fisslthaler et a l ,  2000), 
or with anti-sense oligonucleotides (Fisslthaler et a l ,  1999). It has also been 
demonstrated that EETs can relax and hyperpolarize coronary arteries by increasing 
open probability of Kca channels (Campbell et a l ,  1996; Fisslthaler et a l ,  1999). Taken 
together this evidence would suggest that EETs are a strong candidate for EDHF, at 
least in coronary arteries (Busse et a l ,  2002).
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There is no doubt that EETs are synthesised by endothelial cells (Campbell et al., 1996), 
however, there is little evidence that they can be released in sufficient amounts to cause 
relaxation and hyperpolarization of smooth muscle cells. Furthermore, the Kca channels 
activated by EETs are BKca (Zhang et a l ,  2001) rather than SKca or IKca, again 
indicating that diffusible EETs are unlikely to account for most EDHF-mediated 
responses. EETs could, however, act within the endothelium to regulate intracellular 
Ca^ "^ , possibly by regulating intracellular Ca^’*’ stores (Hoebel et a l ,  1997), by increasing 
endothelial Kca channel sensitivity to Ca^ "^  (Baron et a l ,  1997), or even modulating gap 
junction permeability (Popp et a l ,  2002).
(iii) as endothelium-derived hyperpolarizing factor
Small increases in extracellular potassium concentration can produce vasodilatation and 
increases in local blood flow that is physiologically significant. Indeed loss from 
contracting skeletal muscles increases blood flow to the active muscle (Juel et a l ,  2000; 
Skinner & Powell, 1967). Similarly, efflux of from active areas of the CNS produces 
localised vasodilatation, presumably helping to supply nutrients to these areas 
(Kuschinsky & Wahl, 1978; McCaiTon & Halpem, 1990). It has been proposed that 
opening of endothelial cell Kca currents leads to an accumulation of in the 
extracellular space between endothelial and smooth muscle cells, resulting in a 
hyperpolarization and relaxation of the smooth muscle by activating inward rectifier 
( K ir )  and Na/K-ATPase (Edwards et a l ,  1998; Nelson & Quayle, 1995). Indeed, 
EDHF-mediated responses can be attenuated in the rat hepatic artery by using barium 
(30 pM) to inhibit Kir and ouabain to inhibit the Na/K-ATPase (Edwards et a l ,  1998). 
Furthermore, in the rat mesenteric and hepatic arteries (Edwards et a l ,  1998), mouse
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mesenteric arteries (Ding et a l ,  2000), and porcine coronary arteries (Beny & Schaad, 
2000), exogenously applied (<25 mM) can mimic the effect of EDHF; i.e. it causes 
hypeipolarization (and relaxation) of the smooth muscle, indicating that EDHF may 
simply be released from the endothelium.
The idea that derived from the endothelium is EDHF has been challenged, and in 
many vascular preparations where EDHF-mediated responses can be observed, 
exogenously applied does not evoke consistent smooth muscle hypeipolarization or 
relaxation (Doughty et a l ,  2000; Edwards et a l ,  1999b; Harris et a l ,  2000; Lacy et a l ,  
2000). However, a simple explanation may account for such variability: In some tissues 
the researchers were studying vascular tone and therefore used a vasoconstrictor agent. 
In such experiments where tension recording and hypeipolarization were measured 
simultaneously, it was demonstrated that the ability of to mimic EDHF diminished 
as agonist-induced tone was increased (Dora & Garland, 2001; Richards et a l ,  2001). 
Therefore, it is possible that when vasoconstrictor tone is high, the resultant 
depolarisation and increase in intracellular Ca^’*' in smooth muscle cells causes 
activation of Kca, forming a “cloud” in the intercellular space already maximally 
stimulating their Kir or Na/K-ATPase. Thus, additional K'*' released from the 
endothelium following activation of SKca and IKca will not further stimulate these 
processes.
1.2.4.4 Endothelium-derived hyperpolarizing factor in vascular disease
Diseases that cause endothelial dysfunction are likely to affect EDHF-induced 
responses, just as they affect nitric oxide-mediated responses. However there is 
relatively little information on the role of EDHF in pathophysiology. There are reports
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of a reduction of endothelium-dependent vasodilatation that is nitric oxide- and 
prostacyclin-independent (Fukao et a l ,  1997) (Makino et a l ,  2000) in experimentally- 
induced diabetes, which may be indicative of a reduced role of EDHF in this condition. 
However, it has been reported that diabetes can potentiate EDHF-mediated relaxation in 
the rabbit renal artery (Alabadi et a l ,  2001). This may reflect a compensatory 
mechanism for the apparent loss of nitric oxide-mediated vasodilatation found in this 
study. In isolated coronary arteries from patients with atherosclerosis, endothelium- 
dependent responses are unaffected despite a reduction in the contribution of nitric 
oxide (Garland et a l ,  1995); the EDHF component of vasodilatation appears to 
compensate for loss of nitric oxide in these arteries (Selemidis & Cocks, 2002).
1.3 Vasodilator mechanisms in the eye
The anatomy of the vascular system of the bovine eye has already been discussed in 
Section 1.1.2. This section will describe the current understanding of the contribution of 
nitric oxide, prostacyclin and EDHF to vasomotor control in the eye.
1.3.1 Nitric oxide
There is a wealth of evidence to suggest that nitric oxide is an important regulator of 
vascular tone in the eye (for review see, Koss, 1999). Furthermore, nitric oxide synthase 
has been shown to be located in many regions of the eye (Koss, 1999), including the 
nerve supply to the arterial circle of the iris (Tamm et a l ,  1995). There is also heavy 
immunostaining for nitric oxide synthase throughout the vascular endothelium of the 
choroid in a wide range of species (Koss, 1999).
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1.3.1.1 Basal release
There is compelling evidence that there is a basal release of nitric oxide in the blood 
vessels of the eye, since inhibition of nitric oxide synthase causes a reduction in the 
basal blood flow in a wide range of species, as measured using radiolabelled 
micro spheres (Hardy et a l ,  1996; Nilsson, 1996; Seligsohn & Anders, 2000) or laser 
Doppler flowmetry (Koss, 1998; Luksch et a l ,  2000; Zagvazdin et a l ,  1996). It remains 
to be determined whether this tonic vasodilator influence of nitric oxide on the ocular 
vasculature in vivo is derived from the endothelium as a result of basal release, release 
stimulated by agonists (Benedito et a l ,  1991a; Gidday & Zhu, 1995), or flow (Rubanyi 
& Vanhoutte, 1986), or release from perivascular nitrergic nerves (Nilsson, 1996; Toda 
et a l ,  1998; Zagvazdin et a l ,  1996). Nevertheless, in studies using the porcine isolated 
perfused eye, where neural influences can be excluded (Meyer et a l ,  1993), and in 
isolated segments of ophthalmic, ciliary, retinal and irideal arteries from a variety of 
species including pig, cattle and rat (Benedito et a l ,  1991a) (Haefliger et a l ,  1993) (Hill 
& Gould, 1995; Su et a l ,  1994; Yao et a l ,  1991), where the effects of both flow and 
nerves can be excluded, augmentation of vasoconstrictor tone by inhibitors of nitric 
oxide synthase provides evidence of basal release of nitric oxide from the endothelium 
in the ocular circulation.
1.3.1.2 Agonist-stimulated endothelial release
There are numerous reports of agonist-induced, endothelium-dependent vasodilator 
responses which are inhibited by antagonists of nitric oxide synthase in ocular arteries 
in a wide range of species (Koss, 1999). For example, in vivo vasodilatations to 
acetylcholine in new born pigs (Gidday & Zhu, 1995), or to substance P in dogs 
(Kitamura et a l ,  1993), are sensitive to nitric oxide synthase inhibitors. In vitro, using 
the porcine isolated perfused eye preparation (cannulated via the ophthalmic artery),
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vasodilatations induced by bradykinin were inhibited by L-NAME. Furthermore, in 
isolated ocular vessels inliibition of nitric oxide synthase can inliibit vasodilatation to 
acetylcholine in cattle (Benedito et a l ,  1991a, b), pigs (Gidday & Zhu, 1995; Yao et a l ,  
1991), and guinea pigs (Tamai et a l ,  1999a); and to bradykinin in pigs (Haefliger et a l ,  
1993; Yao et a l ,  1991; Zhu et a l ,  1997).
1.3.1.3 Neural release
It is highly likely that neural release of nitric oxide modulates vasomotor tone in the 
eye. There is evidence showing localisation of nitric oxide synthase with the 
parasympathetic nerves that innervate the ocular blood vessels (Cuthbertson et a l ,  
1997; Tamm et a l ,  1995; Toda et a l ,  1994; Toda et a l ,  1996). Evidence from 
neuroanatomical studies suggests that these nerves arise from the ptreygopalatine 
ganglion via the facial nerve in mammals (Nilsson, 1996) and from the ciliary ganglion 
in birds (Zagvazdin et a l ,  1996). Furthermore, parasynipathetically mediated 
vasodilatation in the eye, in vivo, is inhibited by nitric oxide synthase inhibitors in 
rabbits (Nilsson, 1996) and pigeons (Zagvazdin et a l ,  1996). A role for neural release 
of nitric oxide in ocular vasomotor control is supported by experiments with isolated 
ocular arteries stimulated by transmural electrical stimulation; in these experiments, 
parasympathetic neural vasodilatations were attenuated by inhibitors of nitric oxide 
synthase in ciliary arteries of monkeys (Toda et a l ,  1998), cattle (Wiencke et a l ,  1994), 
dogs (Toda et a l ,  1999), and pigs (Su et a l ,  1994; Toda et a l ,  1997).
1.3.2 Prostacyclin and endothelium-derived hyperpolarizing factor
In contrast to the overwhelming evidence supporting the involvement of nitric oxide in 
ocular vasomotor control, there is little evidence of endogenous prostacyclin being of
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much importance. Exogenously added prostacyclin does, however, cause vasodilatation 
in bovine isolated small retinal arteries (Benedito et a l ,  1991), in the porcine isolated 
perfused eye (Meyer et a l ,  1993) and in the ocular circulation of newborn pigs (Hardy 
et a l ,  1996).
Prior to this study there have also been very few reports of EDHF-mediated 
vasodilatation being involved in ocular vasomotor control, indeed in the examples listed 
below the authors never suggested that EDHF mediated the vasodilator responses 
observed. In isolated porcine ciliary artery the endothelium-dependent vasodilatation is 
mediated primarily by nitric oxide (Zhu et a l ,  1997), but after inhibition of nitric oxide 
synthase, a residual vasodilator response insensitive to glibenclamide (an inhibitor of 
K a t p  channels) but abolished by TEA (an inhibitor of K c a )  was observed, which may 
have been mediated by EDHF. In addition, in guinea pig choroidal arterioles, the 
majority of the vasodilator response is resistant to inhibition of nitric oxide synthase and 
cyclo-oxygenase (Tamai et a l ,  1999b). This vasodilator response was attenuated by 
TEA, apamin or charybdotoxin; furthermore, the combination of apamin and 
charybdotoxin virtually abolished this vasodilatation, strongly indicating that it was 
mediated by EDHF.
1.4 Aim
The aim of the study was to characterise endothelium-dependent vasodilator responses 
in the ciliary vascular bed of the bovine eye. As will be seen, these were found to be 
mediated almost entirely by an EDHF-like substance.
40
In the course of this investigation, a chance observation revealed that endothelium- 
dependent vasodilatation induced by acetylcholine or bradykinin in the ciliary vascular 
bed of the bovine eye was blocked by ascorbate. This observation was intriguing since 
ascorbate is known to potentiate the actions of nitric oxide by protecting it under 
conditions of oxidant stress (Dudgeon et a i ,  1998; Fontana et a l ,  1999). In the eye, 
ascorbate delivered in the plasma is greatly concentrated by the ciliary epithelium in its 
production of aqueous humour. As the concentration of ascorbate in the aqueous 
humour is so high (~ ImM), studies of aqueous humour dynamics using the bovine 
isolated perfused eye preparation have routinely included ascorbate (50 pM) in the 
perfusion medium (Shahidullah & Wilson, 1999; Wilson et a l ,  1993). This was to 
ensure the aqueous humour formed was similar in composition to that formed in vivo.
The remainder of the study was thus devoted to characterising the ability of ascorbate to 
block EDHF in the ciliary vascular bed of the bovine eye and in several other 
preparations where EDHF contributes to vasodilatation.
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Chapter 2
Methods
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2.1 Bovine eye
2.1.1 Preparation of the bovine isolated arterially perfused eye
The ciliary vascular bed of the bovine eye was perfused using a modification of the 
constant flow method first described by Wilson et al. (1993). Bovine eyes were 
obtained from a local abattoir and transported to the laboratory at ambient temperature; 
previous work had shown that transport on ice caused the fatty tissue around the orbit to 
solidify, making cannulation difficult (Wilson et a l ,  1993). Also it is very likely that 
cooling would slow the return of the eye’s core temperature to 37°C during 
experiments, which was considered undesirable. In the laboratory excess tissue was 
removed from the globe of the eye, with care to avoid damaging the blood vessels 
mnning over the surface of the eye. However, a few mm of extraocular muscle was left 
attached to the globe to aid location of vortex veins. A long posterior ciliary artery was 
then selected, carefully cleaned, then cannulated at a point proximal to the pigmented 
region where it enters the sclera and distal to where it leaves the ophthalmic artery. The 
cannulae used were hand-made from polythene tubing (bore 2.5 mm, wall thickness 1 
mm). The eye was then placed in a heating jacket, and covered with tissue and foil for 
insulation. The eye cannulated via the ciliary artery was then perfused at 37°C with 
Ki-ebs solution containing mM: NaCl, 118; KCl, 4.7; CaCE, 2.5; KH2PO4, 1.2; MgS04  
1.2; NaHCOs, 25; glucose, 11.5; and gassed with O2 containing 5% CO2, to adjust the 
pH to 7.4 (Figure 2.1).
Perfusion of the eye was nonnally begun within 90 min of slaughter; successful 
perfusion was indicated by flow of a small amount of blood from the cut ends of the 
vortex veins. The flow was induced by peristaltic pumps (Watson-Marlow, model 502S; 
Figure 2.1) and was commenced at a rate o f -0.2-0.5 ml miiT  ^and gradually
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Figure 2.1 The bovine isolated perfused eye preparation and apparatus showing 
perfusion of the ciliary vascular bed through one long posterior ciliary artery. The 
perfusion pressure was measured by a pressure transducer via a sidearm located 
immediately proximal to the inflow cannula and was displayed and recorded using a 
PowerLab data acquisition system.
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increased in 5-10 increments to a final flow rate of 2.5 ml min'^ over a 50 min period. 
The flow was increased in this gradual manner to allow the eye to warm up and to 
prevent damaging the microvasculature of the eye. After the final flow rate was 
achieved, eyes were perfused for an equilibration period of at least 30 min before 
starting the experimental protocols. Perfusion pressure was measured by pressure 
transducers (Gould Statham, P32ID) via a side arm located immediately proximal to the 
inflow cannula and displayed and recorded using a computer system (PowerLab/800, 
ADInstniments, Hastings, UK; figure 2.1). Only eyes that had a basal perfusion 
pressure of 20-60 mmHg were used for further study.
2.1.2 Experimental Protocols with the bovine isolated arterially perfused eye 
2.1.2.1 Basal perfusion pressure
After the equilibration period, drugs were added either to the Ki'ebs reservoir for 
continuous infusion, or as bolus doses injected through rubber tubing immediately 
proximal to the infusion cannula (figure 2.1). Experiments were conducted to assess the 
effects of a range of drugs on the basal perfusion pressure. These drugs were: the nitric 
oxide synthase inhibitor, L-NAME (100 pM; Rees et a l ,  1990); the soluble guanylate 
cyclase inhibitor, ODQ (10 pM; Garthwaite et a l ,  1995) both toinvestigate the role of 
nitric oxide; and the non-selective phosphodiesterase inhibitor, papaverine (150 pM; 
Martin et a l ,  1986). In these experiments the drugs were infused for at least 20 min and 
any response allowed to stabilise before measurements of their effects on perfiision 
pressure were recorded.
2.1.2.2 Vasoconstrictor screen and general experimental procedure for 
experiments involving vasodilator responses
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Experiments were conducted to select a suitable vasoconstrictor agent. These involved 
constmcting cumulative concentiation-response curves to a range of commonly used 
vasoconstrictor agonists. These drugs were: the endogenous adrenoceptor agonist, 
noradrenaline; the synthetic ai-adrenoceptor agonist, phenylephrine; the thromboxane 
Ai-mimetic, U46619; the prostaglandin, prostaglandin p 2a; and the endogenous 
neurotransmitter agonist, 5-hydroxy tryptamine (5-HT). In these experiments 
vasoconstrictor responses to each concentration of agonist, infused continuously, were 
allowed to stabilise before a higher concentration was added. Noradrenaline and 5-HT 
are unstable in aqueous solution so ascorbic acid (50 pM) and EDTA (10 pM) were 
added to the perfusate to prevent them from oxidising.
The effect of the NOS synthase inhibitor, L-NAME was assessed on perfusion pressure 
elicited by 5-HT (300 nM), noradrenaline (100 pM) or U46619 (100 nM). These 
concentrations of the vasoconstrictor agonists were chosen so that the perfusion 
pressure was similar in each experiment. In these experiments the increase in perfusion 
pressure produced by the vasoconstrictors was allowed to stabilise before infusion of L~ 
NAME (100 pM) for 20 min or until tone re-stabilised.
Vasodilatation to bolus doses of acetylcholine was also assessed on perfusion pressure 
induced by sub-maximal concentrations of 5-HT, noradrenaline or U46619. In these 
experiments after vasoconstrictor tone stabilised, acetylcholine-induced vasodilatations 
were elicited by injecting 10 pi volumes of the appropriate concentration with a 
Hamilton micro-syringe.
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In ail subsequent experiments where vasodilatations were elicited, continuous infusion 
of U46619 at a concentration of 50-500 nM was chosen to achieve a sub-maximal 
perfusion pressure (-130 mmHg) that was suitable for conducting experiments with 
vasodilators. In some experiments full dose-response curves to: acetylcholine (1 pmol- 
100 nmol); bradykinin (0.1 pmol- 10 nmol); the K a t p  channel opener, levcromakalim 
(0.1-30 nmol; Katnik & Adams, 1997); the putative openers of IKca channels, 1-EBIO 
(1 nmol -  1 pmol; Adeagbo, 1999; Edwards et a l ,  1999a) and DCEBIO (0.1 nmol -  1 
pmol; Singh et a l ,  2001); the opener of BKca channels, NS1619 (1 -  100 nmol; Olesen 
et a l ,  1994b); and the endogenous cannabinoid, anandamide (1 -  100 mnol; Randall et 
a l ,  1996), were constructed. In other experiments only a single dose of acetylcholine 
(10 nmol), bradykinin (10 pmol) or the nitric oxide donor, glyceryl trinitrate (GTN, 10 
nmol) was used. The endothelial dependence of vasodilator responses was assessed by 
infusing the detergent CHAPS (0.3 %, 2 min), to selectively damage the endothelial cell 
layer (Randall & Hiley, 1988).
2.1.2.3 Characterisation of vasodilator responses
The effects of a number of blocking drugs were examined in order to characterise the 
nature of vasodilator responses to acetylcholine and bradykinin. These drugs were: the 
nitric oxide synthase inhibitor, L-NAME (100 pM); the inhibitor of soluble guanylate 
cyclase, ODQ (10 pM); the cyclooxygenase inhibitor, flurbiprofen (30 pM); the non- 
selective K c a  channel blocker, TEA (10 mM; Cook & Quast, 1990); the K a t p  channel 
blocker, glibenclamide (10 pM; Katnik & Adams, 1997); the non-selective intermediate 
and large Kca (IKca/BKca) and Kv channel blocker, charybdotoxin (10 nM; Smith et a l ,  
1986); the selective large conductance Kca (BK^ca) channel blocker, iberiotoxin (100 
nM; Candia et a l ,  1992); the selective small conductance Kca (SKca) channel blocker.
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Experiments were conducted to test the effects of ascorbate on vasodilator responses in 
the bovine eye. In such experiments ascorbate was included in the perfusion medium. 
As will be seen in chapter 4, acetylcholine elicited only vasodilator responses when 
bovine eyes were perfused with normal Krebs solution. In contrast, when eyes were
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apamin (100 nM; Robertson & Steinberg, 1990); the Kir channel blocker, Ba^^ (30 pM; IEdwards & Hirst, 1988); the Na/K ATPase inhibitor, ouabain (lOpM; Feletou & 4-I
- ÏVanhoutte, 1988); and non-selective blockade of K channels by a high K (30 mM;
Adeagbo & Triggle, 1993) concentration in the Krebs solution. In experiments with 30 
mM K'*', a proportionate reduction in the NaCl concentration was made in order to 
maintain isotonicity. For each experiment the blocking drug was infused for at least 20 
min before the effects on the vasodilator response were tested. In some experiments the 
blocking dmgs themselves (L-NAME, ODQ, TEA, high [K^], charybdotoxin and 
iberiotoxin) affected the U46619-induced perfusion pressure, these effects are described 
in the first Results section (Chapter 3). Therefore, where necessary, the concentration of 
U46619 was adjusted so that the perfusion pressure was similar to that seen in control 
experiments.
2.1.2.4 Characterisation of effects of ascorbate on EDHF-mediated vasodilator 
responses
As will be shown in Chapter 3 the vasodilator responses to both acetylcholine and 
bradykinin in the bovine eye are mediated entirely by an EDHF-like substance and do 
not involve a contribution of a nitric oxide or cyclooxygenase product. Therefore, 
inliibitors of nitric oxide synthase or cyclo-oxygenase were not used to study the EDHF- 
like responses in this preparation.
perfused from the outset of the experiment with Krebs solution containing ascorbate (50 
pM, > 120 min), acetylcholine produced vasoconstrictor responses, immediately 
followed by a residual vasodilator response.
Experiments were conducted to assess the time course of the ability of ascorbate to 
reverse acetylcholine-induced vasodilatation to vasoconstriction. In control 
experiments, acetylcholine (10  mnol)-induced vasodilator responses were elicited every 
15 min during a 120 min study period in eyes perfused from the outset with Krebs 
solution in order to assess their reproducibility. When effects of ascorbate were 
assessed, control acetylcholine-induced vasodilator responses were allowed to stabilise 
before inclusion of ascorbate in the perfusion medium. The effects of ascorbate on 
acetylcholine-induced responses, elicited every 15 min, were then assessed during the 
ensuing 120 min. During this period, the vasodilator response declined and a 
vasoconstrictor response developed, often resulting in a biphasic response. 
Consequently, vasodilator and vasoconstrictor components were measured separately 
and graphed at each of the 15 min time points. Similar experiments were conducted to 
deteimine if ascorbate had any effect on vasodilator responses to bradykinin (10  pmol) 
in the bovine eye.
The ability of other drugs to mimic the effects of ascorbate on acetylcholine-induced 
responses were also assessed in similar time course experiments. These drugs were: the 
redox-inactive analogue, dehydroascorbate (50 pM;), the thiol reducing agents, 
glutathione (1 mM; Kosower & Kosower, 1978), N-acetyl-L-cysteine (ImM; 
Weinander et a l ,  1994) and dithiothreitol (100 pM; Faulstich & Heintz, 1995), and the 
antioxidant enzymes, superoxide dismutase (250 units ml'^) and catalase (1250 units ml"
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)^. Experiments were also conducted to assess if the blocking effects of ascorbate could 
be reversed by washing. In such experiments, from the outset, eyes were perfused with 
Krebs containing ascorbate (50 pM, 120 min). When reproducible acetylcholine (10 
nmol)-induced control vasoconstrictor responses had been obtained, perfusion then 
switched to ascorbate-free Ki'ebs, Changes in acetylcholine-induced responses were 
then assessed for the ensuing 120 min.
Experiments were conducted to assess the concentration-dependence of the ability of 
ascorbate to reverse acetylcholine-induced vasodilatation to vasoconstriction. In control 
experiments full dose-response curves to acetylcholine were constructed in eyes 
perfused with normal Krebs solution. Full dose-response curves were also constructed 
in eyes that had been perfused from the outset (>120 min) of the experiment with Krebs 
containing 10, 50 or 150 pM of ascorbate. These dose-response curves were compared 
to those obtained in control eyes. The vasodilator and vasoconstrictor responses to 
acetylcholine were plotted and compared separately.
Experiments were conducted to assess the nature of the vasoconstrictor response. In 
these experiments eyes were perfused from the outset with Krebs solution containing 
ascorbate (50 pM, >120 min). When reproducible acetylcholine (10 nmol)-induced 
vasoconstrictor responses had been obtained, the effect of the cyclooxygenase inhibitor, 
flurbiprofen (30 pM), and the non-selective muscarinic antagonist, atropine (100 nM), 
were assessed.
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2.1.2.5 Selectivity of effect of ascorbate on EDHF-mediated vasodilatation
Experiments were conducted to investigate the selectivity of the blockade of EDHF- 
mediated vasodilatation by ascorbate. In these experiments a control dose-response 
curve was constructed to the ATP-sensitive potassium channel ( K a t p )  opener, 
levcromakalim (0.1-30 nmol). This was compared to those obtained following the 
infusion of ascorbate (50 pM, >120 min). The effects of 50 pM ascorbate were also 
assessed on vasodilatation caused by a single dose of the nitric oxide donor, glyceryl 
trinitrate (10 nmol). The effect of the IKca blocker, charybdotoxin (50 nM) was also 
assessed on vasodilatation induced by DCEBIO.
2.1.2.6 Effect of preventing the concentration of ascorbate on EDHF-mediated 
vasodilatation
As the ciliary body of the eye is known to actively transport ascorbate (Millar & 
Kaufman, 1995), it is possible that accumulation of ascorbate in the aqueous humour at 
a concentration greater than that infused (50 pM), is a prerequisite for its ability to 
block vasodilator responses. This hypothesis was assessed in a series of experiments 
where the ability of the eye to accumulate ascorbate was impaired. Firstly, as the ciliary 
hody secretes ascorbate into the posterior chamber of the eye (figure 2 .2) the ability of 
the aqueous humour to accumulate ascorbate was prevented by continually flushing the 
posterior and anterior chambers with Krebs solution (lacking ascorbate) at a rate of 0.25 
ml min"\ This was done by inserting an inflow cannula (23 G needle) through the 
cornea and placing it so that its tip sat between the iris and the lens in the posterior 
chamber. A second (outflow) cannula (26G needle) was inserted thiough the cornea and 
placed so as to sit in front of the lens and iris in the anterior chamber (figure 2.2). The 
second experimental approach involved making an incision in the cornea and removing
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the lens, thus allowing the aqueous humour to drain freely. This prevented any possible 
accumulation of ascorbate by effectively destroying the posterior and anterior chambers. 
In these eyes, a second incision was then made around the optic nerve at the point where 
it inserts into the sclera. This formed an opening through which the vitreous humour 
was removed, producing a preparation where there were no intact ocular chambers, 
thereby preventing accumulation of ascorbate and removing the potential ascorbate 
“reservoirs” of vitreous and aqueous humour. In both these experiments the effects of 
ascorbate on acetylcholine-induced vasodilatation were assessed as described for the 
time-course experiments. It should also be noted that in the flushing experiments the 
aqueous and vitreous humours were sampled for assay of ascorbate (see section 2.4.4).
2.2 Perfused mesenteric arterial bed of the rat
2.2.1 Preparation of the rat isolated perfused mesenteric arterial bed
Male Wistar rats (200-350 g) were killed by concussion followed by exsanguination. 
The mesenteric arterial bed was then prepared using a modification of the method 
described by McGregor (1965). An incision was made along the abdomen and the 
stomach and liver were removed to aid location of the superior mesenteric artery. Once 
this artery was located it was cannulated in situ (using a cannula made from polythene 
tubing bore 2.5 mm, wall thickness 1 mm) at its junction with the aorta. The mesenteric 
arterial vasculature was then dissected away from the intestines. It was then suspended 
in a heating jacket, allowed to hang freely and perflised at 37°C with Krebs at a flow 
rate of 5 ml min“^ (using the same apparatus as for bovine eye preparations). There was 
no need to increase the pressure in a stepwise manner, as there was little chance of 
damaging the microvasculature,
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Figure 2.2 Diagram of the anterior segment of the eye showing the projection of the 
ciliary body into the posterior chamber and the location of cannulae during flushing 
experiments. The posterior chamber of the eye is defined as the aqueous-filled space 
behind the iris. The anterior chamber of the eye is the aqueous-filled chamber in front of 
the iris and lens, bound anteriorly by the cornea.
53
because only the arterial vessels were present. The mesenteries were then perfused for 
an equilibration period of at least 30 min before experiments were begun. As with 
the bovine eye the perfusion pressure was measured by pressure transducers via a side 
arm proximal to the infusion cannula.
2.2.2 Experimental protocols with the rat isolated perfused mesenteric arterial bed
Experiments were conducted with the rat isolated perfused mesenteric vascular bed in 
order to determine if the EDHF-mediated vasodilator responses to acetylcholine were 
also blocked by ascorbate in this preparation. In order to observe vasodilator responses, 
perfusion pressure was first raised to -120 mmHg using phenylephrine (3-10 pM). All 
experiments investigating the actions of ascorbate were conducted on tissues treated 
with L-NAME (100 pM) and indomethacin (10 pM) in order to block any vasodilator 
contribution by nitric oxide and prostanoids. Under these conditions acetylcholine- 
induced vasodilatation is mediated by EDHF (McCulloch et a l ,  1997
Control dose-response curves for EDHF-mediated vasodilatation to acetylcholine (100 
fmol -  100 nmol) were constructed in mesenteries perfused with Ki'ebs solution. These 
were compared with those obtained in preparations perfused with Krebs solution 
containing ascorbate (50 pM, 180 min). In addition, experiments were conducted to 
determine the time course over which ascorbate inhibits acetylcholine-induced, EDHF- 
mediated vasodilatation. In order to assess their reproducibility, control vasodilator 
responses to acetylcholine (10 nmol) were elicited eveiy 15 min during a 180 min 
period in mesenteries perfused from the outset with normal Krebs solution. When the 
effects of ascorbate were to be assessed, control acetylcholine-induced vasodilator 
responses were allowed to stabilise before addition of ascorbate (50 pM) to the Ki'ebs
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assessed every 15 min during the ensuing 180 min.
2.3.1 Preparation of porcine left anterior descending coronary artery rings
Sections of myocardium containing the left anterior descending coronary artery were 
cut from porcine hearts at a local abattoir and transported to the lab in Ki’ebs solution. 
The left anterior descending coronary artery was dissected out, cut into 2.5 mm ring 
segments, suspended between two steel hooks within 10 ml organ baths and maintained 
at 37°C in Krebs solution gassed with O2 containing 5% CO2. Some tissues were not 
used on the day they were obtained, in which case they were stored in Krebs solution at 
4°C and used the next day. The tension was recorded isometrically using Grass FT03C 
transducers and displayed and recorded using a computerised data acquisition system 
(MacLab/8e, ADInstruments). The resting tension was adjusted to 2g and tissues were 
allowed to equilibrate for 60 min before proceeding with experimental protocols, during 
which time the tension was readjusted to 2 g, if  necessary.
2.3.2 Experimental protocols with the porcine left anterior descending coronary 
artery
In order to observe vasodilator responses, the rings of coronaiy artery were contracted 
to about 60% (6.6 ± 0.5 g) of the maximal U46619-induced tone using concentrations of 
10-100 nM. Some of the blocking agents used, namely charybdotoxin and L-NAME,
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solution. The effects of ascorbate on acetylcholine-induced vasodilatation were then
2.3 Porcine coronary artery
N.B All experiments with the porcine coronary artery were conducted by my colleague 7
Silvia Nelli in a collaborative study.
enhanced the U46619-induced tone. Consequently, when these drugs were used, the 
concentration of U46619 was adjusted to ensure that the level of tone was similar to that 
of control experiments.
The effects of ascorbate were also assessed on EDHF-mediated, bradykinin-induced 
vasodilatation in the presence and absence of the SKca and BKca/IKca blocking drugs 
apamin and charybdotoxin (both 100 nM), each alone and in combination. In these 
experiments ascorbate (150 pM) was included in the Krebs solution used to bathe the 
arterial rings and was present for at least two hours before vasodilator responses were 
elicited.
Vasodilatation to bradykinin in the porcine coronary artery has a nitric oxide-mediated 
and an EDHF-mediated component. Therefore, to assess EDHF-mediated vasodilatation 
to bradykinin, the nitric oxide synthase inhibitor, L-NAME (100 pM), and the
'Ï:cyclooxygenase inhibitor, indomethacin (3 pM) were present throughout all 
experiments. |
In control rings, EDHF-dependent vasodilatations were elicited by the addition of
•?
bradykinin (0.1- 300 nM). The effects of the small conductance calcium-sensitive 
potassium channel (SKca) inhibitor, apamin (100  nM), and the large and intermediate 
conductance calcium-sensitive potassium channel (BKca/IKca) inhibitor, chaiybdotoxin 
(100 nM), each alone and in combination were assessed. Apamin and charybdotoxin 
were present for at least twenty min before effects on vasodilator responses were tested.
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2.4 Spectrophotometric assay o f ascorbate
In some experiments samples (-1.5 ml) of aqueous and vitreous humour were removed 
from bovine eyes using a syringe and their ascorbate content was measured using a 
modification of an established spectrophotometric assay for ascorbate (Ortega-Barrales 
et a l ,  1998; Pascual-Reguera et a l ,  1997). The basis of this assay is that ascorbate can 
reduce Fe(III) to Fe(II), which reacts with ferrozine in acidic conditions (see below) to 
produce a magenta coloured product (Pascual-Reguera et a l ,  1997).
Ascobic acid + 2Fe^^+ 6Fz^" -> dehydroascorbate + [FeFzs'^'jz + 2H’*'
2.4.1 General procedure
0.5 ml of samples or authentic ascorbate standards (2.5-500 pM) were added to 
centrifuge tubes. To these, 0.5 ml volumes of Fe(III)Cl3 (1 mM), sodium ferrozine (10 
mM) and hexamethylenetetramine buffer (HMTA, 0.23 M, pH 5), were added. The final 
volume was adjusted to 5 ml with distilled water and the samples were mixed by 
vortexing. The tubes were incubated at 25°C for 10 min, then centrifuged at 100 g for 
15 min at 4°C (lEC Centra-8R). Absorbance was then measured at 562 nm using a 
spectrophotometer (Pye Unicam, model SP6-550). Authentic ascorbate standards were 
prepared from a 100 mM stock that was prepared daily. The HMTA buffer was 
prepared by dissolving 3.5 g in 4 M HCl and made to a final volume of 100 ml with 
distilled water and the pH of the buffer was adjusted to 5 by addition of a few drops of 
NaOH (4 M). The buffer is only stable for a week at 4°C (Ortega-Banales et a l ,  1998), 
therefore a solution was made weekly. The feiTozine solution is stable for a month at 
4°C (Ortega-Ban'ales et a l ,  1998), therefore fresh ferrozine solution was prepared at 
least once a month.
2.4.2 Standard curve and absorption spectra
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Experiments were first conducted to assess the absorption spectrum of the magenta 
Fe(II)/ferrozine complex foimed in the assay, when ascorbate (50 pM) was present, 
using a dual-beam scanning spectrophotometer (Shimadzu, UV-240IPC). The single 
absorbance peak was maximal at 562 nm (range of scan: 400-800 nm), confirming that 
indicated by Pascual-Reguera et al (1997; Figure 2.3). Experiments were performed to 
ascertain the upper and lower detection limits of the assay and the linearity of the 
standard curve (figure 2.4). In these, known concentrations o f ascorbic acid (2.5-500 
pM, 0.5 ml) were added to the assay mixture. The limit of detection was -5-25 pM 
ascorbate and the standard curve linear to 500 pM (figure 2.3). If absorbance of samples 
exceeded 1 absorbance unit, they were diluted with distilled water to bring them into the 
linear range; the absorbance value was then multiplied by the dilution factor.
2.4.3 Measurement of ascorbate concentration from samples of vitreous and 
aqueous humours
Samples of vitreous humour were obtained by inserting a needle (19G) into the sclera 
toward the rear of the eye and removing about 1.5 ml with a 2.5 ml syringe. Care was 
taken to place the needle to minimise the risk of removal of retinal or other cellular 
tissue. When sampling aqueous humour, each sample was obtained from both the 
posterior and anterior chambers, as it is reported that there is a slight difference in 
ascorbate concentration in each chamber (Davson, 1980). The aqueous humour was 
collected by piercing the cornea with a needle (23G) and placing it in the posterior 
chamber, where some aqueous (-0.75 ml) was removed with a 2.5 ml syringe. The
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Figure 2.3 Absorbance (Abs) spectmm (400-800 nm) for the magenta Fe(II)/feiTozine 
complex formed in the presence of a single concentration of authentic ascorbate (50 
pM). At this concentration of ascorbate the assay produced a single large absorbance 
peak, which was maximal at 562 nm. A scan of a blank containing all assay chemicals 
but no ascorbate shows that there was no significant absorbance, at any wavelength 
above 500 nm.
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Figure 2.4 Standard curve for the spectrophotometric measurement of ascorbate. The 
graph shows the absorbance produced by known concentrations of ascorbate (2.5 -  500 
jliM) under the assay conditions described in section 2.4.2. N.B. the absorbance values 
over one absorbance unit were calculated from diluted standard samples.
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needle was then relocated to the anterior chamber and an equal volume aqueous 
removed to give a final sample volume of about 1.5 ml. As the concentration of 
ascorbate was expected to be around 1 mM (Davson, 1980; Halliwell & Gutteridge, 
1989) the samples of both aqueous humour and vitreous humour were diluted (1:10) 
with saline (0.9%), to give an absorbance value which would fall in the linear part of the 
standard curve; the absorbance value obtained was then multiplied to coiTect for the 
dilution. In order to validate that the absorbance levels measured in samples were truly 
reflective of the presence of ascorbate, experiments were conducted to determine if they 
were affected by ascorbate oxidase (1.5 u ml"\ 20 min, 25°C). In these experiments the 
absorbance value obtained from the diluted samples was then compared to an equivalent 
concentration of standard ascorbate (100 qM) that had also been incubated with 
ascorbate oxidase (figure 2.5). As degree of the reduction of absorbance by ascorbate 
oxidase was similar in both samples and authentic ascorbate standards, it was 
considered that the signal did indeed represent ascorbate. The inability of ascorbate 
oxidase to fully digest all the ascorbate present, even in standards, may result from end 
product inhibition; it is unlikely to be due to insufficient ineubation time or the amount 
of aseorbate oxidase used, longer incubation times or as higher concentrations of 
enzyme had no further effect on the ascorbate signals generated (data not shown).
2.5 Drugs and solvents
Acetylcholine chloride, ascorbic acid, ascorbate oxidase (from Cucurbita sp.), apamin 
(from bee venom), atropine sulphate, barium chloride, bradykinin acetate, catalase 
(from bovine liver), CHAPS (3-[(cholamidopropyl)dimethyl-ammonio]l-propane 
sulphonate), dehydroascorbate, dithiothreitol, DMSO (dimethyl sulfoxide) EDTA 
(ethylenediamine-tetraacetic acid disodium salt), glutathione,
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Figure 2.5 Histogram showing the digestion of ascorbate in authentic ascorbate 
standards and samples by ascorbate oxidase (1.5 u ml ', 20 min, 25°C). As the samples 
of aqueous and vitreous humour were expected to have a coneentration of ~1 mM they 
were diluted 1:10 with saline (0.9 %) before being added to the reaction mixture to give 
an absorbance value fell within the linear part of the standard curve. For comparison, a 
concentration of authentic ascorbate (100 qM) that would be similar to those in the 
diluted samples was incubated with ascorbate oxidase.
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hexamethylenetetramine (HMTA), 5-hydroxytryptamine (5-HT) creatinine sulphate 
complex, indomethacin, L-NAME (N'^-nitro-L-arginine methyl ester), N-acetyl-L- 
cysteine, noradrenaline hydrochloride, NS1619 (1,3-dihydro-1 -[2-hydroxy-5-
(trifluromethyl)phenyl]-5-(trifluromethyl)-2H-benzimidazol-2-one), ouabain,
papaverine (free base), phenylephrine hydrochloride, prostaglandin Fza, sodium 
feiTozine (3-2(pyridyl)-5,6-bis(4-phenylsulphonic acid)-1,2,4-triazine), superoxide 
dismutase (from bovine eiythrocytes), and U46619 (9,11 -dideoxy-11 a,9a-epoxy- 
methanoprostaglandin F2a) were all purchased from Sigma (Poole, UK). Charybdotoxin 
(synthetic) and iberiotoxin (synthetic) were purchased from Latoxan (Valence, France). 
ODQ ( 1 -H-[ 1,2,4]oxadiazole[4,3-a]quinoxalin-1 -one) was purchased from Alexis 
(Nottingham, U.K). Anandamide (water soluble emulsion), DCEBIO (5,6-dichcloro- 
1 ethyl-l,3-dihydro-2H-benzimidazol~2-one) and 1-EBIO (l-ethyl-2-benzimidazolinone) 
were all purchased from Tocris (Avonmouth, UK). Flurbiprophen was a gift from the 
Boots Pure Drug Company (Nottingham U.K.). Glyceryl trinitrate (10 % w w“' in 
lactose) was a gift from NAPP laboratories (Cambridge, UK). Glibenclamide was a gift 
from Hoechst (Hounslow, U.K.). Levcromakalim was a gift fi'om GlaxoSmithKline 
(Harlow, U.K.). All drugs were dissolved and diluted in 0.9 % saline except: DCEBIO 
(100 mM stock), glibenclamide (3 mM stock) and levcromakalim (10 niM stock) which 
were dissolved in 70 % ethanol; U46619 (1 niM stock) was dissolved in 50 % ethanol; 
papaverine (100 mM stock) and 1-EBIO (100 mM stock) were dissolved in DMSO; 5- 
HT (10 mM stock) and ferric chloride hexahydrate (100 mM stock) were dissolved in 
HCl (10 mM); and indomethacin (10 mM stock) was dissolved in Na2C03  (1 M) 
solution.
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2.6 Statistical analysis
All results are expressed as mean ± s.e.mean of n separate observations; n or the number 
of observations represent the number of eyes studied, except for data from the rat 
mesentery and porcine coronary arteiy where n corresponds to number of animals and 
the number of arterial rings, respectively.Vasoconstrictor responses are given in mmHg 
or as percentage (%) increase of U46619-induced perfusion pressure. Vasodilator 
responses are expressed as percent (%) reduction of U46619- (bovine eye) or 
phenylephrine-induced (rat mesentery) perfusion pressure or U46619-induced tone 
(porcine coronary artery). Graphs were drawn and statistical comparisons were made 
using Student’s t-test, either paired or unpaired, or one-way analysis of variance with 
Bonferroni’s post-test, as appropriate, with the aid of a computer program. Prism 
(GraphPad, San Diego, USA). A probability (P) less than or equal to 0.05 was 
considered significant.
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Chapter 3
Results: 1
Characterisation of endothelium-derived 
hyperpolarising factor (EDHF)-like 
vasodilatations in the ciliary vascular bed of
the bovine eye
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In order to characterise endothelium-dependent vasodilatation in the bovine eye it was 
first necessary to investigate how the ciliaiy vascular bed behaves under basal perfiision 
conditions, factors such as intrinsic tone or basal release of vasodilator substances could 
affect the conditions used in later experiments. It was also nessecery to try and optimise 
the experimental conditions, such as the vasoconstrictor and vasodilator agonists used, 
in order to obtain the best data in subsequent experiments.
3.1 Characterisation of basal perfusion pressure
The basal perfusion pressure of the ciliary vascular bed of the bovine eye at a constant 
flow of 2.5 ml min  ^ was 31.8 ± 1.5 mmHg {n = 105). Infusion of a general smooth 
muscle relaxant, the non-selective inhibitor of phosphodiesterases, papaverine (150 pM, 
20 min), caused a small but signifreant fall in this basal perfusion pressure (change of -
5.0 ± 1.0 mmHg, n = 5, P<0.01, paired t-test; Figure 3.1). Addition of the inhibitor of 
nitric oxide synthase, L-NAME (100 pM, 20 min), to the perfusate caused no 
significant change in the basal perfusion pressure (change of -0.6 ±3.3  mmHg, n = 8; 
Figure 3.1). However, the inhibitor of soluble guanylate cyclase, ODQ (10 pM, 20 min), 
produced a small but significant rise in the basal perfusion pressure (14.6 ±3 .6  mmHg, 
M =10, P<0.01, paired t-test; Figure 3.1).
3.2 Characterisation of responses to vasoconstrictor agonists
Concentration-response cuiwes were constructed in the ciliary vascular bed of the 
bovine eye for a number of agonists commonly used to induce vasoconstrictor 
responses. These drugs were; the thromboxane A2 mimetic, U46619; prostaglandin Fa»; 
the endogenous adrenoceptor agonist, noradrenaline; the synthetic a  1-adrenoceptor
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agonist, phenylephrine and 5-HT. Each of these drugs produced concentration- 
dependent rises in perfusion pressure (Figure 3.2a and table 3.1).
As will be seen in the Discussion (Chapter 5) only noradrenaline, 5-HT and U46619 
were used for further study. A single concentration of each vasoconstrictor was infused 
constantly to cause a sub-maximal rise in perfusion pressure; the concentration of each 
vasoconstrictor was chosen to give a similar perfusion pressure in each experiment 
(Table 3.2). Additional infusion of the nitric oxide synthase inhibitor, L-NAME (100 
pM) caused a significant increase in the sub-maximal perfusion pressure for all three 
vasoconstrictor agonists (Table 3.2). In experiments to assess vasodilator responses, the 
perfusion pressure was raised with concentrations of noradrenaline, 5-HT, or U46619 
which produced a submaximal vasoconstriction. In these experiments, bolus injections 
of acetylcholine (1 pmol -  10 nmol) produced dose-dependent falls in perfusion 
pressure (Figure 3.2b). However, the acetylcholine (10 nmol)-induced vasodilatation 
was greater when vasoconstriction was induced by U46619 (maximum fall of 59.5 ± 4.9 
%) than when vasoconstriction was induced by noradrenaline (maximum fall of 29.0 ±
5.2 %) or 5-HT (maximum fall of 10.5 ± 4.6 %).
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Figure 3.1 Histograms showing the effects a range of drugs on the basal perfusion 
pressure of the ciliary vascular bed of the bovine eye. (a) Effect of the non-selective 
phosphodiesterase inhibitor, papaverine (150 pM). (b) Effect of the nitric oxide 
synthase inliibitor, L-NAME (100 pM). (c) Effect of inhibition of soluble guanylate 
cyclase using, ODQ (10 pM). Data represent the mean ± s.e.mean of five to ten 
observations. "^*E<0.01 indicates a difference from control (paired t-test).
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Figure 3.2 (a) Cumulative concentration-response curves showing vasoconstriction 
induced on the ciliary vascular bed of the bovine eye by: the endogenous adrenoceptor 
agonist, noradrenaline (10 nM - lOOpM); the synthetic ai-adrenoceptor agonist, 
phenylephrine (100 nM -  1 mM); the thromboxane Ai-mimetic, U46619 (I nM -  10 
pM); prostaglandin p2a (1 nM -  10 pM); and 5-HT (10 nM -  10 pM). pECso and 
maximum constrictions are provided in Table 3.1. (b) Dose-response curves showing 
vasodilatation to acetylcholine (ACh, 1 pmol-100 nmol) in the presence of submaximal 
concentrations of the vasoconstrictors U46619 (maximum vasodilatation = 65.6 ± 5.7%, 
pED$o = 9.4 ± 0 .2 , n = S) noradrenaline (vasodilatation of 30.0 ± 5.2 at 1 0 0  nmol ACh, 
n = S) and 5-HT (vasodilatation of 10.5 ± 4.6% with 100 nmol ACh, n = 5). pEDso 
values could not be calculated for the ACh-induced vasodilations in the presense of 
noradrenaline and 5-HT as no maximal vasodilatation was obtained. Data represent the 
mean ± s.e.mean of five to fourteen observations.
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Drug Maximum constriction: mmHg pECso n
noradrenaline 102.2 ±20.9 5.4 ±0.3 6
Phenylephrine 54.4 ± 6 . t N/A 14
U46619 187.6 ±5.6 5.6 ±0.3 6
prostaglandin p2a 90.8 ± 22.3"^ N/A 6
5-HT 121.4 ±7.7 6.5 ± 0.1 5
Table 3.1 The maximal vasoconstrictor response and the pECso, as predicted by 
GraphPad Prism, in the ciliary vascular bed of the bovine eye, for a range of 
vasoconstrictor agonists; the adrenoceptor agonists, noradrenaline and phenylephrine; 
the thromboxane A2-mimetic, U46619; prostaglandin p2a; and 5-HT. N.B Maximal 
contractions could not be obtained for phenylephrine or prostaglandin p 2a the stock 
concentrations required were insoluble, therefore Prism could not calculate pEC^o 
values were not calculated for these dmgs. ^The constriction induced by phenylephrine 
at a concentration of ImM. ^^The constriction induced by prostaglandin p2a at a 
concentration of 10 pM, Data are expressed as the mean ± s.e.mean of five to fourteen 
observations.
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Drug Perfusion pressure: 
mmHg
Perfusion pressure 
+ L-NAME: mmHg
n
noradrenaline 98 ± 15.4 134.3 ± 19.7* 4
5-HT 107.7 ±9.3 151.6 ± 10.4* 6
U46619 139.2 ±26.8 163.0 ±27.5* 8
Table 3.2 Table showing the effect of infusion of the nitric oxide synthase inhibitor, L- 
NAME (100 pM) on perfusion pressure induced by noradrenaline (100 pM), 5-HT (300 
nM) and U46619 (100 nM) in the ciliary vascular bed of the bovine eye. Data represent 
the mean + s.e.mean of four to eight observations. *P<0.05 represents a significant 
increase in perfusion pressure in the presence of L-NAME (paired t-test).
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3.3 Endothelial dependence of vasodilator responses to acetylcholine and 
bradykinin and effects of L-NAME, ODQ and flurbiprofen
As indicated in Chapter 3, all further experiments in the bovine eye were conducted 
using U46619 as the vasoconstrictor agent, as bigger vasodilator responses to 
acetylcholine could be elicited when using this drug. Following infusion of U46619 (50- 
500 nM), which increased the perfusion pressure to 131.8 ± 16.3 mmHg {n = 8), bolus 
injections of acetylcholine (1 pmol-100 nmol) immediately proximal to the preparation 
produced dose-dependent falls in the perfusion pressure (pED^o 9.42 ± 0.16, 
maximum fall of 64.1 ± 4.3 %, Figure 3.3a, 3.4a). As L-NAME (100 pM, 20 min) and 
ODQ (10 pM, 20 min) enhanced the U46619-induced perfusion pressure (see sections 
3.1, 3.2), when experiments were conducted with these agents the concentration of 
U46619 was adjusted such that the final perfusion pressures obtained were not 
significantly different to control preparations (134.9 ± 10.9 mmHg, « = 9, and 116.4 ±
17.3 mmHg, « = 5, respectively). Under these conditions, neither L-NAME (Figure 
3.3b, 3.4a) nor ODQ (Figure 3.4a) had any effect on the vasodilator actions of 
acetylcholine. Furthermore, the fall in perfusion pressure induced by 10 nmol 
acetylcholine (45.6 ± 3 .2  %, n=18) was unaffected by the cyclo-oxygenase inhibitor, 
flurbiprofen (30 pM, 20 min) alone, nor by the combination of flurbiprofen and L- 
NAME (Figure 3.5a).
72
O)X
I  ac ACh nm ol 1000.1 1 10 ^2gl20HW0) looH a  
C 8 0"o
g  6 0 "
Q)OL 4 0 "
1000 s
w W  U 4 6 6 1 9
2 0 0  n M
CD
2  1 5 0 -
3  W
8100-
C  5 0 -0
1  0-
ACh nm ol
0.01 0.1 ^ 10 iOO 
W Ê K ^ r y  I L-NAME
hU 4 6 6 1 9  i * I O O n M  
2 0 0  n M
Figure 3.3 Original traces showing acetylcholine-induced vasodilatation in the bovine 
isolated perfused eye. The perfusion pressure was increased using the thromboxane A2- 
mimetic, U46619 (200 nM), prior to addition of graded doses of ACh. (a) Dose- 
dependent vasodilatation produced by ACh (0.01-100 nmol), (b) Addition of the nitric 
oxide synthase inhibitor, L-NAME (100 pM), produced vasoconstriction but had no 
effect on ACh-induced vasodilatation.
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Figure 3.4 Control dose-response curves showing vasodilatation induced by bolus 
doses of (a) ACh (control Rmax= 65.6 ± 5.7 %, pEDso =  9.4 ± 0 .2 ;  1 pmol-100 nmol) and 
(b) BK (control Rmax = 69.1 ±  5.7 %, pEDso = 10.9 ±  0.05; 100 fmol-10 nmol) on the 
bovine isolated perfused eye preparation. The effects of treatment with the nitric oxide 
synthase inhibitor, L-NAME (100 pM, ACh; R m ax=63.1 ±  4 .6  %, pEDso=10.9 ±  0.9; 
BK: R m ax= 62 .4  ±  1.5 %, pEDso=l 1.1 ± 0 .1 ) , the inhibitor of soluble guanylate cyclase, 
ODQ (lOpM, ACh: R m ax=50.6  ±  1 .2  %, pEDso=10.3 ± 0.1), or a high concentration of 
KCl (30 mM, ACh: R m ax=7.6 ± 0.3 % , pEDso=9.9 ± 0 . 1 ;  BK: R m ax= 23 .4  ±  2 .0  % , 
pEDso=10.3 ± 0 .2 )  are also shown. Data represent the mean ±  s.e.mean of five to twelve 
observations. * P<0.05 and *** P<0.001 indicate a difference from control.
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Bradykinin (0.1 pmol-10 nmol) also produced dose-dependent falls in U46619-induced 
perfusion pressure (pED5o=10.95 ± 0.05, maximum fall of 68.8 ± 1.1 %, « -  6, Figure 
3.4b). In the presence of L-NAME (100 pM, 20 min), bradykinin-induced falls in 
perfusion pressure were completely unaffected (Figure3.4b). In addition, the fall in 
perfusion pressure produced by 10 pmol bradykinin (47.0 ± 4.4 %, n ~  \5) was 
unaffected by flurbiprofen alone, nor by the combination of flurbiprofen and L-NAME 
(Figure 3.5b).
Infusion of the detergent CHAPS (0.3 %, 2 min), in order to selectively damage the 
endothelium (Randall & Hiley, 1988), had no effect on U46619-induced perfusion 
pressure (160.0 ± 16.4 and 170.2 ± 16.6 mmHg, n = 13, before and after CHAPS, 
respectively), but resulted in a profound reduction in the fall in perfusion pressure 
induced by 10 nmol acetylcholine or 10 pmol bradykinin (Figure 3.5a, 3.5b).
3,4 Effect of high [IC^ ] on vasodilator responses to acetylcholine and bradykinin
The ability of acetylcholine and bradykinin to induce vasodilator responses in the 
bovine eye was examined in the presence of Ki'ebs solution containing a high 
concentration of KCl (30 mM). In these experiments KCl itself produced a sustained 
increase in perfusion pressure to 98.7 ±7.1  mmHg {n = 12), but in order to examine 
vasodilator responses at levels of pressure similar to control experiments the pressure 
was increased to 137.6 ± 12.3 mmHg {n =12) with the infusion of U46619 (5-10 nM). 
Under these conditions, vasodilator responses to acetylcholine (1 pmol-100 nmol) and 
to bradykinin (0.1 pmol-10 nmol) were inhibited (Figure 3.4a, 3.4b).
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Figure 3.5 Histogram showing the effects of damaging the endothelium in the ciliary 
vascular bed of the bovine eye with CHAPS (0.3%, 2 min), inhibiting cycloxygenase 
with flurbiprofen (FBP, 30 pM) and combined treatment with flurbiprofen and the 
inhibitor of nitric oxide synthase, L-NAME (100 pM), on vasodilatation induced by (a) 
ACh (10 nmol) or (b) BK (10 pmol). Data represent the mean ± s.e.mean of ten to 
eighteen observations. *** P<0.001 indicates a difference from control.
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3.5 Effect of channel blockers and ouabain on acetylcholine-induced 
vasodilatation
A number of agents that block specific potassium channels were infused in the bovine 
eye for 20 min and their effects on acetylcholine (10 nmol)-induced vasodilator 
responses assessed. The K a t p  channel blocker, glibenclamide (10 pM), had no effect on 
U46619-induced perfusion pressure (104.7 ±7.1 mmHg before and 106.1 ± 9.6 mmHg 
after infusion; M = 10) or on acetylcholine-induced vasodilatation (Figure 3.6a). In 
contrast, the non-selective Kca channel blocker, TEA (10 mM), produced a large 
transient increase in U46619-induced perfusion pressure (291.9 ± 57.5 mmHg, n -  4) 
which returned to a perfusion pressure similar to that seen before the addition of TEA 
after ~15 min. TEA also produced a significant inhibition of acetylcholine-induced 
vasodilatation (Figure 3.6a).
The Kir channel blocker, barium (30 pM), had no effect on the U46619-induced 
perfusion pressure (128.2 ± 8.0 mmHg, before and 118.4 ± 7.8 mmHg, after infusion; n 
= 13 and 11, respectively) or on acetylcholine-induced vasodilatation (Figure 3.6b). The 
Na/K ATPase inhibitor, ouabain (10 pM) caused a slow, small but transient rise in 
perfusion pressure, which returned to normal (131 ± 11.6 mmHg, M = 18) after about 1 
hour. Ouabain also produced significant blockade of acetylcholine-induced 
vasodilatation (Figure 3.6b). The combination of barium and ouabain produced a greater 
blockade of acetylcholine-induced vasodilatation than was seen with ouabain alone 
(Figure 3.6b), This combination had no further effect on the U46619-induced perfusion 
pressure than ouabain alone.
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The SKca channel blocker, apamin (100 nM), had no significant effect on U46619- 
induced perflision pressure (154.8 ± 18.6 mmHg before, and 172.8 ±11.2 mmHg after, 
n = 9) but the IKca/BKca inhibitor, charybdotoxin (50 nM; Figure 3.7), and the BKca 
channel inhibitor, iberiotoxin (50 nM), each produced a large transient vasoconstriction 
(rise in perfusion pressure of 339.6 ± 18.8 mmHg, n = 8, and 298.5 ±38.1 mmHg, n = 
7, respectively) that rapidly returned (-15 min) to a similar perfusion pressure to that 
seen before exposure to the drugs (Figure 3.7). Neither apamin (100 nM) nor iberiotoxin 
(50 nM) alone had any significant effect on acetylcholine (10 nmol)-induced 
vasodilatation (Figure 3.8b), whereas charybdotoxin (50 nM) produced significant 
blockade, and uncovered a vasoconstriction (Figure 3.7, 3.8a). A lower concentration of 
charybdotoxin (10 nM) had no significant effect on perfusion pressure or acetylcholine- 
induced vasodilatation by itself, but significantly attenuated the vasodilatation when 
combined with apamin (100 nM, Figure 3.8a, 3.8b). In contrast, the combination of 
iberiotoxin (50 nM) and apamin (100 nM) had no effect on acetylcholine-induced 
vasodilatation (Figure 3.8b).
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Figure 3.6 Histograms showing the effects of potassium channel blockers and of 
ouabain on vasodilatation induced by ACh (10 nmol) in the ciliary vascular bed of the 
bovine eye. (a) Effects of the K a t p  channel blocker, glibenclamide (10 pM), and of the 
non-selective Kca channel blocker, tetraethylammonium (TEA, 10 mM). (b) Effects of 
the inward rectifier K channel ( K i r )  blocker, barium (30 pM), and of the Na/K ATPase 
inhibitor, ouabain (10 pM), each alone and in combination. Data represent the mean ± 
s.e.mean of six to eighteen observations. *** ?<0 .0 0 1  indicates a difference from 
control (ANOVA with Bonferroni’s post-test).
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Figure 3.7 Original trace showing the effects of charybdotoxin (ChTX, 50 nM) on 
perfusion pressure and on vasodilatation to ACh (10 nmol) in the ciliary vascular bed of 
the bovine eye. The addition of charybdotoxin resulted in a large transient increase in 
perfusion pressure followed by reversal of ACh-induced vasodilatation to 
vasoconstriction.
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Figure 3.8 Histograms showing the effect of calcium-sensitive potassium channel 
inhibitors on vasodilatation induced by ACh (10 nmol) in the ciliary vascular bed of the 
bovine eye. (a) Effects of the large/intermediate conductance (BKca/IKca) calcium- 
sensitive channel blocker, charybdotoxin (ChTX, 10 nM and 50 nM). (b) Effects of 
the small conductance calcium-sensitive (SKca) channel blocker, apamin (100 nM), 
alone and in combination with a low concentration of ChTX (10 nM), and of the large 
conductance calcium sensitive (BKca) channel blocker, iberiotoxin (IbTX, 50 nM), 
alone and in combination with apamin (100 nM). Data represent the mean ± s.e.mean of 
six to sixteen observations. *** P < 0.001 indicates a difference from control and ^ P < 
0.005 shows that the combination of iberiotoxin and apamin was different from 
iberiotoxin alone.
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3.6 Effects of channel openers and anandamide
The effects of a range of channel openers conmionly used to characterise or mimic 
EDHF were studied in the bovine eye. The opener of K a t p  channels, levcromakalim 
(0.1 -  30 nmol), produced dose-dependent vasodilatations (maximum fall in perfusion 
pressure of 66.0 ± 7.8 %; Figure 3.9). In contrast, the putative opener of IKca, 1-EBIO 
(Inmol -  1 pmol), produced small dose-dependent vasodilatations (maximum fall in 
perfusion pressure of 30.0 ± 4.8 mmHg, n = 7; Figure 3.9). A more potent analogue of 
1-EBIO, DCEBIO (100 pmol -  1 pmol) produced dose-dependent vasodilator responses 
(maximum fall in perfusion pressure of 82.2 ± 6.0 mmHg, n -  l \  \ Figure 3.9); however, 
the vasodilatations produced by DCEBIO were only slightly inhibited by the infrision of 
chaiybdotoxin (50 nM, 20 min; Figure 3.9), indicating that the opening IKca channels 
was not the primary cause of the vasodilator responses to this dmg. Furthermore, the 
opener of BKca channels, NS1619 only produced a small vasodilator response at the 
highest dose studied (fall in perfusion pressure of 19.1 ± 2.4 %, n = 1 ,  100 nmol). The 
putative candidate for EDHF, anandamide also failed to produce dose-dependent 
vasodilatations with only the highest dose studied (100 nmol) producing a vasodilator 
response (fall in perfusion pressure of 21.0 ± 1.5 %, « = 3),
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Figure 3.9 Dose-response curves showing vasodilatation in the ciliary vascular bed of 
the bovine eye, produced by bolus doses of a range of potassium channel openers; the 
opener of K a t p  channels, levcromakalim (R m ax=79.1  ±  2 .1  %, pED5o=9 . 0  ±  0 .0 4 ;  0 .1  -  
3 0  nmol); and the putative openers of IKca, 1-EBIO (relaxation at 1 pmol = 3 0 .0  ±  4 .8  
% ; 1 nmol -  1 pmol) and DCEBIO (R m ax= 102  ±  6 .5  % , pED5o=7 . 2  ± 0 . 1 ;  1 0 0  pmol -  1 
pmol). The effect of the IKca channel inhibitor, charybdotoxin (ChTx, 5 0  nM), on 
DCEBIO-induced vasodilatation is also shown (R m ax= 87 .6  ± 1 8 . 1  %, pEDso=7.4 ± 0 .5 ) .  
Data represent the mean ± s.e.mean of six -  ten observations. * P < 0 .0 5  indicates that 
vasodilatation-induced by DCEBIO is significantly different in the presence of ChTx.
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Chapter 4
Results; 2
The effect of ascorbate on EDHF-mediated
vasodilatation
LER
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4.1 Effect of ascorbate on acetylcholine-induced, EDHF-dependent vasodilatation 
in the ciliary vascular bed of the bovine eye
In Chapter 3 it was demonstrated that the vasodilator responses to acetylcholine and 
bradykinin are mediated solely by an EDHF-like substance in the ciliary vascular bed of 
the bovine eye. In experiments with noradrenaline and 5-HT, ascorbate was included 
from the outset and acetylcholine-induced vasodilator responses appeared to be 
inhibited compared to experiments with U46619 where ascorbate was never included; 
therefore, experiments were conducted to assess the effect of ascorbate on 
acetylcholine-induced EDHF-mediated vasodilator responses when U46619 was used as 
the vasoconstrictor agonist. In these experiments when bovine isolated eyes were 
perfused with normal Krebs solution, acetylcholine (10 nmol) produced a large fall 
(59.5 ± 4.5 %, n = 8, figure 4.1a) in the U46619-induced perfusion pressure. In contrast, 
in eyes perfused with Krebs solution containing ascorbate (50 pM, >120 min) from the 
outset, acetylcholine produced a vasoconstrictor response (87.0 ± 16.8 mmHg, n ~  6), 
immediately followed by a small residual vasodilator response (17.3 ± 6.3 %, « = 6, 
Figure 4.1b). This reversal of vasodilatation to vasoconstriction was similar to that 
previously seen with the blocker of EDHF, charybdotoxin (see chapter 3; Figure 3.7). 
The acetylcholine-induced vasoconstriction obtained in the presence of ascorbate was 
unaffeeted by the cyclooxygenase inhibitor, flurbiprofen (30 pM, 20 min, Figure 4.2) 
but was reduced to -7.6 ± 5.3 mmHg (n =14, ?<0.001) by the non-selective muscarinic 
antagonist, atropine (100 nM, 20 min. Figure 4.2); indicating that the vasoconstriction 
was mediated by muscarinic receptors, not release of a vasoconstrictor prostanoid. The 
perfusion pressure generated by U46619 (300 nM) was not, however, different in 
control eyes (123.3 ± 10.0 mmHg, n = 1) and in eyes treated with ascorbate (122.7 ± 
12.0 mmHg, M = 8, Figure 4.1).
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Figure 4.1 Original traces showing the difference in the responses produced by 
acetylcholine (ACh; 10 nmol) in the bovine isolated eye following perfusion with (a) 
Control Krebs solution in which acetylcholine elicited only vasodilator responses, or (b) 
Krebs containing ascorbate (50 pM, 120 min) in which acetylcholine produced large 
vasoconstriction, followed by small residual vasodilatation.
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Figure 4.2 Histogram showing the effects of the cyclooxygenase inhibitor, flurbiprofen 
(FBP, 30 pM), and the non-selective muscarinic receptor antagonist, atropine (100 nM), 
on the acetylcholine-induced vasoconstrictor response obtained in eyes perfused with 
Krebs containing ascorbate (50 pM, >120 min). Data represent the mean ± s.e.mean of 
fourteen to eighteen observations. ***P<0 . 0 0 1  indicates a significant difference from 
control.
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4.2 Time course of ascorbate-indced reversal of acetylcholine-induced 
vasodilatation to vasoconstriction
The effect of ascorbate on acetylcholine-induced, EDHF-mediated vasodilator 
responses was not immediate and was only seen when eyes had been perfused from the 
outset with ascorbate. Therefore, the time course of the ability of ascorbate to inhibit 
acetylcholine-induced vasodilatation and uncover a vasoconstrictor response was 
studied over a 120 min period. In control experiments, acetylcholine (10 nmol) induced 
only vasodilatation and these responses, elicited every 15 min over the 120 min period 
remained stable (fall in perfusion pressure of 57.6 ± 6.4 %, « = 6; Figure 4.3a, 4.4a). In 
contrast, inclusion of ascorbate (50 pM) into the perfusion medium led to a time- 
dependent attenuation of the acetylcholine (10 nmol) induced vasodilatation and 
development of vasoconstriction; vasodilator responses first began to decline after 30 
min and were virtually abolished (fall in perfusion pressure of 5.8 ± 3.0 %, /î = 6) after 
120 min (Figure 4.3b, 4.4a). Vasoconstrictor responses (Figure 4.4b), first observed 60 
min after treatment with ascorbate (4.3b, 4.4b), were fully developed and remained 
stable after 90 min (rise in perfusion pressure of 88.1 ± 13.7 mmHg, « = 6; Figure 4.3b, 
4.4b). Once the effects of ascorbate were established, washing out the anti oxidant for up 
to 120 min failed to restore the vasodilator responses to acetylcholine (fall in perfusion 
pressure of 25.7 ± 3.8 % « = 11; Figure 4.5a). Washing out ascorbate appeared to 
reduce the acetylcholine-induced vasoconstrictor response (rise in perfusion pressure of
43.6 ± 21.0 mmHg ^ = 11; Figure 4.5b) but this fall in the vasoconstrictor response was 
not statistically significant; furthermore, an actual reduction of the vasoconstrictor 
response was only seen in 3 of 11 eyes. Therefore the ability of ascorbate to reverse
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Figure 4.3 Original traces showing acetylcholine-induced responses during time course 
experiments, (a) Acetylcholine-induced, EDHF-mediated vasodilator responses, elicited 
every 15 min over a 120 min study period, remained stable, (b) In eyes perfused with 
ascorbate (50 pM, >120 min), acetylcholine-induced, EDHF-mediated vasodilatation 
was blocked in a time-dependent manner and a normally masked vasoconstrictor 
response to acetylcholine developed. • 0  are control, responses to acetylcholine ( 1 0  
nmol) to ensure that the vasodilator response was reproducible before starting the time- 
course experiment or addition of ascorbate.
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Figure 4.4 Control experiments showing that vasodilator responses to acetylcholine 
(ACh; 10 nmol) elicited in the bovine isolated perfused eye every 15 min remained 
stable for a 120 min study period. In contrast, inclusion of ascorbate (50 pM) in the 
perfusion medium led to a time dependent loss of vasodilatation (a) and development of 
vasoconstriction (b). The redox-inactive analogue, dehydroascorbate (50 pM) lacked the 
activity of ascorbate. Data represent the mean ± s.e.mean of six to seven observations. 
***P<0.001 indicates a difference from control
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Figure 4.5 In eyes perfused with ascorbate (50 pM, >120) acetylcholine-induced 
vasodilatation was inhibited and a normally suppressed vasoconstrictor response 
developed. These graphs show the results experiments conducted to see if washing out 
ascorbate over a 1 2 0  min period would reverse these effects, i.e. restore acetylcholine- 
induced vasodilator responses (a) or attenuate vasoconstriction (b). Data represent the 
mean ± s.e.mean of eleven observations.
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acetylcholine-induced, EDHF-mediated vasodilatation to vasoconstriction is slow and 
the effect cannot be quickly washed out.
4.3 Concentration-dependence of the ability of ascorbate to reverse acetylcholine- 
induced vasodilatation to vasoconstriction
The concentration of ascorbate (50 pM) used in experiments was chosen as it is close to 
the normal plasma concentration, therefore experiments were conducted to assess if 
ascorbate could inhibit acetylcholine-induced, EDHF-mediated vasodilatation to 
vasoconstriction across the entire physiological range of blood plasma concentrations. 
In these experiments bovine eyes were perfused with a range of concentrations of 
ascorbate (10, 50 and 150 pM) for 120 min before constructing dose-response curves to 
acetylcholine (1 pmol-1 pmol). Figure 4.6 shows that the ability of ascorbate to inliibit 
the acetylcholine-induced vasodilator response and uncover a vasoconstiictor response 
was indeed concentration-dependent, with the highest concentration (150 pM) causing 
the largest degree of blockade (Figure 4.6). Nevertheless, even the lowest concentration 
of ascorbate tested (10 pM) resulted in a significant loss of acetylcholine-induced 
vasodilatation and development of vasoconstriction (Figure 4.6). Therefore, it would 
appear ascorbate can inhibit acetylcholine-induced, EDHF-mediated vasodilatation in a 
concentration-dependent manner, across the normal physiological range.
4.4 Time course of ascorbate-indueed blockade of bradykmin-induced 
vasodilatation
Having established that acetylcholine-induced EDHF-mediated vasodilator responses 
were attenuated by ascorbate, experiments were conducted to determine if bradykinin- 
induced, EDHF-dependent vasodilator responses were also blocked by ascorbate in the
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Figure 4.6 Dose-response curves showing acetylcholine (ACh; 1 pmol-1 pmol)-induced 
responses in the bovine isolated perfused eye. Under control conditions, acetylcholine 
produced only vasodilator responses (Rmax= 65.4 ± 5.6 %, pED5o= 9.4 ± 0.2.) In 
contrast, following perfusion for 120 min with ascorbate (Asc; 10, 50 or 150 pM), a 
concentration-dependent loss of vasodilatation (a) and the development of 
vasoconstriction (b) was seen. Responses in the presence of ascorbate were therefore 
biphasic, consisting of an initial vasoconstriction followed by a residual vasodilatation. 
In the presence of 10 pM ascorbate: Rmax= 40.1 ± 3.0 % pED5o= 8 . 8  ± 0.2 and a 
vasoconstriction of 59.4 mmHg at 1 pmol ACh; in the presence o f 50 pM ascorbate: 
Rmax= 29.0 ± 2.7 %, pED5o= 8.9 ± 0.4 and a vasoconstriction of 155.3 ± 43.8 mmHg at 
1 pmol ACh; in the presence of 150 pM ascorbate: Rmax= 14.3 ± 1.7%, pED5o= 8 . 8  ± 
0.3 and maximum vasoconstriction= 237.1 ± 13.7 mmHg, pED5o= 8.1 ± 0.1. Data 
represent the mean ± s.e.mean of 5-10 observations. *P<0.05, **P<0.01 and 
***P<0.001 indicate a difference from control.
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bovine eye. In control experiments bradykinin (10 pmol) induced vasodilator responses 
(43.8 ± 3.9 %, n -  8), and these, elicited every 15 min, remained stable over the 120 
min study period (Figure 4.7). In contrast, inclusion of ascorbate into the perfusion 
medium led to a time-dependent attenuation of bradykinin-induced vasodilatation; 
vasodilator responses began to decline after 60 min and were virtually abolished after 
120 min (Figure 4.7). In contrast to acetylcholine, vasoconstiictor responses were never 
observed, even when the vasodilator blockade by ascorbate was frilly established.
4.5 Effects of antioxidants on acetylcholine-induced vasodilatation
One of the main functions of ascorbate in the body is as an antioxidant; therefore 
experiments were conducted to assess if the ascorbate-induced blockade of EDHF- 
mediated vasodilatation was due to an antioxidant action. In these experiments, control 
vasodilator responses to acetylcholine (10  mnol) were obtained before examining the 
effects of a range of agents over the ensuing 120 min. Inclusion of the redox-inactive 
analogue, dehydroascorbate (50 pM) in the perfusion medium failed to reproduce the 
reversal of acetylcholine-induced vasodilatation to vasoconstriction seen with ascorbate 
(Figure 4.4). Moreover, superoxide dismutase (250 units ml'*) and catalase (1250 units 
ml'*), which scavenge superoxide anion and hydrogen peroxide, respectively, also had 
no effect on acetylcholine-induced vasodilatation (Figure 4.8).
Perfusion with the endogenous anti oxidant and thiol reducing agent, glutathione (1 
mM) also had no effect on acetylcholine-induced vasodilatation (Figure 4.8). In 
contrast, perfusion with two other thiol-reducing agents, N-acetyl-L-cysteine (ImM) 
and dithiothreitol (100 pM), did inhibit vasodilatation and uncovered a vasoconstrictor
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Figure 4.7 Control time course experiments showing that vasodilator responses to 
bradykinin (10 pmol), elicited in the bovine isolated perfused eye every 15 min, 
remained stable for a 120 min study period. In contrast, inclusion of ascorbate (50 pM) 
in the perfusion medium led to a time-dependent loss of vasodilatation. Data represent 
the mean ± s.e.mean of five to nine observations. *P<0.05 and **P<0.01 indicate a 
difference from control.
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Figure 4.8 After having obtained control vasodilator responses to acetylcholine (ACh; 
10  nmol), the effects of infusion of a number of antioxidants, namely, glutathione (1 
mM), N-acetyl-L-cysteine (NAC; 1 mM), dithiothreitol (DTT; 100 pM), superoxide 
dismutase (SOD; 250 units mf') and catalase (1250 units ml''), were examined on these 
vasodilator responses over the ensuing 120 min. Loss of acetylcholine-induced 
vasodilatation and any development of vasoconstriction are shown in a and b, 
respectively. Data represent the mean ± s.e.mean of five to ten observations. *P<0.05, 
**P<0.01 and ***P<0.001 indicate a difference from control.
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response to acetylcholine, with dithiotlii’eitol being the most effective (Figure 4.8). 
Thus, the ascorbate-induced blockade of EDHF-mediated vasodilatation can be 
mimicked by other antioxidants and may involve the reduction of a critical disulphide 
group.
4.6 Selectivity of the blockade of EDHF-mediated vasodilatation by ascorbate in 
the ciliary vascular bed of the bovine eye
It is possible that ascorbate could non-selectively attenuate vasodilator responses in the 
bovine eye. Therefore, experiments were conducted to determine if vasodilator 
responses mediated by mechanisms other than EDHF could be inhibited by ascorbate. 
The vasodilator responses to 10 nmol of the nitric oxide donor, glyceryl trinitrate were 
completely unaffected following treatment with ascorbate (50 pM, >120 min; Figure 
4.9a). Similarly, dose-dependent vasodilatations induced by the opener of Katp 
channels, levcromakalim (100 pmol -  30 nmol) were unaffected in the presence of 
ascorbate (Figure 4.9b). Furthermore the vasoconstrictor response induced by the nitric 
oxide synthase inhibitor, L-NAME (100 pM) was unaffected in the presence of 
ascorbate (increase in perfusion pressure of 30.0 ± 6.0 and 30.5 ± 5.9 mmHg, 
respectively). These results strongly support the hypothesis that ascorbate selectively 
attenuates EDHF-mediated vasodilatation in the bovine eye.
4.7 Effects of ascorbate on acetylcholine-induced, EDHF-mediated vasodilatation 
in the rat isolated perfused mesenteric arterial bed
Experiments were conducted to determine if the ability of ascorbate to attenuate EDFIF- 
dependent vasodilator responses in the bovine eye could also be observed in a 
preparation where an EDHF-mediated vasodilator response had been previously
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Figure 4.9 (a) Histogram showing the effect of infusing ascorbate (50 pM, >120 min) 
on vasodilatations induced by the nitric oxide donor, glyceryl trinitrate (GTN, 10 nmol), 
(b) Dose-response curve showing the effect of infusing ascorbate (50 pM, >120 min) on 
vasodilatations induced by the opener of K atp  channels, levcromakalim (L K , control 
Rmax= 79.1 ± 2.1, pED5o= 9.0 ± 0.4, in presence of ascorbate Rmax= 79.5 ± 3.7, 
pEDso=9.0 ± 0.1; 0.1 -  30 nmol). Data represent the mean ± s.e.mean of six to seven 
observations.
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characterised, the rat perfused mesenteric arterial bed preparation (Adeagbo & Triggle, 
1993; McCulloch et ah, 1997). Following perfiision with Krebs solution and 
vasoconstriction with phenylephrine (3-10 pM) to give a final perfusion pressure of
102.3 ± 6.0 mmHg {n = 6), acetylcholine (1 pmol-100 nmol) elicited vasodilatations 
that were dose-dependent (Figure 4.10a). The EDHF-dependent component of 
vasodilatation was revealed by inclusion of the nitric oxide synthase inhibitor, L-NAME 
(100 pM), and the cyclo-oxygenase inhibitor, indomethacin (10 pM), in the perfusion 
medium (McCulloch et a l ,  1997). This EDHF-component of acetylcholine-induced 
vasodilatation was inliibited when ascorbate (50 pM) was present in the perfiision 
medium for 180 min (Figure 4.10a). In contrast to the bovine eye, vasoconstrictor 
responses to acetylcholine were never observed in the rat mesentery even when 
vasodilator blockade by ascorbate was fully established.
Experiments were conducted to determine the time course over which ascorbate (50 
pM) attenuated acetylcholine-induced vasodilatation in the rat mesentery. In control 
experiments acetylcholine (10 nmoI)-induced vasodilatation, elicited every 15 min, did 
not change significantly over a 180 min study period (Figure 4.10b). In contrast, 
inclusion of ascorbate (50 pM) in the perfusion medium lead to a time-dependent 
attenuation of acetylcholine-induced vasodilatation: vasodilator responses first began to 
decline at 120 min and fell steadily during the remaining 60 min (Figure 4.10b). These 
results indicate that ascorbate can inhibit EDHF-mediated vasodilatation in vascular 
beds other than the ciliaiy vascular bed of the bovine eye.
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Figure 4.10 Graphs showing the ability of ascorbate to inhibit acetylcholine (ACh)- 
induced, EDHF-dependent vasodilatation in the rat perfused mesenteric arterial bed. (a) 
Control dose-response curves to acetylcholine (Rmax= 85.3 ± 5.7 %, pEDso= 12.3 ± 0 .1 ;  
1 pmol-100 nmol) and the residual EDHF-dependent vasodilatation seen following 
treatment with the combination of L-NAME (100 pM) and indomethacin (10 pM; 
Rmax= 86.3 ± 22.0 %, pEDso= 10.4 ± 1.0). This residual EDHF-dependent vasodilatation 
was inhibited following inclusion of ascorbate (50 pM) in the perfusion medium for 180 
min (vasodilatation of 37.3 ± 4.8 % at 100 nmol ACh). (b) Control time course 
experiments showing that the EDHF-dependent vasodilatation produced by 
acetylcholine (10 nmol) in preparations treated with L-NAME and indomethacin did not 
change significantly during a 180 min study period. In contrast, inclusion of ascorbate 
(50 pM) into the perfusion medium led to a time-dependent loss of vasodilatation. Data 
represent the mean ± s.e.mean of five to eleven observations. *P<0.05, **P<0.01 and 
***P<0.001 indicate a difference from control. ^^P<0.01 and ^^^P<0.001 indicate a 
significant blockade by ascorbate of EDHF-induced vasodilator responses, obtained in 
the presence of L-NAME and indomethacin.
100
4.8 Effects of ascorbate on bradykinin-induced, EDHF-mediated vasodilatation in 
the porcine left anterior descending coronary artery. N.B. These experiments were 
conducted by a colleague, Silvia Nelli
The ability of ascorbate to attenuate EDHF-mediated vasodilatation in the bovine eye 
and rat mesentery may be due to the small resistance arterioles which control the 
perfusion pressure; therefore experiments were conducted to assess if  ascorbate could 
attenuate the well characterised EDHF-mediated vasodilator response in the large 
conduit arteiy, the porcine coronary artery. In the porcine coronary artery, bradykinin- 
induced, EDHF-mediated vasodilatation was revealed by inclusion of the nitrie oxide 
synthase inhibitor, L-NAME (100 pM), and the cyclooxygenase inhibitor, 
indomethacin (3 pM), in the bathing medium. In rings bathed in normal Krebs solution 
the EDHF component of bradykinin (100 pM -300 nM)-indueed vasodilatation was 
large and concentration-dependent (max 80.3 ± 6.5 %, n = 10, Figure 4.11a). In the 
presence of the BKca/IKca inhibitor, charybdotoxin (100 nM), the bradykinin-induced, 
EDHF-mediated vasodilatation was unaffected (maximum vasodilatation of 71.3 ± 9.2 
%, M = 8 , Figure 4.11a). The SKca inhibitor, apamin (100 nM), appeared to slightly 
attenuate the bradykinin-induced EDHF-mediated vasodilatation (maximum 
vasodilatation of 62.2 ± 5.2 %, « = 8 , Figure 4.11a), but this was not statistically 
significant. In contrast, the combination of charybdotoxin plus apamin virtually 
abolished EDHF-mediated vasodilatation (maximum vasodilatation of 11.3 + 3.3 Vo, n = 
10, P<0.001, Figure 4.11a).
Experiments were conducted to assess the effect of ascorbate on bradykinin-induced, 
EDHF-mediated vasodilatation in the porcine coronary artery. In these experiments the 
control vasodilatations were completely unaffected (maximum vasodilatation of 76.7 ±
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4.7 %, n = 11, Figure 4.11b) by ascorbate (150 pM, >120 min). Ascorbate also failed to 
affect bradykinin-induced, EDHF-mediated vasodilatation in the presence of 
charybdotoxin (maximum vasodilatation of 76.1 ± 5.9%, w = 8 , Figure 4.11b). 
Furthermore, ascorbate failed to enhance the small blockade of EDHF-dependent 
vasodilatation produced by apamin. Thus, ascorbate does not attenuate EDHF-mediated 
vasodilatation in the porcine coronaiy arteiy.
4.9 Effect of inhibiting the ability of the eye to concentrate ascorbate on the 
blockade of EDHF-mediated vasodilatation in the ciliary vascular bed of the 
bovine eye
The bovine eye has the ability to concentrate ascorbate in the aqueous humour; ^
's
therefore experiments were conducted to assess if accumulation of ascorbate in the w
aqueous humour is a prerequisite for the blockade of EDHF-mediated vasodilatation. f
The concentration of ascorbate in the aqueous and vitreous humours of unperfiised 
bovine eyes measured within 1 hour of slaughter were 1.1 ± 0.1 and 0.9 ±0.1 mM (n ^
8 ; Figure 4.12), respectively. These concentrations of ascorbate did not change when the 
eyes were perfused for 120 min with normal Krebs solution (0.9 ± 0.2 and 1.1 ± 0.1 
mM, « = 9, respectively); perfusion with K ebs solution containing ascorbate (50 pM) 
also failed to significantly change the concentration of ascorbate in the aqueous and 
vitreous humours (1.0 ±0.1 and 0.8 ±0.1 mM, respectively, n = 6; Figure 4.12).
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Figure 4.11 Concentration-response curves showing bradykinin (0.1-300 nM; Rmax=
82.4 ± 5.7 and 82.9 ± 3.3 %, pED5o= 8.3 ± 0.1 and 7.5 ± 0.05 in the absence and 
presence of ascorbate, respectively)-induced, EDHF-mediated vasodilatation in rings of 
porcine left anterior descending coronary artery. These also show the effects of the 
inhibitor of small conductance calcium-sensitive potassium channels (SKca), apamin 
(100 nM; Rmax= 64.9 ± 2.0 and 56.3 ± 0.5 %, pEDso= 7.8 ± 0.04 and 7.9 ±0.01, in the 
absence and presence of ascorbate, respectively ), and of the intermediate conductance 
calcium-sensitive potassium channels (IKca), charybdotoxin (ChTx, 100 nM; Rmax=
70.5 ± 2.6 and 79.8 ± 3.6 %, pED$o= 8.2± 0.1 and 7.9 ± 0.07, in the absence and 
presence of ascorbate respectively), each alone and in combination (Rmax= 12.8 ± 0.4 
and 10.3 ± 3 . 4  %, pED5o= 8.2 ± 0.04 and 7.2 ± 0.6, in the absence and presence of 
ascorbate, respectively) . Experiments were conducted in the absence (a) and presence 
(b) of ascorbate (150 pM). All responses were obtained in the presence of the nitric 
oxide synthase inhibitor, L-NAME (100 pM), and the cyclo-oxygenase inhibitor, 
indomethacin (3 pM). Data represent the mean ± s.e.mean of eight to eleven 
observations. *P<0.05, **P<0.01 and ***P<0.001 indicate a difference from control.
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In experiments where the anterior and posterior chambers were continually flushed with 
Ki'ebs solution (0.25 ml min'^) to prevent the accumulation of ascorbate (see Figure 2.2) 
the concentration in the aqueous humour was below detectable limits (<10 pM, Figure
4.12); however, flushing had no effect on the concentration of ascorbate in the vitreous 
humour, even when the eyes were perfused with Krebs containing ascorbate (1.0 ± 0.06 
and 0.7 ± 0.08 mM, respectively, n = 6). The process of flushing the anterior and 
posterior chamber of the eye had no effect on control acetylcholine-induced, EDHF- 
mediated vasodilatation obtained over a 120 min period when eyes were perfused with 
Krebs solution lacking ascorbate (Figure 4.13). Flushing also failed to prevent the 
blockade of acetylcholine-induced EDHF-mediated vasodilatation and the uncovering 
of a vasoconstrictor response when eyes were perfused with Krebs solution containing 
ascorbate (50 pM, >120 min. Figure 4.13).
In some experiments the aqueous humour and vitreous humours of the eye were 
removed in order to create a preparation with no intact ocular chambers or “reservoirs” 
of ascorbate. When the ciliary vascular bed was perfused after removal of both the 
aqueous and vitreous humours the EDHF-mediated vasodilatation was still blocked 
when ascorbate (50 pM, >120 min) was included in the perfusion medium (Figure
4.13). These experiments indicate that ability of ascorbate to attenuate EDHF-mediated 
vasodilatation in the bovine eye is a direct vascular effect and does not involve the eye’s 
ability to concentrate ascorbate in the aqueous and vitreous humours.
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Figure 4.12 Histogram showing the concentration of ascorbate found in samples of 
aqueous humour and vitreous humour taken from freshly obtained bovine eyes (fresh), 
from eyes perfused via a ciliary artery for 120 min with normal Krebs solution 
(perfused) or with Krebs solution containing ascorbate (perfused + ascorbate, 50 pM). 
Also shown are the levels of ascorbate found following continuous flushing of the 
anterior chamber with Krebs solution in eyes whose ciliary vascular bed had been 
perfused with either normal Krebs solution (flushed) or Krebs containing ascorbate 
(flushed + ascorbate, 50 pM). Data represent the mean ± s.e.mean of six to nine 
observations. *** P<0.001 indicates a significant difference from the level of ascorbate 
in fresh eyes.
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Figure 4.13 Histogram showing control acetylcholine (10 nmol)-induced, EDHF- 
mediated vasodilatation in the ciliary vascular bed of the bovine perfused eye. This 
response was blocked, and a normally suppressed vasoconstrictor response uncovered, 
following treatment with ascorbate (+ asc, 50 pM, >120 min). When the anterior 
chamber of the eye was continuously flushed with Krebs solution to prevent the 
accumulation of ascorbate in the aqueous humour (flushed), or when the aqueous 
humour and vitreous humour were removed (drained), normal vasodilator responses to 
acetylcholine were seen. Nevertheless, when ascorbate (50 pM, >120 min) was added to 
the perfusion fluid under these conditions, it still resulted in blockade of the EDHF- 
mediated vasodilatation (flushed + asc, drained + asc, respectively). Data represent the 
mean ± s.e.mean of five to eight observations. *** P<0.001 indicates a significant 
blockade of the EDHF-mediated vasodilatation by ascorbate.
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Chapter 5
Discussion
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5.1 Perfusion of the ciliary vascular bed of the bovine eye and responses to 
vasoconstrictor agonists
The main aim of this study was to investigate endothelium-dependent vasodilatation in 
the ciliaiy vascular bed of the bovine eye. However, before characterising the 
vasodilator responses in this tissue it was important to observe the behaviour of this 
vascular bed under basal, unstimulated perfiision conditions so that the correct 
conditions could be selected to examine vasodilator responses. When bovine eyes were 
perfused at a constant flow rate of 2.5 ml min'^ the basal perfusion pressure was 38 ±
1.5 mmHg {n -  105). Experiments were conducted to determine if this perfusion 
pressure was due simply to the resistance to flow in the preparation, or if it was due to 
intrinsic (myogenic) tone. In order to test the latter possibility a large vasodilator 
papaverine (150 pM, a non-selective inhibitor of phosphodiesterases) was infused; 
papaverine caused a small but significant vasodilator response indicating that there is a 
very low level of myogenic tone under basal conditions in this preparation. These 
results are in contrast to those obtained from resistance vessels from many vascular beds 
including the mesenteric and coronary beds (Miller et a l ,  1997; Rajagopalan et a l ,  
1995; Sun et a l ,  1992) where myogenic tone is observed.
Inhibition of nitric oxide synthase has been shown to cause elevations in blood pressure 
in vivo (Rees et a l ,  1990), and in vitro (Mügge et a l ,  1991) and inhibiting guanylate 
cyclase increases resting tone in isolated vessels such as the rabbit aorta (Martin et a l ,  
1986); these observations indicate that, in some vascular preparations, there may be a 
basal release of nitric oxide (for review see; Martin, 1988). Therefore, experiments 
were conducted to establish if basal release of nitric oxide was suppressing basal 
perfusion pressure in the ciliary vascular bed of the bovine eye. In these experiments.
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inhibition of nitric oxide synthase with L-NAME (100 pM) had no effect on the basal 
perfusion pressure. However, inhibition of soluble guanylate cyclase with ODQ (10 
pM; Garthwaite et a l ,  1995), resulted in a small vasoconstrictor response indicating that 
despite the lack of effect of L-NAME, there is probably a small basal production of 
nitric oxide under resting perfusion conditions. This conclusion was based on the 
assumption that ODQ is more effective at terminating the actions of nitric oxide than L- 
NAME, and that the ODQ-induced vasoeonstrictor response is not due to a non- 
seleetive aetion of this agent. However, it would be easier to conclude whether there 
was a basal release of nitric oxide if the myogenic tone was larger; results obtained in 
the presence of vasoconstrictor agonists appear to confirm the conclusion that there is a 
basal release of nitric oxide (see below). Nethertheless, these results indicate that there 
is a small component of intrinsic tone, which may be suppressed by a tonic influence of 
nitric oxide in the ciliary vascular bed of the bovine eye.
In order to obseiwe vasodilator responses the perfusion pressure must first be increased 
using a vasoconstrictor agonist. Five commonly used vasoconstrictor agonists were 
examined in the ciliary vascular bed of the bovine eye in order to assess their suitability: 
prostaglandin Fia; the thromboxane A2-mimetic, U46619; the non-seleetive 
adrenoceptor agonist, noradrenaline; the selective a  i-adrenoceptor agonist, 
phenylephrine; and 5-HT. All these dmgs caused concentration-dependent rises in 
perfusion pressure with the rank order of potency: 5-HT > U46619 > noradrenaline > 
prostaglandin F2« > phenylephrine. However, due to problems with poor solubility, full 
concentration-response curves to prostaglandin p2a and phenylephrine could not be 
obtained, even though these agents produced vasoconstrictor responses. Therefore these 
dmgs were not used in further experiments.
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Having established that concentration-dependent vasoconstriction was obtainable, 
experiments were conducted to determine which of the remaining vasoconstrictor 
agonists would be most suitable for use in experiments where vasodilator responses 
were to be elicited. In these experiments, the effect of inhibiting nitric oxide synthase 
was assessed following preconstriction with submaximal concentrations of U46619, 5- 
HT or noradrenaline. Inhibition of nitric oxide synthase with L-NAME (100 juM) 
resulted in a frirther inerease in perfiision pressure of around 30 mmHg, regardless of 
the vasoconstrictor used. These results suggest that when the perfusion pressure is 
elevated with an agonist, the basal release of nitric oxide (alluded to above) is exerting a 
considerable tonic vasodilator effect in the resistance vessels of the bovine ciliary 
vasculature. Indeed, under similar conditions, a tonic inhibitory action of nitric oxide 
has been reported in the porcine isolated perfused eye preparation (Meyer et a l ,  1993). 
Whether this “basal” release of nitric oxide results from a tonic unstimulated release 
(Martin et a l ,  1986), from release stimulated by flow-induced shear stress (Rubyani et 
a l ,  1986), from release due to stimulation of the vascular endothelium by the 
vasoconstrictor agonists themselves (Cocks & Angus, 1983), or even release from 
nitrergic nerves (Toda & Okamura, 1990), remains to be determined. Nevertheless, 
studies using bovine isolated retinal arterial rings (Benedito et a l ,  1991) and porcine 
ophthalmic and ciliary arterial rings (Haefliger et a l ,  1993) in tissue baths where shear 
stress is absent also indicate the presence of a tonic vasodilator action of basal nitric 
oxide. Moreover, the ability of inhibitors of nitric oxide synthase to reduce ocular blood 
flow in species as diverse as rat (Koss, 1998), rabbit (Nilsson, 1996), dog (Kitamura et 
a l ,  1993) and human (Luksch et a l ,  2000), demonstrates an important role for basal 
nitric oxide release in regulating blood flow in the eye.
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Experiments were then conducted to determine if vasodilator responses could be elicited 
in the presence of vasoeonstrictor agonists. In these, the ciliary vascular bed was again 
preconstricted (to -120 mmHg) with submaximal concentrations of noradrenaline, 5- 
HT, or U46619 and the effect of the commonly used endothelium-dependent 
vasodilator, acetylcholine (1 pmol -100 nmol; Furchgott & Zawadzki, 1980), 
investigated. In these experiments, acetylcholine produced dose-dependent vasodilator 
responses regardless of the agonist used to raise perfusion pressure. However, the 
vasodilator responses obtained in the presence of U46619 (maximum fall of perfusion 
pressure of 59.5 ± 4.9 %) were far larger thasn those observed in the presence of 
noradrenaline (maximum fall of perfusion pressure 29.0 ±5 . 2  %) or 5-HT (maximum 
fall of perfusion pressure 10.5 ± 4.6 %). A possible reason that the acetylcholine- 
induced vasodilatation was smaller when 5-HT or noradrenaline were used to increase 
perfusion pressure, is that these vasoconstrictors are both known to stimulate release of 
nitric oxide from the vascular endothelium (Cocks & Angus, 1983; Cohen et al., 1983). 
Therefore, any additional stimulation of the endothelium may not cause vasodilatation, 
as nitric oxide release may already be close to maximal. Alternatively, the vasodilator 
response may have been reduced as the antioxidant, ascorbate (50 pM), was included in 
the Ki’ebs solution to prevent these drugs from oxidising, whereas the more stable 
U46619 was infused in Krebs containing no ascorbate. At this stage of the study the 
action of ascorbate on endothelium-derived hyperpolarizing factor (EDHF)-mediated 
vasodilatation was unknown and for simply pragmatie reasons U46619 was used to 
preconstrict the ciliaiy vascular bed in all subsequent experiments.
I l l
5.2 Acetylcholine- and bradykinin-induced vasodilatation in the bovine eye is 
endothelium-dependent but resistant to blockade of nitric oxide synthase and 
cyclo-oxygenase
When U46619 was used as a vasoconstrictor, acetylcholine and bradykinin both 
produced dose-dependent vasodilatation in the ciliary vascular bed of the bovine eye. 
Therefore, experiments were conducted to investigate the role of the endothelium in the 
responses to these commonly used vasodilators. In these experiments, infiision of the 
detergent, CHAPS, which has previously been used to induee selective damage of the 
vaseular endothelium in the rat perfused mesentery preparation (Randall & Hiley, 
1988), almost abolished the vasodilator responses to acetylcholine and bradykinin in the 
bovine eye. Surprisingly, CHAPS failed to produce the same increase in U46619- 
induced perfusion pressure seen when basal nitric oxide activity was abolished with L- 
NAME. However, it is possible that CHAPS might have caused some slight additional 
damage to the vascular smooth muscle, which obscured this additional rise. Although, 
as the perfusion pressure obtained before the addition of CHAPS was maintained after 
infusion of this agent, any damage to the smooth muscle could not have been to great. A 
recent report suggested that rather than destroy the endothelium, detergents may simply 
solublise receptors on the vascular endothelium and that infusing distilled water instead, 
was a more effective way to remove the endothelium (Ralevic & Randall, 2002). 
However, in the bovine eye, perfusing with distilled water for up to 5 minutes had no 
effect on the acetylcholine-induced vasodilator responses (data not shown). Regardless, 
based on the results with CHAPS in this study, it seems reasonable to conclude that the 
vasodilator responses to bradykinin and acetylcholine are endothelium-dependent in the 
ciliary vascular bed of the bovine eye.
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Having established that the vasodilatations to acetylcholine and bradykinin were likely 
to be endothelium-dependent, experiments were conducted to investigate whether they 
were mediated by nitric oxide. In these experiments, despite nitric oxide being tonically 
active, vasodilatations were completely unaffected by the inhibition of nitric oxide 
synthase using L-NAME. Furthermore, the inliibitor of soluble guanylate cyclase, ODQ, 
also failed to inhibit the vasodilator response to acetylcholine. Thus, these findings 
indicate that nitric oxide does not contribute at all to the vasodilator responses to 
acetylcholine or bradykinin in the bovine eye. These findings are surprising and are in 
sharp contrast to those obtained in isolated rings of ocular arteries such as the porcine 
ophthalmic artery (Yao et a l ,  1991) and ciliary artery (Haefliger et a l ,  1993; Zhu et a l ,
1997), and strips of monkey ciliary artery (Toda et a l ,  1998), where vasodilatations to 
both bradykinin and acetylcholine were sensitive to inhibition of nitric oxide synthase. 
However, uncharacterised, residual vasodilatations were observed in all these 
preparations. It is possible that nitric oxide has greater importance in regulating vascular 
tone in larger vessels than in resistance vessels in the bovine ciliary vasculature. Indeed, 
such a decreasing role for nitric oxide with decreasing blood vessel diameter has been 
noted in the rat mesenteric vascular bed (Hwa et a l ,  1994). However, in direct contrast 
to the findings in the bovine eye reported here, the bradykinin-induced vasodilator 
responses in the porcine isolated perfused eye were blocked by L-NAME (Meyer et a l ,  
1993), suggesting an important role for nitric oxide in such responses in this species. 
Furthermore, the vasodilatation to acetylcholine in vivo in the retinal circulation of 
newborn pigs, is sensitive to inhibition of nitric oxide synthase (Gidday & Zhu, 1995). 
In the study of the porcine eye by Meyer and colleagues (1993), constant pressure 
conditions were used and vasodilatation was measured as a change in flow, whereas in 
this study, a constant flow rate was employed and vasodilatation was measured as a
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change in perfusion pressure; it may be possible that these differences in experimental 
procedure explain the different sensitivity of the vasodilator response to inhibition of 
nitric oxide synthase. Regardless of the methodology used, it is more likely that the 
insensitivity of vasodilatation in the bovine eye to inhibition of nitric oxide synthase 
represents a species difference.
The vasodilator responses to acetylcholine and bradykinin in the bovine eye are also 
completely unaffected by treatment with the cyclo-oxygenase inhibitor, flurbiprofen 
(Nozu, 1978), thus indicating that vasodilatation is not mediated by prostacyclin. 
Furthermore, the vasodilator responses were unaffected following combined treatment 
with flurbiprofen and L-NAME. It is, therefore, clear that neither prostacyclin nor nitric 
oxide is responsible for the vasodilator responses to acetylcholine or bradykinin in the 
ciliary vascular bed of the bovine eye.
The finding that endothelium-dependent vasodilatation induced by acetylcholine or 
bradykinin is entirely independent of involvement of nitric oxide is somewhat 
surprising, but similar findings have been made in the rabbit hindlimb (Mügge et a l ,  
1991) and rat renal artery (Jiang & Dusting, 2001), and is highly suggestive that in the 
bovine eye the vasodilatation is mediated by another process, perhaps EDHF. However, 
in perfused vascular beds where EDHF-mediated vasodilatation has been obsei*ved, 
such as the rat mesenteric vascular bed (Adeagbo & Triggle, 1993; Randall et a l ,  1997) 
and in vivo in the human coronary circulation (Kato et a l ,  1997) or forearm resistance 
vessels (Honing et a l ,  2000), it is more common to find it functioning along with nitric 
oxide. This is also true in isolated strip/ring arterial preparations where EDHF-mediated
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responses can be observed, such as in the rat mesenteric or hepatic arteries (Edwards et 
a l ,  1998) and porcine coronary artery (Kilpatrick & Cocks, 1994).
5.3 Endothelium-derived hyperpolarizing factor mediates vasodilatation 
induced by acetylcholine and bradykinin in the ciliary vascular bed of the isolated 
perfused bovine eye
Having established that the endothelium-dependent vasodilator responses produced by 
acetylcholine and bradykinin are not mediated by nitric oxide or prostacyclin, 
experiments were conducted to assess if they were mediated by EDHF. The 
characterisation of EDHF is complicated as the nature of the EDHF(s) is still unresolved 
(see Chapter 1). Possible candidates for EDHF include a cytochrome P450 metabolite 
(Bauersachs et al., 1994), perhaps an epoxyeicosatrienoic acid (EET; Fisslthaler et a l ,
1999), hydrogen peroxide (Matoba et a l ,  2000), an endogenous cannabinoid (Randall et 
a l ,  1996) and potassium ions (Edwards et a l ,  1998). Moreover, evidence has been 
reported suggesting that the process of relaxation involves hyperpolarization of 
endothelial cells (Edwards et a l ,  1998; Edwards et a l ,  2000), and possible subsequent 
gap junctional transmission of this from endothelium to smooth muscle, resulting in 
smooth muscle relaxation (Chaytor et a l ,  1998). Regardless of the conflicting evidence 
for the proposed candidates, there is consensus that EDFIF responses are mediated by an 
increase in K^ conductance and are thus sensitive to depolarising solutions of K"^  
(Adeagbo & Triggle, 1993)(the depolarisation is such that the equilibrium potential for 
K^ as predicted by the Nernst equation, will be changed such that opening of K^ 
chamiels will no longer cause hyperpolarization) and by inhibitors of certain types of K^  
channels (see below). Consistent with the possibility that EDHF-mediates 
acetylcholine- and bradykinin-induced vasodilatation in the bovine eye, vasodilatation
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was virtually abolished following infusion of a depolarising concentration of in the 
Krebs solution (30 mM).
It has been suggested that K^ released from the endothelium can act as an EDHF by 
stimulating the Na^/K^ATPase or inwardly rectifying K^ channels ( K ’^ ir )  on smooth 
muscle of rat hepatic arteries (Edwards et a l ,  1998), Therefore, the effects of the K’^ ir 
inhibitor, barium, and the Na'^/K’^ ATPase inhibitor, ouabain, were examined on 
vasodilator responses to acetylcholine in the ciliary vascular bed of the bovine eye. In 
fact, vasodilatation was unaffected by barium, inhibited by ouabain and further inhibited 
by the combination of the two inhibitors. The finding that vasodilator responses to 
acetylcholine in the bovine eye are sensitive to inhibition of the Na/K-ATPase and Kir 
could be consistent with the hypothesis that K"^  ions can act as EDHF (Edwards et a l ,
1998). However, the possibility that K^ released from the endothelium is EDHF has 
been challenged by the finding that EDHF-mediated responses are unaffected by 
ouabain or barium in the guinea-pig carotid artery, porcine coronary artery (Quignard et 
a l ,  1999) and rat hepatic artery (Andersson et a l ,  2000). Moreover, in rat mesenteric 
(Harris et a l ,  2000; Lacy et a l ,  2000) and renal arteries (Jiang & Dusting, 2001), 
potassium-induced vasodilatation is abolished following removal of the endothelium, 
thus casting doubt on a role for this ion as EDHF in these vessels. However, some of 
these studies used tension reeording to measure the EDHF response and as such 
required the use of vasoconstrictor agents. Recently it has been demonstrated that the 
ability of K"^  to mimic EDHF, i.e. to produce hyperpolarization and vasodilatation, 
decreases as vasoconstrictor tone is increased (Dora & Garland, 2001; Richards et a l ,  
2001). It is thought that the rise in smooth muscle intracellular Ca^^ due to presence of 
vasoconstrictors can open Kca channels, causing K"^  release from smooth muscle cells
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creating an extracellular “cloud”. This “cloud” would maximally activate the Na/K- 
ATPase and Kir such that it would prevent hyperpolarisation of smooth muscle cells 
upon release of more K^ (EDHF?) from the endothelial cells (Dora & Garland, 2001). 
These findings indicate that in experiments employing vasoconstrictor agonists in order 
to measure decreases in tension (or perfusion pressure) to vasodilators, care must be 
taken in interpreting the role of K^ in the EDHF-mediated responses.
Having established that a high K^ concentration inhibited endothelium-dependent 
vasodilatation in the bovine eye, the possible involvement of potassium channels was 
investigated on acetylcholine-induced vasodilatation. K a t p  channels are not generally 
considered to be involved in EDHF-mediated vasodilatation (Corriu et a l ,  1996) and 
consistent with this, addition of glibenclamide, a blocker of K a t p  channels (Feelisch & 
Noack, 1987), had no effect on the vasodilatation induced by acetylcholine in the 
bovine eye. Tetraethylammonium (TEA) is a relatively non-selective inhibitor of 
calcium-sensitive K^ (Kca) channels (Cook & Quast, 1990), although it does not block 
small conductance Kca (SKca), even at concentrations up to 4 mM (Povstyan et a l ,
2000). Infusion of TEA caused a large, transient vasoconstrictor response, indicating 
that Kca channels are probably tonically active in the bovine eye. In addition, the 
acetylcholine-induced vasodilatation was blocked by -50%  by TEA, which is in 
keeping with its ability to inhibit EDHF-mediated vasodilatation in human forearm 
resistance vessels (Honing et a l , 2000) and in rat mesenteric arteries (Chen & Cheung, 
1997).
The vast majority of evidence suggests that the action of EDHF is normally abolished 
by the combination of the small conductance K c a  ( S K c a )  channel blocker, apamin, with
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the large and intermediate conductance Kca (BKca/IKca) blocker, charybdotoxin, but not 
by the combination of apamin with the large conduetance Kca (BKca) inhibitor, 
iberiotoxin (Edwards et a l ,  1998; Edwards et a l ,  1999a; Zygmunt & Hogestatt, 1996). 
On the basis of these findings, the EDHF pathway is thought to involve the opening of 
SKca channels and IKca channels but not BKca channels, on the endothelial cell 
(Edwards et a l ,  1998; Ohashi et a l ,  1999). In the bovine eye, apamin (100 nM) had no 
significant effect on U46619-induced perfusion pressure but charybdotoxin (50 nM) and 
iberiotoxin (50 nM) both caused a large transient, vasoconstrictor response of -300 
mmHg lasting -15 min, similar to that seen with TEA (see above). These 
vasoconstrictor responses may have been due to inhibiting BKca channels and inhibition 
of these channels is known to inhibit nitric oxide-induced vasodilatation (Demirel et 
a l ,  1994) (Champion & Kadowitz, 1997); it is however unlikely that in the bovine eye 
these large transient vasoconstrictions reflect inhibition of basal nitric oxide activity, 
since the nitric oxide synthase inhibitor, L-NAME, produced much smaller rises in 
perfusion pressure (-30 mmHg) which were maintained for many hours. It is more 
likely that these findings indicate that BKca channels are normally open under the 
conditions used in the current study, as TEA, charybdotoxin and iberiotoxin all inhibit 
this channel. Indeed, a similar contraction in response to charybdotoxin has been 
observed in the saphenous artery of the mouse (Ding et a l ,  2000) and charybdotoxin 
and iberiotoxin can augment phenylephrine-induced vasoconstriction in rat mesenteric 
arteries (Dora et a l ,  2002). Regardless of any effects on U46619-induced perfusion 
pressure, apamin (100 nM) and iberiotoxin (50 nM) alone or in combination had no 
significant effect on the acetylcholine-induced vasodilatation. In contrast, charybdotoxin 
(50 nM) alone significantly attenuated acetylcholine-induced vasodilatation, and 
uncovered a vasoconstrictor response (see below). In previous studies (Edwards et a l .
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1998; Edwards et a l ,  1999a; Zygnumt & Hogestatt, 1996), charybdotoxin alone did not 
attenuate acetylcholine-induced vasodilatation, as was seen in the ciliary vascular bed of 
the bovine eye. This may reflect the requirement of the eombination of charybdotoxin 
and apamin to inhibit EDHF in these preparations, or the absence of the unusual 
aeetylcholine-indueed vasoconstriction observed in the bovine eye. A lower 
concentration of charybdotoxin (10 nM) had no effect on perfusion pressure or 
vasodilatation. Nevertheless, when this lower concentration was combined with apamin, 
a significant attenuation of acetylcholine-induced vasodilatation was observed. Thus, 
the attenuation of the acetylcholine-induced vasodilatations with the combination of 
apamin and chaiybdotoxin, and the lack of effect of the combination of apamin and 
iberiotoxin is consistent with the possibility that the vasodilator responses observed in 
the ciliary vascular bed of the bovine eye involve both SKca and IKca and may be 
mediated by EDHF.
In an attempt to elucidate further the nature of the EDHF in the ciliary vascular bed of 
the bovine eye, the effects of a range of potassium channel openers commonly used to 
characterise, or mimic the effects of EDHF were assessed. EDHF-mediated 
vasodilatation is not thought to involve the opening of K a t p  channels, however the 
endothelium-independent opener of K a t p  channels, levcromakalim (Katnik & Adams, 
1997), elicited large vasodilatations, thus demonstrating that the vascular smooth 
muscle cells of the ciliary vascular bed are capable of vasodilatation to hyperpolarizing 
stimuli independent of EDHF. The opening of IKca channels is thought to be involved 
in the EDHF-response (Edwards et a l ,  1998; Edwards et a l ,  1999a)and 1-EBIO is a 
putative opener of IKca channels (Adeagbo, 1999). Moreover, it has previously been 
used to demonstrate that the opening of endothelial IKca channels and the subsequent
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release of K.^  may underpin the actions of EDHF (Edwards et a l ,  1999a). In the bovine 
eye 1-EBlO caused a small dose-dependent vasodilatation (maximum fall in perfusion 
pressure of 30.0 ± 4.8 mmHg). A newly introduced, more potent analogue of this, 
DCEBIO (Singh et a l ,  2001), did, however, elicit large dose-dependent vasodilator 
responses (maximum fall in perfusion pressure of 82.2 ± 6.0 mmHg). These results 
could be consistent with K"*" released from the endothelium being the EDHF in bovine 
eye and would support the evidence gained from the blockade of EDHF observed in the 
presence of ouabain and barium. However, the vasodilator responses induced by 
DCEBIO were completely unaffected by the inhibitor of IKca, charybdotoxin (50 nM), 
indicating that this agent causes vasodilatation, in the bovine eye, by a mechanism 
distinct from the opening of IKca- Indeed, it has been previously reported in the rat 
mesenteric artery that 1-EBIO could promote vasodilatation at concentrations less than 
those required to elicit hypeipolarization and this relaxation was insensitive to 
charybdotoxin or iberiotoxin (Walker et a l ,  2001), Consequently, the results with this 
and similar agents should be treated with caution. The effects of the opener of BKca 
channels, NS1619 (Olesen et a l ,  1994b), were also assessed, but it could only elicit a 
small vasodilatation at the highest concentration (100 nmol) studied (fall in perfusion 
pressure of 19.1 ± 2.4 %, n = 7). It is unlikely that this vasodilatation in response to 
NS1619 was poor due to the absence of BKca channels in this preparation, as agents 
which block this channel such as charybdotoxin, iberiotoxin and TEA all produced 
vasoconstrictor responses (see above). It is more likely that, because the BKca channels 
appear to be constitutively active in the bovine eye, NS1619 cannot produce much 
further activation of these channels. These results confirm the established literature that 
a BKca channel is unlikely to be involved in the EDHF-mediated vasodilatation in the 
bovine eye (see above). The effect of the putative candidate for EDHF, anandamide
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(Randall et a l ,  1996), was also examined in the bovine eye. However, in this study, 
only the highest dose of anandamide studied (100 nmol) produced a small vasodilator 
response (21.0 ± 1.5 %), suggesting that some other mechanism underpins the EDHF- 
mediated response in the ciliary vascular bed of the bovine eye. No further attempt was 
made to elucidate the nature of the EDHF in this study.
5.4 Ascorbate inhibits EDHF-mediated vasodilatation and uncovers a 
vasoconstrictor response in the ciliary vascular bed of the bovine eye
Having established that the vasodilatation induced by acetylcholine and bradykinin are 
mediated by an EDHF-like substance, the effects of the antioxidant, ascorbate, were 
examined on these vasodilator responses in the ciliary vascular bed of the bovine eye. 
The effects of ascorbate were studied as this antioxidant is known to protect nitric 
oxide-dependent vasodilator responses under conditions of oxidant stress (Dudgeon et 
ah, 1998; Fontana et a l ,  1999). Furthermore, as ascorbate supplied by the plasma is 
concentrated in the aqueous humour (to ~1 niM), previous studies using the bovine 
isolated perfused eye have included ascorbate in the perfusion medium (Shahidullah & 
Wilson, 1999; Wilson et a l ,  1993). Suiprisingly, the present study demonstrated that 
ascorbate, at concentrations similar to those occurring in normal human plasma (mean
46.8 + 8, range 30 -150 pM; Keaney & Vita, 1995; Levine et a l ,  1996), blocks EDHF- 
mediated vasodilatation. Specifically, when the ciliary vascular bed was perfused with 
Krebs solution containing ascorbate (50 pM, >120 min), acetylcholine induced 
vasoconstrictor responses that were biphasic with a small, residual, vasodilator 
response. This is in direct contrast to when the ciliary vascular bed is perfused with 
normal Krebs solution (i.e. containing no ascorbate), where acetylcholine produces only 
vasodilator responses that are mediated by EDHF (see Chapter 3 and Section 5.2). This
121
acetylcholine-induced vasoconstriction was unaffected by the cyclo-oxygenase 
inhibitor, flurbiprofen (30 pM), eliminating the involvement of a vasoconstrictor 
prostanoid. The vasoconstriction was, however, abolished by atropine (100 nM), 
indicating that it was muscarinic in nature, and ruling out the possibility that the 
vasoconstriction was due to stimulation of nicotinic acetylcholine receptors on 
perivascular nerves and the subsequent release of noradrenaline. Accordingly it is likely 
to result from the well-characterised direct contractile action of acetylcholine on 
vascular smooth muscle (Furchgott & Zawadzki, 1980). In the absence of ascorbate, 
when CHAPS was infused to selectively destroy the endothelium, acetylcholine- 
induced vasoconstrictor responses were not always observed. Therefore it may be 
possible that the vasoconstrictor response produced by acetylcholine may be 
endothelium-dependent. Indeed, acetylcholine-induced, endothelium-dependent 
vasoconstrictor responses have been observed in rat aorta (Franchi-Micheli et a l ,  2000). 
However, it is likely that in this study CHAPS also caused some damage of the smooth 
muscle cells (cf. the vasoconstrictor response induced by inhibiting nitric oxide 
synthase with L-NAME. A similar vasoconstrictor response would be expected upon 
removal of the endothelium, but was not observed, indicating a degree of smooth 
muscle cell damage, see Section 5.2) and this damage may have been enough to prevent 
the acetylcholine-induced vasoconstrictor response.
As reported in Chapter 3 and Section 5.3 a similar “reversal” of vasodilatation to 
vasoconstriction is seen in the bovine eye when charybdotoxin was used to attenuate 
acetylcholine-induced EDHF-mediated vasodilatation. Based on this observation, it is 
likely that ascorbate blocks the EDHF pathway at some point, thus uncovering a 
normally masked acetylcholine-induced vasoconstrictor response. Indeed, this
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conclusion is strengthened by the results of time course experiments. These showed that 
although control acetylcholine-induced, EDHF-mediated vasodilator responses were 
reproducible during a 120 min study period, inclusion of ascorbate (50 pM) in the 
perfusion medium led to a time-dependent fall in vasodilatation and development of 
vasoconstriction. By the end of the 120 min period vasodilatation was almost abolished 
and vasoconstriction had developed fully, while at intermediate time points, a biphasic 
response, consisting of an initial vasoconstriction followed by weak residual 
vasodilatation was obseiwed. Furthermore, before the intermediate biphasic responses 
were observed, the acetylcholine-induced vasodilator response had already begun to 
decline.
Further investigation revealed that the ability of ascorbate to reverse acetylcholine- 
induced vasodilatation to vasoconstriction was concentration-dependent, with even the 
lowest concentration studied (10 pM), producing a significant attenuation of 
vasodilatation and uncovering of the vasoconstrictor response. Moreover, at the highest 
concentration of ascorbate tested (150 pM), vasodilator responses were virtually 
abolished, with acetylcholine now producing almost exclusively vasoconstriction. Thus, 
the inhibitory action of ascorbate was seen over the full range of concentrations 
nonnally found in human plasma (30-150 pM; Keaney & Vita, 1995) and even at 
concentrations lower than this.
Bradykinin also elicits EDHF-dependent vasodilatation in the bovine isolated perfused 
eye (see Chapter 3 and Section 5.3), so it was important to detennine if the blocking 
action of ascorbate extended to this vasodilator. In time-course experiments, control 
bradykinin-induced, EDHF-mediated vasodilator responses were stable during the 120
123
min study period when the eye was perfused with standard Krebs solution. Moreover, in 
common with experiments when acetylcholine was used as the vasodilator, inclusion of 
ascorbate (50 pM) in the perfusion medium led to a time-dependent fall in bradykinin- 
induced vasodilatation, such that at 120 min the response was virtually abolished. In 
contrast to acetylcholine, vasoconstrictor responses to bradykinin were never observed, 
even when the blocking action of ascorbate was fully established. This observation 
therefore strengthens the conclusion that the effect of ascorbate in the bovine eye is to 
block EDHF-mediated vasodilatation and not to invoke a normally-absent 
vasoconstrictor response. Moreover, these findings indicate that the blocking action of 
ascorbate is mediated by an action on an element of the EDHF signal transduction 
cascade common to both acetylcholine and bradykinin.
5.5 Ascorbate inhibits EDHF in the ciliary vascular bed of the bovine eye by an 
antioxidant action
One of the main functions of ascorbate in the body is to act as a low molecular weight 
antioxidant (Halliwell & Gutteridge, 1989). Therefore, time course experiments were 
conducted to assess the possibility that the ascorbate-induced blockade of EDHF- 
mediated vasodilatation was due to an antioxidant action. In such experiments, the 
failure of the redox-inactive analogue, dehydroascorbate (50 pM), to mimic the effects 
of ascorbate on acetylcholine-induced vasodilatation supports this view. In addition, due 
to the instability of dehydroascorbate in aqueous solution (Bogdanski & Bogdanska, 
1955), these results eliminate the possibility that the breakdown products of 
dehydroascorbate, i.e. oxalic and L-threonic acids (Halliwell & Gutteridge, 1989), could 
account for the ability of ascorbate to block EDHF-mediated vasodilatation.
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One of the antioxidant actions of ascorbate is to sequester the superoxide anion (Som et 
a l ,  1983). The superoxide anion can spontaneously react with water to produce 
hydrogen peroxide (Halliwell & Gutteridge, 1989). However, in the bovine eye neither 
superoxide dismutase (250 units mf^) nor catalase (1250 units mf^), enzymes which 
scavenge superoxide and hydrogen peroxide, respectively, shared the ability of 
ascorbate to block acetylcholine-induced, EDHF-mediated vasodilatation. Thus, the 
blocking action of ascorbate cannot be attributed to the scavenging of superoxide anion 
or hydrogen peroxide. The lack of effect of catalase is of additional significance, as two 
recent studies suggest that hydrogen peroxide is the EDHF in mouse (Matoba et a l ,
2000), and human (Matoba et a l ,  2002) mesenteric arteries. Therefore, the lack of 
effect of catalase, in this study, suggests that hydrogen peroxide is unlikely to underlie 
EDHF-mediated vasodilatation in the bovine eye.
Glutathione is another endogenous, low molecular weight antioxidant and thiol- 
reducing agent (Halliwell & Gutteridge, 1989; Kosower & Kosower, 1978). 
Consequently, experiments were conducted to determine if this antioxidant could mimic 
the effects of ascorbate in the bovine eye. In such experiments glutathione (1 mM) 
failed to block acetylcholine-induced, EDHF-mediated vasodilatation. In contrast, two 
other more powerhil thiol-reducing agents, N-acetyl-L-cysteine (1 mM; Weinander et 
a l ,  1994) and dithiothreitol (100 pM; Karlin & Bartels, 1966), each promoted a time- 
dependent fall in acetylcholine-induced vasodilatation and uncovered a vasoconstrictor 
response. These results may simply be explained by the general antioxidant aetion of 
the two compounds, but also raise the possibility that they (and ascorbate) might block 
EDHF-mediated vasodilatation by reducing a critical disulphide group at some point on 
its signal transduction cascade.
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Redox modification of thiol groups has been reported to modulate the gating of IKca 
(Cai & Sauve, 1997), which, together with SKca, is generally involved in EDHF- 
mediated vasodilatation (Edwards et ah, 1998; Feletou & Vanhoutte, 1999). If IKca is 
the target for ascorbate and the thiol-redueing agents in the bovine eye it would be
I
expected that they would block this channel. This is supported by the charybdotoxin- <
induced blockade of EDHF, where a biphasic acetylcholine-induced vasoconstriction is 
also observed. However, IKca channels in bovine aortic endothelial cells are reported to Î
have an increased open probability when treated with thiol-reducing agents (Cai &
Sauve, 1997). Thus, ascorbate's target may be distinct from this channel.
An alternative locus for the inhibitory action of ascorbate might be cytochrome P450. It 
has been suggested that EDHF-dependent vasodilatation may be mediated by a product 
of a cytochi'ome P450 enzyme (Bauersachs et al 1994; Fisslthaler et al., 1999). 
Cytochrome P450s are redox sensitive and ascorbate is known to inhibit their aetivity 
(Anderson & Kappas, 1991; Ghosh et a l ,  1997). It would therefore be of interest to 
determine if inhibition of cytochrome P450 enzymes underlies the ability of ascorbate 
to block EDHF-mediated vasodilatation. In addition, gap junctions have been 
implicated in EDHF-mediated vasodilatations (Chaytor et a l ,  1998). Recently it has 
been reported that a slow blockade of EDHF-mediated responses is associated with the 
use of HEPES-based buffers, possibly by the binding of an amino-sulphonate moiety to 
gap junctions, thus reducing connexin expression (Edwards et a l ,  2001). Thus raising 
the possibility that aseorbate may act in a similar manner.
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The blockade of EDHF-mediated vasodilatation in the bovine eye by ascorbate at 
concentrations well within the normal plasma range raises several important issues. For 
example, if these in vitro experiments reflect the behaviour of the ciliary vascular bed 
in vivo, they would suggest that EDHF aetivity is nonnally greatly suppressed. Such a 
situation seems almost ineonceivabie, since numerous reports describe vasodilator 
responses attributed to EDHF in living animals (Nishikawa et al., 1999; Parkington et 
a l ,  2002; Welsh & Segal, 2000) and humans (Honing et a l ,  2000; Katz & Krum,
2001). Furthermore, the blocking action of ascorbate on EDHF contrasts markedly with 
its actions on nitric oxide, where enhaneement of vasodilator activity is widely reported. 
For example, ascorbate is able to restore nitric oxide-dependent vasodilatation following 
its impairment by oxidant sti'ess in isolated arterial rings (Dudgeon et a l ,  1998) 
(Fontana et a l ,  1999). Moreover, acute treatment of patients with ascorbate has led to 
restoration of impaired nitric oxide-mediated vasodilatation in essential hypertension 
(Natali et a l ,  2000; Taddei et a l ,  1998b), atherosclerosis (Levine et a l ,  1996), 
hypereholesterolaemia (Ting et a l ,  1997), insulin-dependent (Timimi et a l ,  1998) and 
non-insulin-dependent diabetes (Ting et a l ,  1996) and ehronie heart failure (Ellis et a l ,  
2001; Hornig et a l ,  1998).
Although highly speculative, it is possible that ascorbate may act in vivo as a redox 
switch to activate EDHF under conditions of oxidant stress. Under such conditions 
nitric oxide is destroyed by the superoxide anion (Gryglewski et a l ,  1986; Rubanyi & 
Vanhoutte, 1986) and low molecular weight antioxidants such as aseorbate are rapidly 
consumed (see; Frei, 1994). The depletion of ascorbate could then potentially activate 
the normally suppressed EDHF-dependent vasodilator mechanism. Indeed, support for 
this concept comes from a recent report showing that in heart failure, where nitric
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oxide-dependent vasodilatation is impaired by oxidant stress in the forearm circulation, 
EDHF becomes the dominant vasodilator mechanism (Katz & Kiuni, 2001). Further 
evidence of a reciprocal interaction between these two vasodilators is suggested by the 
findings that nitric oxide inactivates EDHF in the porcine coronary circulation both in 
vitro (Bauersachs et a l ,  1996) and in vivo (Nishikawa et a l ,  2000). Furthermore, it has 
been suggested that the EDHF-mediated component of vasodilatation becomes fully 
established in porcine isolated coronaiy arteries only when the nitrie oxide-dependent 
component is inhibited (Kilpatriek & Cocks, 1994). Whatever the precise interaction 
between these two important vasodilators, the findings with ascorbate in the present 
study may have important consequences for cardiovascular pathologies where nitric 
oxide-mediated vasodilatation is impaired by oxidant stress.
5.6 Selectivity of the ability of ascorbate to inhibit EDHF-mediated vasodilatation 
in the ciliary vascular bed of the bovine eye
It was possible that the blockade of EDHF mediated vasodilatation in the bovine eye 
was simply the result of a non-selective damage to endothelial cells. Therefore, 
experiments were eonducted to assess if  EDHF - indep endent vasodilatations could be 
affected by ascorbate (50 pM). In such experiments, the vasodilatation to the nitric 
oxide donor, glyeeryl trinitrate (Feelisch & Noack, 1987) was eompletely unaffected by 
ascorbate suggesting that in the presence of ascorbate the nitric oxide effector pathway 
remains intact. Furthermore, vasodilatation induced by leveromakalim, which causes 
vasodilatation by opening of K a t p  channels on smooth muscle cells (Katnik & Adams, 
1997), leading to hyperpolarization of the smooth musele, was unaffected by the 
infusion of ascorbate. EDHF-dependent vasodilatations are not thought to involve the 
opening of these glibenclamide-sensitive K a t p  channels (Corriu et a l ,  1996). Indeed in
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the bovine eye, EDHF-mediated vasodilatation is not affected by the infusion of 
glibenclamide.
Both glyceiyl trinitrate and leveromakalim elicit endothelium-independent 
vasodilatation and the lack of effect of ascorbate on these show that the smooth muscle 
cell relaxation mechanisms are intact. They do not, however, eliminate the possibility 
that ascorbate-induced blockade of EDHF-mediated vasodilatation results from non- 
selective damage of endothelial cells. This possibility was ruled out, however, as the 
vasoconstrictor response resulting from the tonic vasodepressor actions of basal nitric 
oxide, produced by inhibiting nitric oxide synthase with L-NAME, was completely 
unaffected by the infusion of ascorbate in the ciliary vascular bed of the bovine perfused 
eye. Thus in the presence of ascorbate the basal nitric oxide activity is still present, 
suggesting that the endothelium is functional.
5.7 Ascorbate inhibits EDHF-mediated vasodilatation in the rat isolated 
mesenteric arterial bed
The ciliary body of mammalian eyes actively transports ascorbate (Millar & Kaufman, 
1995), therefore the concentration of ascorbate found in the aqueous humour is 
normally around 1 mM in a wide range of animal species, including humans (Caprioli, 
1992; Halliwell & Gutteridge, 1989; Millar & Kaufman, 1995). Consequently, 
experiments were conducted to determine if the ability of ascorbate to block EDHF- 
mediated vasodilatation was peculiar to the eye, or a more general phenomenon. 
Accordingly, the studies were extended to a different preparation where the role of 
EDHF has been characterised extensively, i.e. the rat isolated perfused mesenteric 
arterial bed (McCulloch et al., 1997). In the present study acetylcholine-induced
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vasodilatations were slightly attenuated in the presence of the nitric oxide synthase 
inhibitor, L-NAME but the maximum vasodilatation was unaffected, and the additional 
infusion of indomethacin had no further effect on vasodilator responses. These results 
are in agreement with previous studies in the rat mesenteiy (McCulloch et a l ,  1997). 
Furthermore, the vast majority of studies indicate that, in rat mesenteric arteries, 
endothelium-dependent vasodilatation resistant to inhibitors of nitric oxide synthase and 
cyclo-oxygenase are mediated solely by EDHF (Dora & Garland, 2001; Edwards et a l ,  
1998; McCulloch et a l ,  1997). The present study revealed that acetylcholine (10 mnol)- 
induced, EDHF-dependent vasodilator responses in the perfused mesentery were indeed 
blocked in a time-dependent manner when ascorbate (50 pM) was included in the 
perfusion medium. The time required for maximal blockade (180 min) was somewhat 
longer than in the bovine eye (120 min), but time-matched experiments conducted in the 
absence of ascorbate showed that acetylcholine-induced vasodilatation was well 
maintained during this period. In addition, blockade by ascorbate (50 pM, >180 min) of 
EDHF-mediated vasodilatations induced by aeetyleholine occurred across the entire 
dose-response range (1 pmol-100 nmol) in this preparation. Thus, the ability of 
ascorbate to block EDHF-mediated vasodilatation is not limited to the bovine eye and 
appears to be a more widespread phenomenon.
5.8 Aseorbate does not inhibit EDHF-mediated vasodilatation in isolated rings of 
porcine coronary artery. A colleague, Silvia Nelli, performed the experimental 
work in this section, in a collaborative study
As has already been established, ascorbate inhibits EDHF-mediated vasodilator 
responses not just in the ciliary vascular bed of the bovine eye, but also in the 
mesenteric arterial bed of the rat. As both these preparations are perfiased vascular beds
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it is likely that the vessels controlling the perfusion pressure are the small resistance 
arterioles. Thus raising the possibility that they may be the locus of the ascorbate- 
induced blockade of EDHF. Consequently, experiments were conducted to determine if 
blockade of EDHF-mediated vasodilatation by ascorbate might also be observed in a 
large conduit artery. The porcine coronary artery was chosen for this purpose because 
EDHF-mediated vasodilatation and hyperpolarization have been extensively studied in 
this tissue (Beny & Schaad, 2000; Edwards et a l ,  2000; Edwards et a l ,  2001; 
Fisslthaler et a l ,  1999; Fleming et a l ,  1999). In the present study, and in agreement 
with the previous reports, it was found that in the porcine coronary artery, EDHF- 
mediated vasodilatation was uncovered by inhibiting nitric oxide synthase and cyclo- 
oxygenase. Inhibiting SKca with apamin, or IKca with charybdotoxin, each alone, had 
no significant effect on bradykinin-induced, EDHF-mediated vasodilatation in this 
preparation. However, as expected (Beny & Schaad, 2000; Edwards et a l ,  2000), the 
combination of charybdotoxin and apamin was required to block the EDHF response. 
Indeed, this combination virtually abolished the non-prostanoid, non-nitric oxide- 
mediated vasodilatation in this preparation, strengthening the view that it was mediated 
by EDHF.
In porcine coronaiy arteries that had been treated with ascorbate (150 pM) the 
bradykinin-induced, EDHF-mediated vasodilatation was completely unaffected. This, 
clearly, is in stark eontrast to the large inhibitory effect of a lower concentration of 
ascorbate (50 pM) in the perfused bovine eye.
It is unclear why physiological concentrations of ascorbate inhibit EDHF-mediated 
vasodilatation in the bovine eye but not in the porcine coronary artery, but several
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explanations are possible. For example, in the bovine eye EDHF-mediated 
vasodilatation is inhibited by ehaiybdotoxin alone and the blockade of EDHF by 
ascorbate was similar in character; both caused an inhibition of vasodilatation and 
unmasked a vasoconstrictor response to aeetyleholine (see Chapter 4 and Section 5.4). 
On this basis, it was possible that ascorbate could be inhibiting EDHF-mediated 
vasodilatation by blocking IKca channels. It might therefore be expected that ascorbate 
alone would have no effect in the porcine coronary artery where blockade of both SKca 
and IKca channels is required to inliibit EDHF-mediated vasodilatation (Beny & 
Schaad, 2000; Edwards et a l ,  2000). However, in the porcine coronary artery, 
ascorbate failed to inhibit the EDHF-mediated vasodilatation in eombination with 
charybdotoxin and failed to enhance the small blocking effect of apamin. Thus, it 
appears that ascorbate does not block either SKca or IKca, at least not in the porcine 
coronary artery. Therefore, the suggestion that ascorbate may regulate Kca channel 
gating by reducing a critical disulphide bond seems unlikely (see Section 5.3). Whether 
there is heterogeneity between Kca channels in the bovine eye and porcine eoronaiy 
artery is unknown at present. As already described (see Chapter 3 and Section 5,3) one 
way to investigate if an IKca channel is the target for ascorbate in the bovine eye would 
be to examine the effects of this antioxidant on vasodilatation induced by an opener of 
IKca channels. Unfoitunately, however, this was not possible as the putative opener of 
IKca channels, DCEBIO (Singh et a l ,  2001), produced vasodilatation insensitive to 
blockade with chaiybdotoxin in the bovine eye.
Another explanation that could potentially account for the difference in the ability of 
ascorbate to inhibit EDHF-mediated vasodilatation in the bovine eye and porcine 
coronary arteiy is the size of the vessel studied. Specifically, the porcine coronary arteiy
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is a large conduit artery, whereas the resistance blood vessels studied in the bovine eye 
are likely to be small arterioles. Indeed, vessel size is known to affect the nature of 
vasodilator responses in the rat mesenteric arterial bed; specifically, as the vessel 
diameter decreases the relative contribution of EDHF to the vasodilator responses 
increases and that of nitric oxide decreases (Hwa et a l ,  1994). Furthermore, 
myoendothelial gap junctional plaque expression increases as vessel diameter decreases 
from the superior mesenterie artery to the third-order arteries (Sandow & Hill, 2000). 
Moreover, the effeetiveness of inhibitors of gap junctional communication to block 
EDHF responses (Chaytor et a l ,  1998; Chaytor et al., 2001) increases with decreasing 
vessel size (Berman et a l ,  2002; Chaytor et al., 2001). Therefore, if ascorbate were 
inhibiting EDHF-mediated vasodilatation by interfering with gap-junctional 
communication it may be one explanation for its effectiveness in the perfused bovine 
eye but not in the porcine coronary artery.
Another difference between the perfused bovine eye and poreine eoronary artery is that 
the ciliary body of the eye has the ability to concentrate ascorbate from blood plasma 
into the aqueous humour (Millar & Kaufman, 1995). This ability to eoncentrate 
ascorbate may result in high loeal eoncentrations of aseorbate in the eye and these high 
local concentrations could potentially underlie the inliibition of EDHF in the bovine 
eye. This argument seems unlikely, however, sinee EDHF-mediated vasodilatation is 
inhibited by ascorbate in the rat perfused mesenteric arterial bed (see Chapter 4 and 
Section 5.7), which lacks the ability to concentrate ascorbate. Nethertheless, the 
aseorbate-induced inhibition of EDHF in the rat mesenteric arterial bed has a far slower 
time course than in the bovine eye; therefore the high concentration of ascorbate in the 
eye could still aid inhibition of EDHF-mediated vasodilatation.
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5.9 Ascorbate appears to inhibit EDHF-mediated vasodilatation in the ciliary 
vascular bed without the need for concentration by the ciliary body
As discussed in Seetion 5.8 it is possible that because the ciliary body of the bovine eye 
can actively transport ascorbate to levels of around 1 mM, the concentration of 
ascorbate that actually blocks EDHF-mediated vasodilatation may be considerably 
higher than the perfusate coneentration (50 pM), Consequently, experiments were 
conducted to assess whether preventing the accumulation of ascorbate in the bovine eye 
would affect the ability of this antioxidant to cause blockade of EDHF-mediated 
vasodilatation. In these experiments, the concentration of ascorbate in the aqueous and 
vitreous humours was measured using a spectrophotometric assay based on those 
described by (Lykkesfeldt et ah, 1995) and (Ortega-Barrales et al., 1998). Using this 
assay the measured concentration of ascorbate in the aqueous and vitreous humours (1.1 
± 0 .1  and 0.9 ± 0 .1  mM, respectively) from freshly obtained eyes (within 1 hour of 
killing) was similar to those previously reported for the bovine eye (1.1 and 0.5 mM, 
respectively; Davson, 1980). Surprisingly, when the eyes were perfused for a 120 min 
period with Krebs solution eontaining no ascorbate, these concentrations of ascorbate 
were maintained. Paradoxically, the levels of ascorbate appeared to be slightly reduced 
when eyes were perfused with Krebs solution containing ascorbate (50 pM); however, 
these falls in ascorbate concentration were not statistically significant and may represent 
the variation within the preparation. It would have been expected that during the 120 
min study period, there would have been some consumption of ascorbate in redox 
reactions; however, the maintenance of the ascorbate concentration may reflect the 
ability of the epithelia of the cornea and iris/ciliary body (and hence the posterior and 
anterior chambers) to rapidly reduce any dehydroascorbate formed back to ascorbate
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(Bode et a l ,  1991; Bode et a l ,  1993). Regardless of the mechanisms involved, the data 
suggest that the concentration of ascorbate in the ocular fluids is stringently controlled.
In experiments where the aqueous humour was continuously flushed by infusing Ki*ebs 
solution into the anterior and posterior chambers, to prevent the accumulation of 
ascorbate, its concentration in the aqueous humour fell below detectable levels (<10 
pM). The concentration of ascorbate in the vitreous humour was unaffected by this 
“flushing” procedure indicating that the “barrier” between the posterior and vitreous 
chambers remained intact. Furthermore, in control experiments the acetylcholine- 
induced, EDHF-mediated vasodilator responses were unaffected by flushing the 
posterior and anterior chamber chambers of the eye with normal Krebs solution. 
However, flushing also failed to prevent the blockade of EDHF-mediated vasodilatation 
when eyes were perfused with Ki*ebs containing ascorbate (50 pM). Therefore, it 
appears likely that an intravascular ascorbate concentration of 50 pM truly is, itself, 
sufficient to block EDHF in the ciliary vascular bed of the bovine eye, and that further 
tissue coneentration of this antioxidant is not necessaiy for blockade to occur.
Further evidence that concentration of ascorbate in aqueous humour is not required for 
the blockade of EDHF was provided by experiments where both the aqueous humour 
and vitreous humour were removed from the eye, resulting in a preparation where the 
ciliary circulation could be studied without the influence of either of the endogenous 
“reservoirs” of ascorbate, as well as preventing its accumulation. Under these 
conditions, when eyes were perfused with Krebs containing no ascorbate, the 
acetylcholine-induced, EDHF-mediated vasodilator responses were completely normal. 
In contrast, when ascorbate (50 pM) was included in the Krebs solution it still produced
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the eharacteristie blockade of EDHF-mediated vasodilatation and uncovered a 
vasoconstrictor response. Thus, it would seem highly unlikely that accumulation of 
ascorbate in the aqueous or vitreous humour is a prerequisite for blockade of EDHF- 
mediated vasodilatation to oceur. Therefore, it is likely that the ascorbate-induced 
blockade is mediated by the concentration that was infused, i.e. usually 50 pM, which is 
the normal plasma concentration (Keaney & Vita, 1995; Levine et ah, 1996). This 
conclusion is further supported by the ability of ascorbate to inhibit EDHF-mediated 
vasodilatation in the mesenteric arterial bed of the rat, a preparation unable to 
concentrate ascorbate.
5.10 Future directions or studies
The evidence from the current study strongly indicates that the endothelium-dependent, 
acetylcholine- or bradykinin-induced vasodilator responses in the ciliary vascular bed of 
the bovine eye are mediated by EDHF. However, this conelusion is only based on 
measurements of perfusion pressure and to date, no electrophysiological recordings of 
membrane potential have been taken from the ciliaiy vascular bed. It would, therefore, 
be desirable for recordings of membrane potential from the ciliaiy vasculature of the 
bovine eye to be obtained to substantiate the infeiTed role for EDHF and to define the 
pharmacology of any hyperpolarization and its relationship to changes in smooth 
muscle tone. It may even be possible to infer changes in membrane potential in whole 
tissue by injecting voltage-sensitive dyes into the ocular blood vessels. Regardless, 
measurement of membrane potential may also give insights to the locus of the 
ascorbate-indueed blockade of EDHF. For example, by impaling the appropriate cell 
type it might be possible to determine whether the bloekade occurs at the level of the 
endothelium or smooth muscle.
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The mechanism by which ascorbate inhibits EDHF-mediated responses in the ciliary 
vascular bed of the bovine eye is far from understood. The evidence suggests that the 
blockade of EDHF is highly selective and is due to an antioxidant action of ascorbate, 
perhaps by reducing a critical disulphide bond. However, the locus of the blockade also 
remains unclear; possible targets may include: Kca channels (Cai & Sauve, 1997; 
Edwards et a l ,  1998; Zygmunt & Hogestatt, 1996), cytochrome P450 (Bauersachs et 
al., 1994), and gap junctional communication (Chaytor et a l ,  1998). The lack of effect 
of ascorbate on EDHF-mediated vasodilatation in the porcine eoronary would appear to 
rule out the possibility that it inhibits EDHF by bloeking a Kca channel. To date, the 
effect of blockade of cytochrome P450 or gap junctional communication has not been 
examined on EDHF-mediated vasodilatation in the bovine eye; if either contributes to 
the EDHF response it would be essential to examine the effects of ascorbate on their 
function.
Regardless of the mechanism of the ascorbate-induced blockade of EDHF-mediated 
vasodilatation in the bovine eye, it is also important to establish the physiological 
significance of such a process. For example this study has raised the possibility that 
ascorbate may act as a molecular “switch” where, under normal conditions, it may 
suppress EDHF-mediated vasodilatation, leading to predominance of the nitric oxide 
pathway. Consequently, it would be of interest to investigate if ascorbate could 
potentiate nitric oxide-dependent vasodilatation at the expense of EDHF in preparations 
in which both a nitric oxide and EDHF-mediated vasodilatation can be observed, such 
as the rat mesenteric arterial bed (McCulloch et al., 1997).
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In addition to ascorbate, there are many other endogenous antioxidants, not examined in 
this study, that have a protective role in vascular diseases (Halliwell & Gutteridge, 
1989). For example, vitamin E defieieney is implicated in atherosclerosis (for review 
see; Carr et a l ,  2000; Keaney & Vita, 1995) and acute supplementation of this vitamin 
can restore nitrie oxide-mediated vasodilatation in a model of atheroselerosis in rabbits 
(Keaney et a l ,  1993). Therefore, it would be prudent to conduct experiments to assess if 
vitamin E can mimic the effects of ascorbate on agonist-induced, EDHF-mediated 
vasodilatation.
In the porcine coronary artery ascorbate does not cause blockade of EDHF-mediated 
vasodilatation, hence it is unlikely that ascorbate blocks EDHF universally. Therefore 
differences in the nature of EDHF response between eoronary and ocular vessels should 
be investigated. For example, EETs seem to play an important role in poreine coronary 
vessels (Fisslthaler et a l ,  1999; Fisslthaler et a l ,  2000; Popp et al., 1996; Popp et a l ,
2002) whereas in other vessels such as rat hepatic artery (Zygmunt et a l ,  1996) and 
mesenterie artery (Edwards et a l ,  1998) K”^ ions seem to account for the EDHF 
response. To date, ascorbate-indueed blockade of EDHF-mediated vasodilatation has 
only been observed in perfused vascular beds (ciliary vascular bed of the bovine eye and 
rat mesenteric arterial bed). A major difference between the perfused vascular beds and 
the isolated coronary artery is the size of the vessels studied (resistance arteries and a 
conduit artery, respectively). Therefore, further investigation of the size of vessel 
studied on the ability of ascorbate to block EDHF-mediated vasodilatation should be 
undertaken. Furthermore, in rings of porcine coronary arteiy there is an absence of flow, 
therefore it would be interesting to investigate the effect of flow on the ascorbate- 
induced block of EDHF-mediated vasodilatation.
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Finally, as nitric oxide synthase is located with the parasympathetic (nitrergic) nerves 
supplying the ocular vasculature in many species including humans (Tamm et a l ,  
1995), pigeons (Cuthbertson et a l ,  1997), dogs (Toda et a l ,  1994) and monkeys (Toda 
et a l ,  1996), it is likely that nitric oxide released from these perivascular nerves 
contributes to vasomotor control in the eye. Indeed, as described in Section 1.3.1.2, 
nitric oxide mediates vasodilatation evoked by stimulation of perivascular nerves in the 
bovine eiliary artery (Weinkle et a l ,  1994). As agonist-induced vasodilatation in the 
ciliaiy vascular bed is mediated entirely by EDHF, it would be interesting to 
characterise the eontribution of neural release of nitric oxide to vasomotor control in 
this preparation.
5.11 Conclusions
The findings of this study demonstrate that in the eiliary vaseular bed of the bovine eye, 
endothelium-dependent, agonist-induced vasodilator responses are mediated entirely by 
EDHF. These EDHF-mediated vasodilatations are blocked in a time- and concentration- 
dependent manner by concentrations of ascorbate within the nomial blood plasma range 
(30-150 pM). This blockade of EDHF-mediated vasodilatation is highly selective and 
appears to be due to an antioxidant action of ascorbate, possibly involving the reduction 
of a critical disulphide bond. Blockade of EDHF by ascorbate appears to be urn-elated to 
the eye’s ability to eoneentrate ascorbate as EDHF-mediated vasodilatation in the rat 
mesenteric arterial bed is also affected by this antioxidant. However, the finding that 
EDHF-mediated vasodilatation is unaffected by ascorbate in the porcine coronary artery 
indicates that ascorbate does not universally block EDHF. Thus, further work will be
139
necessary to characterise the mechanism and physiological relevance of the ability of 
ascorbate to block EDHF at discrete vascular sites.
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